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This thesis demonstrates that compliance is problematic in the elderly population 
studied and requires intervention if treatment failure is to be avoided. Non-
compliance risk level was measured by use of a questionnaire and was found to be 
different for each of the subjects int~rviewed. Four different risk factors were 
identified as problems for over 50% of the subjects interviewed. Lack of 
understanding of regime, general dissatisfaction with prescribed treatment, poor 
provision of information from health professionals, and polypharmacy. However, no 
two subjects had identical combinations of problems and therefore generalisation 
into categories was not possible. Correlation between the categories was low. 
The most commonly required interventions were provision of individually tailored 
verbal information or standardised written information on discharge, attempting to 
simplify the medication regime and finding solutions to various physical problems. 
All elderly hospital inpatients should be offered these interventions as routine 
services. In particular, it is essential that hospital pharmacists provide medication 
information to patients and attempt to achieve concordance as the study suggests that 
this is not a priority to hospital doctors. Polypharmacy should be avoided by regular 
prescription review, however, polyphannacy cannot always be avoided for patients 
with multiple disease states. 
Hospital pharmacists have a vital role in solving compliance. However, primary care 
must therefore be involved in any decision to implement interventions. General 
practitioners and community pharmacists have the greatest opportunity amongst 
health professionals of being able to effect change in compliance behaviour. Many 
changes to the boundary divides between primary and secondary care must be 
bridged by means of cross-sectoral posts in order to ensure that compliance and 
concordance are achieved. 
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Chaptelf' 1: Introduction 
Compliance is a problem that is often overlooked when prescribing medication for 
patients unless it is the direct reason for a patient's admission. This is mainly 
because of a perceived lack of time and an ambiguity as to who holds the 
responsibility to assess compliance. Although absolute compliance in itself is almost 
impossible to measure, many authors have described factors that have been shown to 
affect patients' compliance with prescribed medication (Griffith, 1990). This study 
hoped to show that a pharmacist's interventions to ameliorate or remove the effect of 
these factors has a positive benefit on medicine taking. It was hoped that by using 
specific interventions patient care would improve and non-compliance risk would 
decrease. 
Whilst many authorities describe the potential benefit to be realised by utilising 
pharmacists in discharge planning and compliance checking; there exists little 
soundly based research evidence. This evidence is difficult to attain whilst the 
patient is still in hospital because the quality improvements can only be measured 
after discharge. Following-up patients after discharge from hospital is therefore 
required to reassess their compliance risk and assess the benefits gained from 
interventions made prior to discharge. 
In this thesis the current situation in the National Health Service is discussed 
regarding the responsibility of ensuring patients take their medication in the most 
effective manner. The current opinions of health care professionals regarding 
compliance and concordance are discussed, as are the various problems that can be 
encountered. After describing the objectives of the study and the methods employed, 
the research findings will be presented. 
A number of interesting ideas which have arisen through the course of this research 
are then discussed in detail and illustrated with case studies. These include the 
problem of polypharmacy, why subjects don't want to know information that health 
care professionals may feel is essential, and how health care professionals' opinions 
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of the necessity of compliance differs from the patient's. The results and 
implications are then discussed and concluding recommendations given. 
Current situation in the NHS 
The general situation at the hospital designated as NT in which the study was 
conducted has been a common situation in many hospitals in England. There has 
been a division of labour amongst healthcare professionals with a sharp segregation 
between the various roles of doctors, nurses and pham1acists. This has resulted in a 
situation where compliance has been overlooked somewhat. 
Prescribing decisions have been made in an environment where the issues of 
compliance or concordance were left very much to the individual prescriber and 
could be ignored if they wished. It can be assumed that some prescribers would 
consider the likelihood of poor compliance - especially in the elderly age group 
because of the high risk of non-compliance in this group (Department of Health, 
200 I). However, no formal assessments have been made by any professional as a 
routine part of patients' admission to hospital. 
The second problem is that the supply system for medicines crosses a number of 
professional boundaries, with each professional responsible for his section alone. 
I. The doctor is responsible for prescribing 
2. The nurse is responsible for administration on the ward and ordering 
3. The pharmacist is responsible for dispensing activities and prescription 
monitoring 
4. The nurse is responsible for handing the medicines and any infom1ation to the 
patient on discharge 
This can result in problems being overlooked as each health professional assumes 
one of the others will take responsibility for finding a solution. Conversely, each 
may attempt to solve the problem in isolation, which may result in duplication of 
effort, or in the implementation of solutions which are incompatible. This has been 
further complicated by the third problem; namely, each professional has many duties 
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and therefore insufficient time to assess each patient individually. Better team 
working with sharing of responsibilities and improved interdisciplinary 
communication may improve this situation. 
Certain groups have been targeted as needing special attention within hospital NT, 
for example newly diagnosed diabetics, patients with cancer and those with chronic 
obstructive pulmonary disease (COPD). Most other patients are assumed to be able 
to cope unless an obvious problem appears or the patient has had a compliance-
related admission. Previous studies have suggested that many of these patients have 
unmet needs such as complex regimes, forgetfulness and confusion (Anonymous 
1997b; Ley, 1982; Parkin, 1976; Royal Pharmaceutical Society of Great Britain, 
1997). 
It is essential that the problem of non-compliance is addressed and this thesis 
suggests that the pharmacist is the most appropriate person to address this problem. 
Firstly, pharmacists are therapeutics specialists. They arguably have greater 
knowledge of side effects and drug interactions which may precipitate poor 
compliance than other practitioners. A greater knowledge of drug formulations and 
brand names is also helpful when discussing drug histories with patients. 
A hospital pharmacist-led review of compliance-risk status may also be of benefit, as 
all patients need to obtain further prescriptions from a community pharmacist after 
discharge. This allows continuity of care within the same profession as community 
pharmacists arguably have more time to spend discussing compliance problems than 
general practitioners, especially as they are seen as a free advice service for those 
patients who 'do not want to bother the doctor'. Community pharmacists can also 
continue to supply any medication aids that are identified as being necessary in any 
compliance review. 
Meeting these needs is an essential part of The NHS Plan published in July 2000. 
The implications for Pharmacy have been further described: 
'making sure that people can get medicines or pharmaceutical advice 
and, as far as possible, in a way, at a time and at a place of their 
choosing; second more support in using their medicines. Extra help 
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for those who need it to get the best out of their medicines - help 
which will mean fewer people being ill because they are not using 
their medicines properly, and which will cut the amount of medicine 
which is simply wasted; third, giving the patients the confidence that 
they are getting good advice when they consult a pharmacist.' 
(Department of Health, 2000: 3-4) 
In the context of this thesis, the above summary incorporates improving discharge 
dispensing and the timeliness and relevance of information given to patients, 
ensuring that they are assessed for problems with compliance and, as far as possible, 
solutions for those problems found. 
The primary/secondary care gap 
The responsibilities of a pharmaceutical care practitioner are to determine the 
patient's wishes, preferences and needs concerning their own health and treatment, 
that is concordance, and to ensure that provision is made for continuing care, 
including when the patient crosses the primary/secondary care interface. This 
concept is described as seamless care (Binyon, 1994). Jackson et al have defined 
seamless care as follows: 
'The process by which a patient is moved from one care environment 
to another with the assurance that all their health care requirements, 
including information, can be communicated in a safe, timely, 
efficient and user friendly way' 
(Jackson, 1993: 58) 
A Department of Health Executive Letter - EL (91) 127 (Anonymous, 1991a) 
discussed the issue of seamless care. As well as the obvious need for good 
communication between hospital doctors and general practitioners, this Executive 
Letter also recommended that there should be liaison with the community pharmacist 
to ensure continuity of supply of the dmg. 
Unfortunately, seamless care within prescribing and therapeutics is not the norm in 
today's National Health Service. One of the causes of this is that patients are not 
registered with community pharmacies, a scenario that is normal in some other 
countries, for example in the USA. The result is that patients can, and do, chose to 
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visit a number of different pharmacies, reducing the potential for continuity of care. 
Although community pharmacies keep Patient Medication Records (a record of all 
medications dispensed for that patient) if patients have prescriptions dispensed at 
other phannacies these records will be incomplete. 
If a patient visits the same pharmacy each month with a prescription the pharmacist 
can become acquainted with that patient and identify potential needs in a manner 
which is not so obvious if prescriptions are dispensed at a number of pharmacies. 
Also many of the interventions required to meet these pharmaceutical needs (e.g. 
large print labels, compliance aids - see later for a fuller list of interventions) require 
forward planning and/or financial outlay and therefore rely on the patient visiting the 
same pharmacy each time. 
Another consequence of the informal relationship between patients and their 
community pharmacies is that when patients are admitted to hospital the community 
pharmacist is not advised of this admission, with the result that valuable information 
regarding compliance is not passed on to the hospital pharmacist and the clerking 
doctor. A similar problem can occur at discharge with the hospital pharmacist 
carrying out a number of interventions, but with this information not reaching the 
community pharmacist. It is not yet routine for community pharmacists to be 
informed of changes to prescriptions and compliance needs, however, this has been 
recommended (Anonymous, 1993; Department of Health, 2001 ). 
Much work still needs to be done within the concept of seamless care before we can 
claim that the patients within the hospital are obtaining total pharmaceutical care. 
Need for research into pharmacy generated quality improvements 
Whilst many authorities describe the potential benefit to be realised by utilising 
pharmacists in discharge planning and compliance checking (Milliken, 1997) there 
exists little soundly based research evidence. Healthcare is currently attempting to 
become evidence based (Muir Gray, 1997). This paradigm dictates that all 
therapeutic interventions should not be based on historical practice or the opinion of 
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one consultant, but be underpinned by sound, reproducible and relevant evidence. 
Much time and effort is being put into collecting and analysing this evidence and 
identifying new areas of research. 
Similarly the Royal Pharmaceutical Society of Great Britain has identified 
compliance and concordance as areas requiring research in order to inform evidence 
based practice (Anonymous, 1997a). Clinical pharmacy, that element of pharmacy 
practice concerned with prescription monitoring, prescribing advice and patient 
centred problem solving, has undergone rapid development in the last ten years. 
However, much of this development has been on an ad hoc basis, with common 
practice stemming from what was originally an interim solution to a newly identified 
problem. For example, compliance aids were introduced to allow patients to be 
reminded whether they had taken a dose of medicine. However, many health 
professionals currently view them as a solution to all compliance problems. This is 
discussed in greater depth later in this thesis but illustrates how appropriate research 
is required to assure those who purchase clinical pharmacy that its functions improve 
patient care. 
Objectives 
The aim of the study was to investigate the role of a hospital pharmacist in 
improving compliance behaviour after discharge from hospital. In order to meet this 
aim there were a number of objectives: 
1. To identify the various ways compliance can be measured. 
2. To describe how a valid measure of compliance can be used to improve patient 
care. 
3. To design a practical tool to measure an improvement in patient care. 
4. To discover whether all elderly in-patients require an assessment of compliance 
when in hospital, or whether generalisations for sub-groups can be made. 
5. To identify changes to current levels of service required in order to implement the 
conclusions ofthe study. 
6. To determine whether the hospital pharmacist is the best health care team member 
to undertake the activities identified in this project. 
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Chapter 2: literature review 
In this literature review the traditional relationship between the prescriber, generally 
a doctor, and the patient will be discussed. This will be contrasted with a discussion 
of the new relationship which health professionals are being encouraged to develop 
with patients. 
In order to identify appropriate practice with regard to identifying and improving 
medication use, the literature review includes a discussion of the following: 
• Patient and prescriber focused therapeutics 
• The relationship between compliance and concordance 
• The failure to achieve concordance 
• The professionals' view of medication compared with the patients' 
~ Why patients do not take medication as directed 
• Measuring compliance 
o Sufficient compliance 
e Improving compliance 
• Compliance in the elderly 
A critique of the ethics of using a control group in health care studies will also be 
included. 
Management of therapeutics in secondary care 
Prescriber focused therapeutics 
Medication is an important armament in the treatment of many morbid conditions. 
Since ancient times, healers have been giving their clients or patients chemicals or 
extracts of plant materials with the intention of palliation or complete cure. In many 
cases these concoctions had little more than a placebo effect. They had little 
therapeutic effect and any improvement was probably due to a blind faith in the 
healer. Often, as in the case of digitalis, use of such substances could cause more 
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damage or even be fatal. Occasionally, however, some substances could bring true 
benefit in certain circumstances and these substances became the forerunners of 
today's medicines. 
Even in these ancient times, it was acknowledged that to gain maximum benefit from 
a cure the paste or mixture needed to be applied or taken in a certain way. These 
ranged from the unlikely direction to take the concoction at midnight at the time of 
the full moon, to more understandable directions such as taking after a meal or 
before bedtime. Even at this early stage the importance not just of taking the right 
amount of a substance, but also of taking it in the correct manner and at the right 
time, was recognised. So too was the importance of obeying the healer who was 
thought to have superior knowledge and experience of treating the condition. If a 
cure failed, it was obviously the fault of the patient, the healer was always right 
(Herxheimer, 2000). 
In modem years the number of available concoctions, or as we more regularly call 
them, medicines, has grown dramatically. In 1952 The National Formulary 
contained details of approximately 1600 preparations on 106 pages (Anonymous, 
1952). By comparison the British National Formulary for September 2000 contained 
over 4000 preparations on 557 pages (Anonymous, 2000b). This number is rapidly 
changing, as exemplified by the fact that a new edition of the BNF is published every 
six months. Many of the substances we now use are extremely potent and can still 
cause more harm than good, some still can be fatal. However, the knowledge of the 
safe and effective use of medicines, therapeutics, has also developed and guidelines 
for their use are available. This has reduced the harm of most medicines and allowed 
doctors to prescribe these medicines and predict the risk of taking them and the 
likely benefit. For most newly marketed drugs this risk benefit ratio is relatively 
well understood, although a few problems still do occur and medicines which cause 
more hann than good are still marketed, for example, Centoxin®. However, the 
belief that the doctor knows best and any therapeutic failure is due to the patient not 
taking the medicine properly, has until recently been all pervasive. This concept is 
called compliance. 
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Compliance with prescribed medication can be described as follows: whether or not 
a patient follows the doctor's instructions (Pharmacy Practice Research Resource 
Centre, 1998). Compliance has also been described as: 
'The consistency and accuracy with which a patient follows the 
regime prescribed by a physician or other health professional' 
(Dirckx, 1997: 181) 
A completely compliant person would follow the prescriber's instructions exactly 
and observe the following points, with regard to medication: taking the prescribed 
dose; in the appropriate way; at the appropriate times; observing cautions relating to 
drug, food and alcohol interactions. 
Patient focused therapeutics 
The current view within pharmacy is that the ideal situation is not a patient who 
complies with their medication but one who acts in concordance with a therapeutic 
plan (Clark, 1998; Royal Pharmaceutical Society of Great Britain, 1997). Marinker 
illustrated the difference between these two terms well. In the case of prescriber 
focused therapeutics and compliance he suggested: 
'What the doctor brings to the consultation - scientific evidence and 
technical skill - is classed as the solution. What the patient brings -
"health beliefs" based on experience, culture, personality, family 
tradition, and so on - is seen by the doctor as the impediment to the 
solution. The doctor's task is to overcome the impediment' 
(Marinker, 1997: 7 4 7) 
His description of a practitioner interested in concordance is as follows: 
'The clinical encounter is concerned with two sets of contrasted but 
equally cogent health beliefs ....... The patient's task is to tell the doctor 
his or her health beliefs and the doctor's task is to enable this to 
happen. The doctor must also convey his or her (professionally 
informed) health beliefs to the patient. The intention is to form a 
therapeutic alliance - to help the patient make as informed a choice as 
possible about the diagnosis and treatment. Although the alliance is 
reciprocal, the most important determinations are made by the 
patient.' 
(Marinker, 1997: 747-748) 
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The concept of concordance came to prommence as evidence showed that 
compliance was affected by the quality of the patient/doctor interaction. The aims of 
concordance is to build a bridge between the prescriber's evidence and/or 
experience-based recommendations and the experiences, beliefs and values of the 
patient (Misselbrook, 1998b; Anonymous, 1998b) and to reach an agreement 
regarding treatment (Sanghani, 1998). Such an agreement has been termed a 
therapeutic alliance. This reinforces the concept that patients don't refuse to comply 
because they are unintelligent, but because they have their own models of the 
problem and the appropriate response (Misselbrook, 1998b ). The aim of 
concordance is to optimise the benefits of medicines usage in line with the patient's 
desires and capabilities (Department ofHealth, 1999a). 
The importance of implementing this new concept was discussed in a recent report 
from a working party of the Royal Pharmaceutical Society of Great Britain (RPSGB, 
1997) of which Marinker was chairman. Informed consent must be obtained from 
the patient and opportunities to withdraw that informed consent need to be available 
(Ley, 1982). The concept of concordance has been further developed in the NHS 
Plan (Department of Health, 2000). 
'A key theme of the NHS Plan is empowering patients to take an 
active role in managing their own care. Patients are not passive 
recipients of prescribing decisions. They have their own beliefs about 
medicines, how they work and how they are best used. Moreover, 
medicines taking has to fit within their normal daily lives' 
(Department of Health, 2000: 15) 
Concordance marks a shift away from the paternalistic model seen in prescriber 
focused therapeutics in which the prescriber tries to convince the patient to do what 
he is told (Misselbrook, 1998b ), towards one in which the patient takes the lead role 
in deciding whether to take medication (Anonymous, 1998b ). In reaching a 
therapeutic alliance, the patient can decide to ignore evidence based medicine but the 
doctor should not allow this to impair the concordant relationship (Anonymous, 
2000a). This is essential in chronic conditions because ownership of the 
responsibility to treat the disease is required to ensure continuation of treatment and 
successful disease management (Mazucca, 1982). 
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Non-concordance is descriptive, not judgmental, and implies an inability to come to 
an understanding between doctor and patient (Royal Pharmaceutical Society of Great 
Britain, 1997). The causes of non-concordance are multifactorial and can occur 
equally on both sides. Non-compliance implies error on the part ofthe patient in not 
following the doctor's, or other health professional's, instructions (Marinker, 1997). 
However, the semantics becomes difficult when assessing whether the patient is 
actually taking his medication in the manner in which it was initially prescribed. 
Equally concordance cannot be measured, but an indication of whether it has been 
achieved could be that the patient is satisfied with the consultation and follows the 
therapeutic plan (Dean, 2000). 
Compliance and concordance 
Compliance vs. non-compliance 
All patients who fail to take a dose at exactly the correct time and in exactly the 
correct way could be classed non-compliant. Non-compliance has been defined as: 
'Any non-trivial deviation from the prescribed medication regimen 
(as judged by us). It can be intentional or unintentional, and includes 
dosage errors ( underuse and overuse), interruption of treatment, 
failure to take drugs at specific times, taking them at incorrect 
intervals, and/or the addition of other drugs.' 
(Col N, 1990: 842) 
It has been estimated that only 50% of patients with chronic diseases take their 
medicines at therapeutically effective doses (Marinker, 1997). However, other 
studies show that this rate varies from 10-90% for different populations (Aronson, 
1992; MacDonald, 1977; McGavock, 1998; Misselbrook, 1998c; Parkin, 1976). 
Rather than poor compliance being deviant behaviour, Professor Marinker argues 
that it is normal behaviour (Anonymous, 1997a). There are many reasons why 
patients do not comply with medication regimes. They include physical and 
psychological difficulties, for example, confusion, forgetfulness and ignorance as 
well as deliberate refusal or lack of faith in the treatment or doctor (Anonymous 
1997b; Cochrane, 1992; Ley, 1982; MacDonald 1977; Parkin, 1976; Royal 
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Pharmaceutical Society of Great Britain, 1997). In one study 103 of 315 (32.7%) 
elderly patients admitted to an acute care hospital admitted to non-compliance within 
the previous year. 81% reported underuse, 17% overuse and 2% misuse. 54% of 
non-compliance was intentional and 46% unintentional (Col, 1990). These 
mediating factors are discussed in more depth later. 
It is generally recognised that if we continue to give patients expensive drugs, it is 
essential to ensure that the patient takes them correctly as this might improve 
efficacy of care and substantially enhance the benefits of treatment (Haynes, 1996). 
There are obviously many benefits from adhering to a therapeutic regime, the main 
one being successful treatment of the condition in question. It has been estimated 
that 4-35% of patients misuse their drugs to such an extent that they endanger their 
health (Wandless, 1977). The consequences of poor compliance may be damaging 
for the patient and distressing for their families, 6-12% of hospital admissions may 
result from problems with medicines (Department of Health, 2000; Col, 1990). Fifty 
percent of all cases of end stage hypertension, 70% of end stage glaucoma, 40-60% 
of end stage diabetes and 91% of all deaths due to organ transplant rejection may be 
caused by non-compliance (McGavock, 1998). 
The cost of such non-compliance also includes increased doctor consultation time, 
increased frequency of laboratory tests, decreased work-force productivity and 
potentially premature death (Grymonpre, 1998). A third problem arising from non-
compliance is the potential wastage resulting from supply of medicines which are not 
subsequently used. Unused medicines worth in excess of £lOOm are returned to 
pharmacies each year (Department of Health, 2000). Compliance may therefore 
ensure that scarce NHS resources are maximised. 
Adherence has a similar dictionary definition to compliance but has been defined as 
'the extent to which the patient fulfils the intention of the prescriber' (Pharmacy 
Practice Research Resource Centre, 1998). It does not carry the same connotations 
of patient inferiority and has therefore been preferred by some authors. In 
assessment of whether the drug therapy is being used optimally by the subjects in 
this study, the term compliance will be used, as adherence can be included in 
'sufficient compliance' (see later in this chapter). 
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Various strategies have been suggested to improve compliance rates with varying 
success. However, Ley ( 1982) suggested: 
'In some ways perhaps the wisest method of increasing patients' 
compliance is to discover the features in the particular situation which 
are contributing to non-compliance and then do something 
appropriate about them.' 
(Ley, 1982:244) 
In this study, it is hoped to discover what contributing factors certain individuals 
have and attempt to measure the effect of appropriate remedial action. 
The relationship between compliance and concordance 
Compliance is a submissive and disempowering action. Compliant patients, by 
definition, submit to the wishes of others. By stressing compliance we ignore the 
health beliefs, opinions and values of the patient and require compliance with the 
beliefs, opinions and values of the prescriber. These beliefs may be professionally 
informed and evidence based and still oppose those of the patient. The task of the 
prescriber is to impose his beliefs on the patient. 
Concordance is a state of agreement between prescriber and patient. The patient is 
empowered and given an opportunity to share his health beliefs, opinions and values 
(Anonymous, 2000a). Those beliefs are considered of equal value to those of the 
prescriber and both parties attempt to appreciate the position of each other. A 
compromise plan is arrived at which reflects both sets of beliefs, etc. and which the 
patient agrees to follow. A failure in concordance occurs when either the doctor or 
patient does not come into the encounter with honesty and openness. Concordance 
can improve compliance (Anonymous, 2000a) but it does not solve all compliance 
problems (Misselbrook, 1998). Concordance should however reduce wastage of 
drugs, as the patient will not be given a prescription if they declare a decision not to 
take it. 
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Within concordance is the possibility of irreconcilable disagreement, in which the 
prescriber does not feel professionally that he can compromise any further yet the 
patient still refuses to follow his advice. The most important determinants are those 
that are made by the patient and the outcome is dependent on his final decision 
(Department of Health, 1999a). If the patient has made an informed decision 
concordance has been conserved. 
Once the decision to prescribe medication is made the patient can either take the 
medicine as prescribed, he is therefore compliant, or he can take it at variance to 
those directions, i.e. non-compliance. This non-compliance may be due to 1) a 
failure in concordance: the doctor did not discuss the decision fully with the patient, 
2) the patient changing his mind about the concordant decision or 3) some other 
unforeseen difficulty. The achievement of compliance and concordance are related 
but not always linked. The following scenarios describe this relationship: 
e A situation where the doctor and patient achieve concordance and the patient 
follows the resultant agreement is equivalent to the patient exhibiting full 
compliance. 
G> A situation where the doctor ignores concordance and imposes his wishes on the 
patient, but they are followed exactly by that patient, is also an example of 
compliance. 
• An encounter in which concordance is achieved but the patient subsequently 
changes his mind and does not follow the agreed plan is an example of intentional 
non-compliance. 
• If the patient chooses to follow an agreement achieved either through concordant 
or non-concordant means, but fails to do so by accident, he is unintentionally non-
compliant. 
20 
• An encounter in which the patient through lack of honesty or openness agrees to a 
therapeutic plan that he does not intend to follow is an example of both non-
concordance and non-compliance. 
A pharmacist attempting to improve this non-compliance has two options: either to 
refer the patient back to the prescriber in order to achieve concordance, or to remove 
the difficulty that is a barrier to compliance. The physician's responsibility in 
developing concordance is described elsewhere (Marinker, 1997). The problems of 
a patient changing his mind about an agreement and other difficulties with 
concordance can be loosely linked together under the terms intentional and 
unintentional non-compliance. It is these problems which are studied in this thesis. 
The professional view versus the patient's view 
We have discussed the desirability of the patient taking medication in the correct 
way and the benefit of involving the patient in making the decision how to treat their 
medical condition. One of the major problems with achieving concordance, 
however, is the wide divide between the views and beliefs of the doctor and those of 
the patient (Misselbrook, 1998). 
No matter how patient-focused a health professional is, his brief is to diagnose 
disease and whenever possible cure it or reduce the severity of consequences and 
improve the quality of life. The health professionals' standpoint is best described in 
the Hippocratic Oath: 
'I will follow that system of regimen which, according to my ability 
and judgment (sic), I consider for the benefit of my patients, and 
abstain from whatever is deleterious and mischievous. ' 
(Adams, 2000) 
In these days of expensive medicines, there is pressure to use the most effective, 
appropriate, safest and economically efficient drug possible. Doctors are inundated 
with guidelines, meta-analyses and reviews from bodies such as NICE (National 
Institute for Clinical Excellence), the Cochrane Group, SIGN (Scottish 
Intercollegiate Guidelines Network), etc. NHS hospitals, and to and increasing 
extent, Primary Care Trusts, are required to produce formularies to restrict the 
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doctor's choice to only those preparations for which evidence of their efficacy exists 
and which the NHS can afford (Anonymous, 1994). They key phrase is evidence 
based medicine. Patients should not be given a therapy of unproven value when 
there is alternative with stronger evidence of efficacy. The pressure of conforming 
to evidence based medicine may pressurise the doctor to prescribe what is 
recommended in the guideline without reference to the patient's wishes. 
The patient by contrast is often only concerned in their own health and whether they 
personally will benefit from treatment. Some may decide to refuse all treatment if 
they do not believe that their health is at risk or if they believe that the risks of 
treatment are greater than the risk of no treatment (Misselbrook, 1998b ). It is 
difficult for a lay person to assess objectively the risk benefit ratio attached to any 
treatment. This is further complicated when made personal. For example, warfarin 
is used to treat deep vein thrombosis, both to reduce pain and inflammation in the 
affected leg but also to prevent the high risk of myocardial infarction and stroke. 
However, the risk of serious haemorrhage following warfarin therapy is also high. 
The patient must decide not only how likely each of these endpoints may occur; 
namely frequency, but also how serious to them is each of these endpoints, i.e. 
severity, and how much they would be willing to suffer to prevent each of them, i.e. 
sacrifice. It is the balance between these three variables of frequency, severity and 
sacrifice that must be calculated by the patient before an informed decision can be 
made. Evidence based medicine only considers the first two of these and assumes 
that the third, sacrifice, is linearly related to these two. Experience, however, tells us 
that no two individuals have an identical view of sacrifice and so no two patients will 
approach concordance in the same way. 
Some patients will find this responsibility too hard to bear and may abdicate 
responsibility to the doctor. The fear of rejection and the anxiety of accepting 
responsibility for deviating from evidence based medicine may be too great to accept 
responsibility (Department of Health, 2000). The patient may even have a fear of 
not being taken seriously. When a patient does not wish to make a decision the 
prescriber must try to understand what underlies this reluctance in order to achieve 
concordance. 
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The choice which patients make is also dependent on their social context. If they 
know someone who has taken a particular medicine previously, their response to it 
will colour the patient's opinions. If it worked, the patient will generally want to try 
the same thing. If it failed or the friend or relative developed a troublesome adverse 
drug reaction then they may wish to avoid it. There will also always be a small 
proportion of people will want the newest drug on the market in order to be different. 
With the increase in access to the Internet, more patients are accessing information 
about their condition and the best way to treat it. This may result in a well-educated 
patient who is better equipped to make an informed decision. However, such 
information is not of a uniform standard (Anonymous, 2000a) and it is often much 
easier to find sites of a poor or anecdotal nature and much harder to find unbiased 
sites. This may result in the doctor being presented with unreliable information and 
being asked to interpret it without the time to assess the quality thereof. 
Sanghani (1998) describes a hypothetical scenario in which a recently diagnosed 
hypertensive male is given a betablocker - a treatment of reliable efficacy. The 
patient returns to the doctor describing an adverse reaction, which he finds 
particularly troublesome. Before visiting his doctor this patient carried out an 
intensive literature search and discovered a number of facts about hypertension. He 
discovered that the risk of any repercussions of untreated hypertension within ten 
years is low, that only a proportion of hypertensives suffer such repercussions and in 
the absence of other risk factors there is no way to predict whether he will thus 
suffer. Although the doctor explains the various options available and the likely side 
effects associated with them, the patient decides he is willing to take the risk and 
refuses all treatment. 
This scenario describes complete concordance - the patient is much better informed 
than average and the decision made was arrived at after serious consideration of all 
risks and potential benefits. However, the end result is that of a patient who has not 
received evidence-based treatment, as the published evidence indicates that 
hypertension must be treated. 
Sanghani then proceeds to ask a number of questions: 
23 
'What if in seven years' time the same patient dies following a 
massive myocardial infarction and his wife asks the GP why he did 
not insist that her husband take medicine? ........ . 
But what if the life insurance company now refuses to honour its 
policy because the husband had clearly acted against the best medical 
advice?' 
(Sanghani, 1998: 84) 
Concordance may improve the relationship between the patient and the doctor, but it 
introduces many difficulties to the doctor, for example, time restraints, 
communication skills, and choice of information to convey, and places a great deal 
more responsibility onto the shoulders of the patient. The doctor must try to 
reconcile the conflicts between wanting the best for the patient whilst respecting 
their health beliefs and remaining faithful to evidence based medicine (Anonymous, 
2000a; Misselbrook, 1998b ). 
Problems in practice 
Why patients do not take their medication as directed 
We have already shown that frequently patients don't take medicines in the manner 
directed and this is for a number of reasons (Misselbrook, 1998a). An understanding 
of the reasons why patients do not take their medication as directed could allow 
amelioration of this effect. 20-50% of patients do not comply with the medicines 
they have been prescribed (Misselbrook, 1998c). The reasons for non-compliance 
can be divided into two categories: patient's ability, which accounts mainly for 
unintentional non-compliance, and patient's motivation, which may account for 
intentional non-compliance (Anonymous, 1997b ). 
Unintentional non-compliance can be caused by a number of factors, the most 
common being forgetfulness (Hughes, 1998; Moriskey, 1986). This can be 
complicated by other problems and may be a consequence of ageing or other disease 
states such as dementia, however, age does not consistently correlate with forgetting, 
except possibly for patients over 65 years-of-age (Ley, 1982). Secondly, unsafe 
storage or administration can lead to forgetfulness; for example, tablets decanted into 
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other bottles can result in patients having no written instructions of how to take their 
medicines. 
Complicated regimes in both the number of drugs (polypharmacy) (Hughes, 1998; 
Ley, 1982) and number of daily doses (Moriskey, 1986; Parkin, 1976; Sweeny, 
1989) can lead to confusion and forgetfulness. Physical problems can also cause 
difficulties in compliance. Opening child resistant closures and removing tablets 
from blister packs (Hughes, 1998; Lorenc, 1993; Sweeny, 1989) and using inhalers 
and other dosing devices (Johnson, 2000) can limit a patient's ability to take their 
prescribed medication at the correct time as they may require assistance with 
accessing the dose, assistance which 1s not immediately available. Liquid 
medication also appears to cause more non-compliance than solid dosage forms 
(Sweeny, 1989), possibly because patients perceive them to be less important. 
Poor vision often means that the patient cannot rely on the label to remind them of 
the directions they need to follow. Poor memory therefore increases the risk of non-
compliance in these patients (Lorenc, 1993; McGavock, 1998; Sweeny, 1989). 
Label clarity may be further compromised if the print is too small or of poor quality, 
for example if the printer is running out of ink. 
Concordance, and the theory behind empowering patients to take responsibility for 
their own treatment, has been discussed. A breakdown in concordance may reduce 
compliance, which is one reason for its desirability. A patient who receives 
insufficient information or who does not understand what they have been told, is less 
likely to remember what the information was and will not have the ability to put it 
into practice (Col, 1990; Eisen, 1990; Lorenc, 1993; McGavock, 1998). Lack of 
satisfaction with the doctor (Anonymous, 1999; Anonymous, 2000a; Ley, 1982) and 
lack of faith in medication (Griffith, 1990) may also contribute to non-compliance. 
Patients may decide not to take medication because of fear of becoming dependant, 
scare stories, unwillingness to use 'artificial chemicals' and worry about side effects 
and what to do if they occur (Anonymous, 1997b; Britten, 1998; Lorenc, 1993; 
McGavock, 1998; Misselbrook, 1998b; Sanghani, 1998). The balance between guilt 
and social stigma also affects an individual's propensity to comply (Griffith, 1990; 
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Misselbrook, 1998b). Interestingly, however, evidence shows that experiencing side 
effects does not decrease compliance, but physicians and patients both believe that it 
does (Ley, 1982). It appears that the fear of side effects may have a greater effect on 
compliance than the actual occurrence of side effects (Misselbrook, 1998b ). In one 
study, a third of patients had concerns about adverse effects (Anonymous, 1997b). 
Patients living alone with low levels of social support and little follow-up from 
health professionals have reduced compliance (Col, 1990; Ley, 1982; Moriskey, 
1986). There is also evidence that women of high parity, the very young, 
adolescents and the elderly and low-income groups comply with treatment to a lesser 
extent (Griffith, 1990). For working adults, the inconvenience of fitting complicated 
regimes into the working day and the expense of prescription charges may reduce 
their willingness to comply (Misselbrook, 1998b). Non-compliance can also occur 
when patients accidentally continue to take drugs which have been discontinued or 
changed because old supplies have not been discarded. This is particularly a problem 
for patients with multiple conditions and on discharge from hospital (Parkin, 1976). 
People do not automatically react to risks and benefits in a logical manner, following 
the option of least harm and maximum benefit. Decisions made by patients are also 
informed by their health beliefs. Approximately 50% of subjects in one study 
believed that medicines were overused and 17% believed they did more harm than 
good (Anonymous, 1997b ). However, 85% believed that medicines were necessary 
for good health. There is some evidence that patients are more keen to take 
medicines for symptomatic, troublesome, acute problems than for enduring problems 
(Britten, 1998), however, other studies showed lower rates of compliance with 
treatment for acute illness than for long-term medication (Lorenc, 1993). It is 
difficult to generalise whether a patient will take a particular medicine, as duration of 
illness does not correlate with compliance (Griffith, 1990; Ley, 1982; Lorenc, 1993). 
It does appear that the reasons for complying are different for chronic and acute 
conditions (Lorenc, 1993), with non-compliance in acute conditions being related to 
the low importance attributed to taking tablets and low motivation. In chronic 
conditions, the fear of addiction appears to be more inhibitory. 
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The decision to comply depends on the patient's perception of the severity of their 
illness and their vulnerability to its effects (Griffith, 1990; Ley, 1982; Misselbrook, 
1998b). If a patient believes there is no hope of a cure or that the prescribed 
treatment is not working, they are less likely to take the medicine as prescribed, even 
if they understand the need for treatment (Col, 1990; Hughes, 1998). A patient may 
not take a medicine if they feel it is unnecessary (Col, 1990; Sanghani, 1998) but the 
judgement of necessity is made on the basis of different fundamental premises in 
each case. 
Some patients have a mistrust of conventional medicines in general. In one study, 
9.4% of patients who reported non-compliance blamed this on dislike of medicines 
in general (Col, 1990). For some people this reluctance to take conventional 
medicines is a matter of religious belief in which they may eschew all medicines, for 
example the Christian Scientist, or specific medical practices, for example the 
Jehovah's Witness. For others, their trust in faith healing may reduce their reliance 
on conventional medicines. Others may prefer altemative therapies such as 
aromatherapy, herbal medicine, acupuncture and homeopathy, among others. It is 
interesting to note that both aromatherapy and herbal medicine work on the same 
principles as conventional medicine as the premise is to introduce a chemical into the 
body to effect a cure. It is also worth noting that these therapies also rely on 
compliance on the part of the patient to ensure efficacy. 
Health beliefs are generally thought to be determined by the knowledge and 
attributes ofthe patient (Griffith, 1990). For patients where these align with those of 
the prescriber, compliance is more consistently achieved. For patients whose health 
beliefs are opposed to those of the prescriber, compliance is unlikely. Although 
memory is necessary for compliance to be achieved, it is not sufficient and does not 
account for deliberate non-compliance and rejection of advice (Anonymous, 1992; 
Parkin, 1976). Patients may deliberately not comply for fundamental reasons that 
are personal to them and do not allow contradiction. 
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There are many different reasons for patients not taking medicines as prescribed and 
in some patient groups with certain conditions, compliance is much rarer than non-
compliance. It is therefore arguable that non-compliance is normal behaviour and 
compliance is an abnormal and deviant activity, which is why it is so difficult to 
obtain. 
Measuring compliance 
The reasons for the desirability of compliance and why patients fail to agree to take 
medicines or follow an agreed therapeutic plan have been discussed earlier. In order 
to be able to address some of these problems it is necessary to assess to what extent 
they affect the patient's likelihood of complying with treatment (Paes, 1998). The 
issue of sufficient compliance will be described later. In this section the emphasis 
will be on the various methods of measuring compliance, and a discussion of the 
many difficulties encountered in trying to make such a measurement. 
Assessing patients' ability and likelihood of complying with a therapeutic regime is 
as complex as it is important. It has been shown that doctors frequently make 
inaccurate estimates of their patient's compliance (Aronson, 1992; van Berge 
Henegouwen, 1999) and prediction without an objective measure is not possible 
(Misselbrook, 1998c ). Problems of estimating compliance rates are caused because 
observable patient characteristics do not correlate consistently with non-compliance 
(Moriskey, 1986). To overcome this difficulty, many methods have been used such 
as structured verbal and written questionnaires, pill counts, blood and urine tests, 
measures of outcomes and using mechanical measuring devices (Aronson, 1992; 
Ley, 1982; Paes, 1998). 
As has been discussed earlier, rates of non-compliance have been estimated at 
anywhere between 4 and 93%. It is likely that this variation is due at least in part to 
methodological variation (Griffith, 1990; Paes, 1998; van Berge Henegouwen, 
1999). It is also the case that different research instruments may measure different 
kinds of behaviour or different aspects of compliance (Paes, 1998) and there is 
conflicting evidence regarding which measure provides the best estimate of overall 
behaviour (Grymonpre, 1998). 
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Pill counts have been used to assess compliance (Parkin, 1976; Smith, 1983) but a 
number of limitations are associated with this method. The patient can 'cheat' by 
removing a number of dosage units prior to counting (Hughes, 1998). Nothing can 
be concluded about the patient with no tablets left in the container as there is no way 
of knowing if these were actually taken. Over consumption, erratic drug use and 
drug holidays, that is when the patient decides not to take any medication for a short 
period of time and then resumes normal dosing, cannot be measured (Paes, 1998) 
and may lead to an overestimate of compliance rate. Finally, decanting of tablets 
into other containers and use of previously dispensed supplies can reduce the 
accuracy of this measure ( Grymonpre, 1998). 
A more workable and informal method of using pill counts can be used for patients 
who get their medication filled by a community pharmacist on a weekly basis in a 
compliance aid such as a Medidos®. It would be less obvious to the patient that a 
check was being made but the community pharmacist, by seeing the number of doses 
left in the box, can assess whether the patient is using it correctly. However, pill 
counts can only be used for discreet dosage forms (tablets, capsules, suppositories) 
and for medicines that are taken regularly (Grymonpre, 1998). Pill counts do not 
take into account when the tablets were taken, for example, with food or in the 
morning, which can be essential for some medicines to have effect. For full 
compliance to be achieved this aspect of the doctors instructions must also be 
followed and so some other method of assessing this aspect of compliance is 
required. 
Electronic measuring devices provide more information than tablet counts in that 
they give some indication of timing of doses, if a patient does not take any tablets 
and then pours a number away at just before the count is to occur this will be 
obvious. However, there are a number of limitations with this method. The first is 
the cost. Any recording device, whether it is a small computer chip or a radioactive 
device will be more expensive to obtain than a simple tablet bottle lid. Also, special 
reading devices will be required to access the records held within the cap. This 
precludes the use of such devices in all environments except research. The container 
may look different to other containers and this may alert the patient to the fact that 
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some record is being made. Electronic measuring relies on the fact that each time 
the bottle is opened a dose has been removed which is the correctly prescribed dose 
and that this dose is subsequently taken (Aronson, 1992). As this is not necessarily 
always the case, the results may not reflect actual compliance behaviour. 
To assess whether a dose has actually been taken there has been some attempt to 
design biological markers which can be measured in blood, urine or faeces. Some 
drugs such as digoxin, phenytoin, theophylline have well understood 
pharmacokinetics and the plasma concentration can be measured directly to give an 
estimate of under or overdosing. This method is often expensive and is unsuitable 
for many drugs. It may be affected by changes in renal and hepatic function and the 
presence of concomitant diseases and interacting drugs (Aronson, 1992). In 
addition, if the patient is aware of the likelihood of a blood level measurement, they 
may improve their compliance for a few days prior to the test (Anonymous, 1991 b). 
However, for suitable medicines with appropriate professional interpretation this is 
the most accurate measure of compliance (Grymonpre, 1998). 
In some disease states, it is possible to directly associate improvement in symptom 
control with compliance, for example in diabetes, hypertension and obesity (Ley, 
1982). However, the result must depend on continued treatment for the assessment 
to be valid or there is the risk of a patient complying for two or three days prior to 
the appointment and giving the impression of long term compliance. This can been 
seen in all aspects of medicine and usually occurs when the desire to please the 
prescriber is strong, but is less strong than the patient's ability, or desire, to comply. 
In some conditions, failure of therapy may be due to the wrong treatment being 
prescribed or a worsening of the condition and so a poor result may not be directly 
related to compliance. However, if a patient is not improving a change in medication 
may improve compliance if the cause of non-compliance was a side effect or 
ineffectiveness. 
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The frequency of prescription renewals has been used by some as a measure of 
compliance (Grymonpre, 1998). This measure has a number of limitations in that it 
does not take into account whether the medication has been taken. This is explained 
by understanding that ordering a prescription does not necessarily coincide with the 
previous supplies being exhausted (Hughes, 1998). A further difficulty with this 
method is that it relies on patients picking up prescriptions from the same Pharmacy 
each time as data from several different Pharmacies is much harder to collate 
(Moriskey, 1986). Information from prescription writing by the general practitioner 
cannot be used for this purpose as 10-20% of prescriptions are not filled despite 
being collected from the surgery (Aronson, 1992; Beard on, 1993; Col, 1990). 
Studies have shown that the data from pill counts is not comparable with the results 
obtained from refill data as the former measures short term compliance and the latter 
long term compliance and may be affected by many factors over time (Grymonpre, 
1998; Paes, 1998). 
Self report has been used to measure compliance. Patients generally do not 
volunteer the problem of non-compliance but a carefully constructed questionnaire 
can help (Moriskey, 1986). Most patients are aware that they occasionally forget to 
take medication and sensitive non-judgmental and non-threatening questioning can 
reveal this problem and the cause. However, patients generally have difficulty 
remembering erratic behaviour and over-consumption (Paes, 1998) and so cannot 
give accurate estimates of the frequency of such behaviour. There is a risk of 
overestimating the level of compliance (Haynes, 1996). 
Diaries have also been used as a measure of compliance (van Berge Henegouwen, 
1999), especially in clinical trials. However, the act of having to write down what 
was taken and when may have the effect of improving compliance and so may not be 
a valid measure. 
Measuring absolute compliance is generally inaccurate (van Berge Henegouwen, 
1999), almost impossible and extremely time consuming. It is more appropriate to 
define a scale of compliant behaviour as full compliance is not always necessary; 
rather, sufficient compliance that results in a therapeutically effective regime is 
required. 
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Sufficient compliance 
Most patients are neither non-compliant nor compliant, but have degrees of 
compliance, which vary with time and are dependent on personal processes (Griffith, 
1990). With antihypertensive medication, it has been shown that blood pressure only 
falls significantly when patients take more than 80% of medication as directed. For 
other conditions and treatments, the rate may be higher or lower. 
Absolute compliance, that is taking the prescribed dose at exactly the correct time on 
all occasions, is only desirable if treatment is appropriate and optimal (Webb, 1999) 
and follows not only evidence based medicine, but is the most appropriate treatment 
for the individual. It is assumed that a fully compliant patient will benefit 
significantly, through the lowering of risk status. Non-compliance is only clinically 
important if therapeutic outcomes are not achieved (Moriskey, 1986). 
It is worth remembering that estimates suggest that 5% of beds in the UK may be 
occupied by patients suffering from iatrogenic problems (Wandless, 1977). If 
treatment is inappropriate or is causing significant side effects it is important that the 
patient does discontinue it, but under the guidance of a doctor. It is arguable that in 
cases of sub-optimal therapy, although compliance may be improved, it may not be 
necessary or desirable. In most studies investigating rates of compliance, the degree 
of value to the patient of the medication has not been defined and so it is difficult to 
assess the importance of drug defaulting to the therapeutic goal. 
Improving compliance 
Patients fail to comply with therapy plans for many different and individual reasons 
and so the options for improving compliance must be as varied. The most effective 
way of improving compliance is to discover the cause and to rectify it (Ley, 1982). 
Unfortunately, poor methods of measuring compliance have made it harder to 
attempt to improve compliance (Anonymous, 1991 b). The aim of treatment must be 
to maximise the extent of compliance whilst minimising the amount of discomfort or 
cost to the patient. Compliance can only be ensured if the patient is directly 
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observed or if a doctor or nurse administers the dose (Anonymous, 1991 b). In all 
other scenarios, compliance relies on the patient having the motivation and ability to 
comply. As recently as 1996, Haynes was of the opinion that the effort expended by 
health professionals to improve compliance was insufficient: 
'Although adherence and treatment outcomes can be improved by 
certain - usually complex - interventions, full benefits of medications 
cannot be realised at current levels of adherence. It is time that 
additional efforts be directed towards developing and testing 
innovative approaches to assist patients to follow treatment 
prescriptions.' 
(Haynes, 1996: 383) 
Simplifying the regime (Anonymous, 1991 b; Eisen, 1990; Lowe, 1995) and aligning 
dosing times with daily activities (Sweeny, 1989) can improve compliance. 
Appropriate provision of information can also help compliance (Lorenc, 1993; 
Smith, 1983; Sweeny, 1989). Regular medication review to reduce polypharmacy 
(Smith, 1983), drug interactions (Hughes, 1998) and adverse drug reactions can also 
reduce the risk of non-compliance. As has been discussed already, achieving 
concordance may also improve non-compliance. 
Providing medicines in appropriate containers, which can be used or opened without 
difficulty, is essential to improve compliance (Lowe, 1995). Allowing patients to 
practise taking new medicines independently in hospital before discharge has also 
been used to decrease unintentional non-compliance and highlight difficulties (Lowe, 
1995; Wandless, 1977). 
Monitored dosage systems (MDS) (Sweeny, 1989) and diaries (van Berge 
Henegouwen, 1999) have been used to help reduce forgetfulness. It is generally 
understood amongst nurses in NHS hospitals that MDS such as the Medidos® 
improve compliance, however, there may still be a problem if filling of the container 
is unsupervised (Sweeny, 1989). 
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We must remember that although much non-compliance is unintentional, and if we 
can find the cause a great deal can be done to avoid the problem or reduce its effects, 
non-compliance is still deliberate for some patients. Concordance may reduce some 
of this intentional non-compliance but a significant proportion may be insoluble. 
Compliance in the elderly 
Studies of the elderly provide evidence of large differences in individual responses to 
medication and compliance (Abrams, 1990; Hudson, 1997). Despite this, there are a 
number of problems that are more common to elderly patients than younger patients, 
each of which can decrease compliance (Col, 1990). For example, the elderly are 
more likely to have multiple disease states and therefore multiple drug therapies 
(Reid, 1997). Patients over 65 are prescribed two or three times as many drugs as 
younger patients (Royal College of Physicians Working Party, 1997). They also 
suffer increased rates of adverse drug reactions and drug interactions (Nolan, 1989). 
Polypharmacy may be necessary to treat the patient's multiple conditions, but it may 
introduce non-compliance and other problems. In one study, half of the elderly 
patients studied hoarded medicines that were not required (Sweeny, 1989). We have 
already discussed the problems this can cause with patients continuing treatment that 
may interact with new treatment or cause overdose. 
Half of all elderly people make errors in compliance, and one third of these may lead 
to damage to health (MacDonald, 1977). These errors are greatest in those patients 
who are over 85 years of age, living alone and/or do not cope well at home, and 
those whose memory is poor or who are confused (Parkin, 1976). The main causes 
of non-compliance in this age group are forgetfulness, polypharmacy, complicated 
drug regime, confusion, adverse drug reactions, poor doctor/patient communication, 
and inconvenience of taking medicines (Cochrane, 1992; Cantrill, 1992; 
Gains borough, 1990; Ley, 1982; Parkin, 1976; Raynor, 1993; Royal College of 
Physicians Working Party, 1997; Smith, 1983). 
The elderly as a whole are prescribed more medicines, have greater problems with 
compliance, and therefore have most to gain from any intervention. This group will 
therefore be used as the client group in this study. 
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The ethics of randomised controlled trials in health care research 
In choosing a research methodology, it is generally recognised by researchers that 
randomised-controlled trials have high internal validity because they exhibit high 
statistical control over systematic and random errors (Daly, 1992; Kerlinger, 1992a). 
A judicious choice of control parameters can reduce the effect of many independent 
variables whilst allowing a small number of dependent variables (those which the 
researcher is attempting to affect) to change with specific interventions. The 
researcher is therefore able to conclude with greater certainty that any measured 
differences between the control and active groups are due to the interventions made. 
The same is true for health research, where ethics will allow. To measure specific 
effects of a particular treatment, all other conditions and non-specific effects must be 
kept equal for two groups of patients with the same disease (Kleijnen, 1994). 
The randomised-controlled trial is a powerful research tool because of its two main 
components: randomisation and control. Randomisation in healthcare is the random 
allocation of patients to one of two or more different treatment groups. The 
important point is that there is equal probability of any one patient being allocated to 
any particular treatment group. For a study to have high internal validity, the 
patients in each group should be similar in relevant characteristics before treatment 
(Anonymous, 1985). The only reliable way to do this is to assign patients to 
treatment groups randomly (Kerlinger, 1992a) and this can also reduce the effects of 
regression to the mean (Yudkin, 1996). However, randomisation can fail if the 
investigator has prior knowledge of the group allocation. This lack of concealment 
can lead to selection bias, for example, delaying entry of a subject until the desired 
treatment group allocation is available (Schulz, 1996). 
Including a control group in a study is important in clinical trials. Indeed, 
randomisation is not possible unless there are a minimum of two groups or phases. 
The full benefit of randomisation cannot be realised unless one of the groups is a 
control and the other receives the experimental intervention. Well-designed control 
conditions take many forms but have two things in common: the outcome is 
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considered to be predictable apart from non-specific effects and comparison between 
the control and study group outcomes yield useful information about the effect of the 
study intervention. In fact, some authors argue that studies without control groups 
seldom provide useful information on efficacy (Anonymous, 1985). 
The ideal randomised-controlled trial is also double-blinded. That is, neither the 
subject, nor the investigator measuring the outcomes, is aware which treatment arm 
the subject is in. This reduces observer bias which otherwise could lead to an 
exaggerated estimate of treatment effect (Schulz, 1996). Observer bias may occur 
because the patient or investigator expects the experimental treatment to have a 
greater effect than the control. Even objective measures may be affected 
(Anonymous, 1985). This may be an extension of the placebo effect. 
The 'John Henry' effect may occur in studies that are not blinded from the subject 
(Baumgartner, 1994). When subjects in the control group know which study arm 
they are in, they will be aware that they are not supposed to respond better than the 
experimental group. Their response maybe to try harder to outperform the 
experimental group. Alternatively, the control group may stop trying, leading to a 
reverse 'John Henry' effect. 
In some studies, double blinding is possible by use of a suitable placebo. In other 
studies a 'double-dummy' is needed, a teclmique by which the patient receives two 
drugs or interventions - one of which is experimental and the other is the control. 
However, it is rarely possible to achieve a double-blind trial in healthcare research 
(Anonymous, 1985; Newell, 1992; Schulz, 1996). A partially blinded study may be 
appropriate, with the patient blinded to treatment am1, but not the investigator. Such 
studies should be treated with caution, as observer bias is a potential hazard. 
The area in health research where the use of the randomised-controlled trial is most 
appropriate is in drug trials. In the case of a new class of drug or procedure in 
development, the randomised placebo-controlled trial is considered most appropriate. 
In fact, all new drugs that enter Phase Ill clinical studies must be compared against a 
placebo product, or the market leader ('gold standard'), in a suitable sample of 
patients (Harman, 1999). 
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A placebo is an intervention designed to simulate active medical therapy but 
believed to be ineffective for the target condition (Turner, 1994). In placebo-
controlled trials, one group of subjects (the control group) receives appropriate 
conservative therapy (mainly symptomatic relief) plus placebo, but is not allowed 
any alternative active treatment; the active group receives the drug under research. 
The outcomes of the two groups are compared. In a well-designed trial, any 
difference can be attributed to the specific effect of the active treatment (Kleijnen, 
1994). 
It is important to ensure that the study is truly placebo controlled, that is both sets of 
subjects receive a similar intervention (for example, a lactose filled capsule rather 
than one containing the active drug) to ensure that any placebo effects are taken into 
account. Otherwise these are not placebo-controlled trials but are comparing treated 
patients to untreated patients, which may not give the same results (Turner, 1994 ). 
Using a placebo in the control group controls for non-specific effects of treatment 
(placebo effect), and allows the specific effects of the active treatment to be 
measured. Failing to control for placebo effects can lead to erroneous claims of 
efficacy for any type of treatment. Placebo effects are effects that are attributable to 
factors other than the specific effect of treatment, and can include the healing setting, 
the apparent attitude of the physician and even the colour of tablets (Turner, 1994). 
The placebo effect is well recognised and has been used as a treatment modality in 
its own right (Chaput de Saintonge, 1994). 
In placebo-controlled trials, strict selection criteria must be adhered to, which usually 
exclude a large proportion of the population (children, the elderly and pregnant 
women) in an attempt to limit the effect of any non-specific effects that may be 
introduced through sampling (Anonymous, 1985). This may limit external validity. 
However, if the sample population is representative of the total population under 
investigation, then a well-designed study will have high external validity. 
37 
The Declaration of Helsinki states: 
'In any medical study, every patient - including those of a control 
group, if any - should be assured of the best proven diagnostic and 
therapeutic method.' 
(World Medical Assembly, 1989) 
It therefore follows that in conditions for which a proven therapeutic method exists, 
the new drug or therapeutic entity should be compared with the 'gold standard'. In 
such a comparator-controlled study, the researcher can ensure that all subjects 
receive active treatment of some kind. The efficacy of the new drug is therefore 
compared with the best treatment currently available. 
Comparator-controlled studies are designed to reduce the effect of independent 
variables either by use of a simple control design, as described for placebo-
controlled trials, or by crossover design. In a crossover study, one group of subjects 
receives the 'gold standard' for a fixed period of time and subsequently receives the 
alternative (experimental) treatment. There is often a 'washout' period between 
these two phases to reduce any residual effect from the first phase. Occasionally a 
second crossover phase is utilised to investigate any errors that arise due to treatment 
order. A second group of subjects (randomly assigned or matched) encounters the 
same treatment phases but the experimental treatment is administered first. This 
type of crossover design confers the benefits of limiting both intra- and inter-
individual variations without compromising patient care (Anonymous, 1985). 
Often randomised-controlled trials have limited applicability to the clinical context 
of patient management, as the results may not be applicable to patients who differ 
from the study population. As Sackett (1997) explains: 
'Randomised controlled trials carried out in specialised units by 
expert care givers, designed to determine whether an intervention 
does more good than harm under ideal conditions, cannot tell us how 
the experimental treatments will fare in general use, nor can they 
identify rare side effects.' 
(Sackett, 1 997: 1636) 
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In circumstances where controlled trials are not possible to achieve, the investigator 
must attempt to limit the effects of extraneous random variables. He must ensure 
that the measured effect was caused by the investigation intervention and not by 
anything else. 
In an attempt to adapt the concept of randomised controlled-trials to an individual 
patient's care, some authors have suggested using an 'n-of-1 trial' (Anonymous, 
1998). In these trials patients alternate between placebo and standard treatment, and 
the investigational drug. The patient and, ideally, the investigator, need to be 
blinded with regard to medication phase. Consequently, these trials are not suitable 
for drugs with characteristic side effects or those needing a long washout period. 
The patient receives the drugs in random order and the outcome of treatment is 
measured. This type of study is therefore unsuitable for conditions that are self-
limiting and drugs with a long Jag time before response is seen. The results from 
such studies may be useful for a physician to make difficult treatment decisions for 
an individual patient. However, the results are patient and drug specific and cannot 
be extrapolated to other patients or drugs. 
In some cases, the intervention is environmental (that is not made intentionally by 
the researcher; such as the effect of air pollution on rates of childhood asthma). In 
these circumstances, matched controls are used. Matched controls are subjects with 
similar baseline measures (background, family medical history, etc. - independent 
variables), but with differences in the dependent variables the researcher is interested 
in (for example, exposure to air pollution during childhood). When these differences 
are compared, matching controls for the effect of the independent variables, and 
hopefully a true representation is seen. However, if more than three characteristics 
need to be matched, it becomes extremely difficult to achieve. Also, the means of 
the two groups may be quite different before the intervention occurred, which may 
lead to type 1 or type 2 errors (Woodward, 1992). 
A single group study, where all subjects receive the same intervention, can cause the 
researcher many difficulties. Unless strict inclusion and exclusion criteria are 
enforced, the inter-individual variations can introduce a large number of dependent 
and eo-dependent variables, thus rendering any measurements meaningless. 
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However, excessively strict selection criteria may result in a group so selective that 
the conclusion, despite having unquestionable validity, carmot be applied to other 
groups under similar but subtly different circumstances. 
Single group studies are at risk of a number of threats to internal and external 
validity. In fact, one group 'one shot' studies, in which all subjects are given the 
same intervention and tested once after that intervention, have been described as 
'scientifically useless' (Kerlinger, 1992b ). In such studies, patients are not selected 
randomly and therefore there is a risk of selection bias. Even without deliberate 
selection bias, the background of the patients may cause differences in outcomes that 
are not representative of the wider population. There is no way of knowing if the 
results are due to the intervention or due to some other variable. 
In health research, however, where patient welfare is at stake if an inappropriate 
methodology is used, single group studies may be unavoidable. Such instances 
include research into conditions that are relatively rare, such as some congenital 
defects, in which suitable subject numbers would not be available to assign any to a 
control group. Another situation occurs when the current recognised method of 
treatment has no basis in evidenced-based therapy but there is no clearly defined 
alternative and the use of a placebo situation would be unethical. 
Pre-test/post-test studies with the same subject are often used to try to overcome 
some of the limitations of single group studies. These are slightly better than 'one 
shot' studies because the majority of independent variables associated with the 
subjects' characteristics are controlled. However, these trials still introduce risks to 
validity, namely, maturation, measurement, testing and regression to the mean 
(Baumgartner, 1992). The problem is not that these factors may operate, but that 
without strict controls we do not know if they have operated or the extent to which 
they affect the final measures (Kerlinger, 1992b ). 
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Chapter 3: Research methodology 
3a: Research design and rationale 
Introduction 
This study was carried out in an attempt to assess the effect and appropriateness of 
pharmacist introduced interventions for subjects who have demonstrated risk of non-
compliance. It was intended to use the results of the study in order to discover 
whether all elderly patients require an assessment of compliance when in hospital, or 
whether generalisations for sub-groups can be made. It was hoped that any changes 
to current levels of service required in order to implement the conclusions of the 
study would be identified. As changes to service levels require resources it was 
essential to determine whether the hospital pharmacist is the best health care team 
member to undertake the activities identified in this project. Ethics committee 
approval was sought and gained to carry out the research within the hospital. A copy 
of the letter can be found in Appendix I. 
In designing this research project, it was necessary to undergo a number of stages: 
Firstly a suitable client group needed to be identified. Secondly, a suitable research 
tool needed to be designed to assess levels of compliance and non-compliance. In 
order to achieve this it was necessary to identify the various ways compliance can be 
measured. Once this was achieved, it was necessary to describe how a valid measure 
of compliance can be used to improve patient care and to use this to design a 
practical tool to measure an improvement in patient care. 
It was necessary in designing this tool to identify potential problems with 
compliance and decide on the most suitable interventions to apply in order to address 
these problems. A method of assessing the response to these interventions was 
required. It was also necessary to attempt to ascertain whether interventions 
instigated by the hospital pharmacist were continued in the community. The 
resulting procedure then had to be applied to a sufficient sample size in order to 
assure statistical significance. 
41 
Monitoring compliance 
In order to measure whether a hospital pharmacist can improve patient compliance, 
compliance must be measured. The various options available to assess compliance 
have been discussed during the literature review. In this section, consideration will 
be given to those which were most appropriate for use in the current research 
protocol. As has already been described, assessing absolute compliance is almost 
impossible (Van Berge Henegouwen, 1999). 
Various measures have been used to assess compliance in prevwus studies 
(Anonymous, 1991 b; Aronson, 1992; Beardon, 1993; Col, 1990; Eisen, 1990; 
Grymonpre, 1998; Hughes, 1998; Lowe, 1995; Lorenc, 1993; Moriskey, 1986; 
Parkin, 1976; Smith, 1983; Sweeny, 1989). These have included pill counts, 
incorporating recording devices into the lids of containers, measuring prescription 
renewal intervals, measuring blood levels of drugs or inert markers, assessing 
therapeutic control and self-report. The limitations of each of these have been 
discussed earlier (see Chapter 2). 
Not all of these measures would be appropriate for the current study. The first three 
measures would require close collaboration from the subjects' general practitioners 
and community pharmacists. Detailed knowledge of prescriptions dispensed prior to 
admission would be required, information which would be difficult to access as 
contacting 23 surgeries and 29 community pharmacists would be required. 
Measuring blood levels is not possible for all drugs and even if it were possible it 
would not feasible for the vast array of medicines prescribed to the study population. 
Similarly biologic markers would not be feasible as each subject would require a 
separate marker for each drug taken because patients do not comply consistently 
with all prescribed medicines. In addition, although some of these subjects would 
have suffered deterioration of therapeutic control because of non-compliance, we 
could not assume that all deterioration was thus caused. 
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The final option for assessing compliance is self report. This is the simplest tool to 
use, can be used in all settings and can be carried out with no prior arrangements 
being made. However, the responses require careful assessment to avoid observer 
bias and to identify when a subject is giving the answer they think the investigator 
wants to hear. Self report can be qualitative - a description of why and when 
problems occur and what the subject does in order to rectify them, or quantitative -
an estimate of how many doses the subject takes each day. 
It has been shown that the way questions are worded (Aronson, 1992) and the 
relationship between the questioner and the subject can affect the results (Paes, 
1998). This can be deliberate with the subject telling the investigator what they 
think he wants to hear (Col, 1990; Hughes, 1998) in order to avoid being 
reprimanded, or an involuntary response to a leading question. 
If a patient denies non-compliance, no conclusion can be made, however, if a patient 
admits to a problem a solution can be attempted. Also, self report cannot reliably 
distinguish between a patient who sometimes forgets and one who regularly forgets 
(Paes, 1990). In one study (Grymonpre, 1998) there was no difference in mean 
percentage compliance when measured by self report or refill data and both gave a 
higher percentage compliance than pill counts. 
The limitations of self report can be great, however the strengths in the current 
situation are many. Self-report will, by necessity, describe actions prior to 
administration and not during the current stay. It does not rely on any prior 
information being known and if a standard questionnaire is used, allows comparison 
of different subjects and of the same subject before and after an intervention. 
Self-report alone cannot accurately assess absolute compliance, however, if worded 
sensitively such a questionnaire would be able to identify possible risk factors which 
may cause non-compliance. Absolute compliance is generally not necessary to know 
for an individual but their risk of non-compliance would be useful to know. An 
appraisal of these risk factors could identify those subjects at greatest risk of non-
compliance and indicate the type of intervention required to improve compliance. 
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Other measures such as pill counts only measure one type of non-compliance. In a 
carefully worded questionnaire, it is possible to obtain information on all causes of 
non-compliance. It was therefore decided that the method of measuring compliance 
utilised in this study was to be a questionnaire. The design of this questionnaire will 
be discussed later in Chapter 3b. 
Client group & sample size 
The client group was chosen to be elderly patients who were admitted as acute 
medical in-patients to the two acute Medicine for the Elderly wards at hospital NT. 
All patients were included except those who fall into the following categories: living 
independently but not self administering; resident in residential or nursing 
accommodation; included in previous pilot projects. The justification for these 
inclusion and exclusion criteria is discussed below. Patients were included with any 
medical or psychological condition except those which would make them unsuitable 
for self-medicating at home. 
The atm of the study was to investigate the role of the hospital pharmacist in 
improving compliance behaviour following discharge; therefore, the client group 
must include hospital patients. Many patients have contact with a hospital as day 
cases, out-patients or as in-patients. However, it is only the latter for whom there is 
adequate opportunity for a pharmacist to have input into their total care. They 
generally remain in hospital for a minimum of2-3 days, which allows sufficient time 
for a pharmacist to assess their therapy and interview them during the daily clinical 
pharmacy visit. This also allows time to remedy some of the identified problems 
before discharge. 
Out-patients may be gtven a prescription to present at the outpatient pharmacy. 
However, during busy periods the pharmacist may only be able to spend a few 
minutes with each patient, which may not be sufficient to elucidate any important 
problems. Patients also may not be willing to spend extra time with the pharmacist if 
this service was offered because of the long waits which they have usually 
experienced. Also, patients often do not bring all the information which would be 
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required to assess compliance behaviour to these clinic appointments. For these 
reasons, this group would not be a suitable client group. 
Patients who visit the hospital as day cases would be a more appropriate client 
group. They potentially would have more time to be interviewed by a pharmacist 
but at hospital NT there is currently no opportunity for a pharmacist to visit these 
patients. Also, these patients are generally admitted for surgical procedures and 
therefore may be unavailable for interview for a large proportion of their hospital 
stay. 
There is one disadvantage to using in-patients as the client group; in-patients do not 
generally self medicate whilst they are in hospital. This presents the difficulty of 
measuring compliance in an attificial situation. On wards where self-medication is 
offered, this would still be an artificial scenario as not all in-patients are suitable for 
self-medication and the nurses could therefore unintentionally provide prompting. 
However, the situation is the same in most day case wards, and out-patients are 
unlikely to need to take their medication at the precise time they present at the 
pharmacy. This therefore is a relative disadvantage of studying compliance in the 
hospital environment rather than one specific to in-patient care. 
In-patients on an acute medical ward would make an appropriate client group for a 
number of reasons. Firstly, in a surgical ward the surgeons usually concentrate on 
the surgical procedure, wound healing and subsequent rehabilitation. Medication is 
not usually altered except for the possible addition of antibiotics, analgesics, 
laxatives and anti-inflammatory drugs on discharge. On acute medical wards often a 
change in medication is the main intervention made by the physician. Many studies 
have shown that a change in drug treatment after a stay in hospital can significantly 
affect compliance (Binyon, 1994; Cochrane, 1982; Parkin, 1976; Royal College of 
Physicians Working Party, 1997). The need for interventions to improve compliance 
is therefore greater on medical wards. 
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Another problem with surgical patients is that the length of stay can be variable, 
ranging from an overnight stay for minor procedures to several months for some 
orthopaedic operations. On acute medical wards, the length of stay is usually in the 
range 2-14 days. This is long enough to be assessed by the pharmacist but not too 
long for the patient to become institutionalised. 
As has been shown previously, the elderly as a whole have greater problems with 
compliance and therefore have most to gain from any intervention. The age group 
70-85 was therefore chosen as the age range for the client group. The lower end of 
the age bracket was chosen as most authorities class this as the lower age range for 
categorisation as elderly (Royal College of Physicians Working Party 1997). The 
upper age range was chosen because the majority of patients over 85 do not self-
medicate, either because they live in nursing or residential accommodation, or have 
carers giving them their medication (Dryden, 1999). This group therefore has less 
chance of benefiting from a pharmacist's intervention. 
Sample size 
The study period was chosen to cover an eight-month period between October 1999 
and June 2000. The sample size required to have sufficient power to show a benefit 
was calculated to be 113 patients. This was calculated from previous data, supplied 
by medical records, in the following way. The study wards held 26 acute medical 
patients with an average length of stay of 14 days. This would give a total of 416 
patients admitted over the eight-month period. On the study wards two day case 
patients were admitted each week and would not be included (see above) leaving a 
total of 352 patients. Due to the case mix of the patients admitted to the study wards 
10% of patients lie outside the 70-85 age range and 50% of the study population 
would be residing in residential or nursing accommodation and therefore not suitable 
for inclusion into the study. This leaves a population size of 160 patients. Using 
standard tables for calculating sample sizes (Bland, 1995) a sample size of 113 
would give a proportion to within ± 0.05 of population proportion at 95 percent 
confidence interval. 
46 
Because of the large sample size compared to the population size, it was decided that 
random sampling would not provide sufficient data. A variation on systematic 
sampling was therefore employed (Kerlinger, 1992a). All patients admitted to the 
study wards were identified. Of these, all patients who met the criteria for interview 
(see below) were identified and alternate patients (chronologically by date of 
admission to the study wards) were included in the study. It has been estimated 
before that between 20-50% of elderly patients have compliance problems 
(Misselbrook, 1998c), a sample size of 113 should therefore identify 23-29 patients 
with compliance problems. 
Inclusion and exclusion criteria 
The inclusion and exclusion criteria can be separated into two stages: those subjects 
suitable for investigation and those subsequently found suitable for follow-up and 
inclusion in the final results. These are shown in Table 3i. 
The reason for choice of age group and ward has been discussed above. The reason 
for the arbitrary time limit of remaining on either ward for three or more days was 
two-fold. Firstly, acutely ill elderly patients often have acute confusion which 
resolves relatively quickly, hence subjects were assessed on their usual ability to 
comply and not the artificial level on admission. Secondly, some interventions may 
take 24 hours or more to apply. As the pharmacist may not see the patient until the 
second day of admission, it may take until the third day to implement any 
interventions. 
Subjects who were not self medicating at home were excluded because in these cases 
compliance with the doctors wishes was not dependant on the patient's ability but on 
that of the carer, the same was applicable to subjects in nursing or residential homes. 
Any pharn1aceutical input would not have had any impact on the outcome after 
discharge. Also, measuring the compliance of such subjects would be irrelevant to 
patient care and would not be representative. 
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Table 3i: The inclusion and exclusion criteria for the study 
SUIT ABILITY FOR INTERVIEW 
Inclusion criteria Exclusion criteria 
• Age 70-85 • Living in nursing or residential 
Cl Admitted to one of two acute accommodation 
Medicine for the Elderly wards at • Included in pilot phase 
Hospital NT • Admitted to hospital more than ten 
8 Remaining on either ward for 3 days days prior to transfer to study wards 
or more f) Having any condition that would 
8 All admissions who fit the above render self-administration 
criteria except those who fit the impracticable e.g., end stage 
exclusion criteria Alzheimer's, massive CVA, paralysis 
or lack of use of both hands, AMT 
<5/10, etc. 
SUITABILITY FOR FOLLOW-UP 
Inclusion criteria Exclusion criteria 
• Meets criteria for suitability for • Not self-administering medication at 
interview home 
• Able to understand and answer • Completely deaf or do not understand 
compliance questionnaire written or spoken English 
• Have an identified compliance • Due to religious or other beliefs 
problem and agree to further follow-up refuses to take western medicines 
• Unavailable for interview at 10-14 
days post discharge 
• Discharged to short stay residential 
care before going home 
• Not prescribed any medication 
• No compliance problems (total score 2: 
40) 
• Intervention not administered by 
pharmacist or no intervention possible 
• Patients deemed unsafe to self-
administer medication as a result of 
applying the baseline questionnaire. 
The chosen research tool was an investigator lead questionnaire. Subjects were 
therefore only included if they had a sufficient understanding of spoken words and 
showed adequate ability to understand and answer the questions asked. As 
compliance was being assessed primarily on the answers to a number of questions, 
lack of understanding or confabulation would cause unreliability in the results. 
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Excluding completely deaf patients and those who did not understand written or 
spoken English may exclude a particularly needy group; however, resources for 
interpreters were not available during this study and the responses of a subject who 
did not completely understand the question could not be assessed as reliable. 
Written questionnaires could have been given to completely deaf subjects in order to 
assess compliance risk, however, this introduces all the complications of written 
questionnaires. Also, a number of supplementary questions were often required to 
prompt subjects with partial memory and to help decide on the most appropriate 
intervention. This may not have been possible for a significant number of 
completely deaf subjects. Excluding these subjects was neither desirable nor strictly 
ethical on the basis of pharmaceutical need, but was expedient in the carrying out of 
the current study. 
As the aim of the study was to investigate the effect a hospital pharmacist might 
have on compliance, subjects were only followed-up if they had an identifiable 
problem with compliance. If a subject had minor or no problems with compliance 
there would not be any need to improve their compliance and also it would be very 
difficult to measure any improvement. 
Also excluded were any subjects that had been enrolled into previous pilot projects. 
Bias may have been introduced by enrolling these subjects as they had already had 
the input of a hospital pharmacist. This may have either changed their activity at 
home or may have changed the answers given to questions. In addition, they would 
have been known to the investigator, which could have introduced investigator bias. 
Subjects who had been in previous wards for longer than 12 days prior to transfer to 
the study wards were excluded. This was because the interview could take place 
more than a fortnight after admission to hospital, long enough for an elderly patient 
with good compliance to forget how they had managed with their medication at 
home and might result in inaccurate answers to questions. Elderly patients rapidly 
become institutionalised in hospital causing enors in assessment of compliance 
ability (Hodkinson, 1981 ). Also, it is arguable that patients who have been in 
hospital for a long time may take longer than the study period (three months) to 
return to their pre-admission state. There appears to be no evidence of whether this 
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is the case but this group was excluded on the basis that such changes in ability or 
behaviour may also be shorter lived and hence introducing the risk of erroneously 
attributing any improvement to the intervention made by the pharmacist. 
Subjects who were not prescribed any medication prior to admission or on discharge 
were excluded from the study. Compliance is only an issue with subjects prescribed 
medication and any assessment method would require a subject to have taken 
medication. An assessment of compliance problems was therefore not possible for 
this sub-group of subjects. 
Subjects who were lost to follow-up or unavailable for interview 10-14 days post 
discharge were excluded. This interview was designed to identify any problems the 
patient encountered in continuing interventions after discharge. Interventions that 
were in place within the first fortnight post-discharge were likely to be continued. 
Those not initiated immediately were unlikely to be started before the final 
reassessment. 
Subjects refusing entry into the study 
Refusing follow-up 
The proportion of males and females refusing entry into the study were the same 
(24%) but the reasons for refusal were subtly different. Whereas women were 
generally worried about the perceived risks involved in being followed-up after 
discharge and the possible inconvenience, the men were more likely to give the 
reason that they were unlikely to benefit from any follow-up, and neither was anyone 
else. Although the figures are too small to be significant this may reflect either a 
general fear of strangers in elderly women or be indicative of a lack of interest in 
medication in men. 
For example, Mrs. LG (37LG061012), Mrs. ML (39ML090414) and Mrs. MM 
(37MM020233) all accepted the intervention offered. However, Mrs. LG refused to 
sign the consent form because she 'wanted a quiet life' and Mrs. ML refused because 
she didn't want bothering at home. Mrs. MM refused to sign the consent form 
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because she didn't want bothering at home and was obviously nervous of inviting the 
investigator into her house. 
This fear of asking someone into the home or not wanting to be bothered after 
discharge may reflect a desire to retain independence. In addition, although not 
usually vocalised by the subjects, a fear of being checked up on may also have 
caused this reluctance. When consent was requested, an explanation was given that 
the suitability of the interventions was being investigated. However, some element 
of assessment of the subject was involved and they may have felt they were being 
examined. Subjects were advised that a friend or relative was welcome to be present 
at the follow-up interview and in fact both Mr. LO (37L0090524) and Mrs. GM 
(39GM031 0 15) had one of their children in attendance at this interview. Although 
every attempt was made to interview the subjects at a hospital appointment, this 
would not always have been possible. In finality, however, only two subjects were 
followed up after discharge, one by interview at home and one at a hospital 
outpatient appointment. 
It was difficult to persuade the male subjects to agree to sign the consent form, as 
most did not see any benefit in signing. For example, Mr. EO (39ED070821 ), Mr. 
JT (39JT060219) and Mr. GR (39GR240 1 07) all accepted the interventions offered. 
However, Mr. ED refused to sign the consent form because he didn't want bothering 
at home. Mr. JT refused because he didn't want to get involved, as he did not see 
any possible benefit. Mr. GR refused to sign the consent form because he did not see 
any possible benefit to him or others. The importance of compliance was not always 
clearly understood by these subjects and they frequently denied having any problems 
with non-compliance and therefore could not perceive how they might benefit or 
how anyone else could benefit from the study. 
Other compliance studies have shown a lower rate of refusal of entry into follow-up 
studies. In one study (Kravitz, 1996) 86% of subjects agreed to follow-up and in 
another discharge follow-up study (Parkin, 1976) 93% agreed to be enrolled. In 
neither paper was any reason for refusal given. Subjects in both groups included 
mainly younger patients. 
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Eisen et al (1990) identified 756 patients who fitted their inclusion criteria, however, 
only 192 agreed to participate, a refusal rate of 75%. Although these subjects were 
not all elderly (69% in one arm were 65 years of age or under) and only represented 
patients with one condition (hypertension) it is representative of some of the 
difficulties involved in recruitment. In this study 48% of refusing subjects were 'not 
interested' in taking part in the study and 34% could not commit to keeping to the 
terms of follow-up (six monthly appointments). The subjects refusing entry were not 
divided into male and female for the purposes of describing reason for refusal and so 
this cannot be compared. Interestingly a similar but smaller study by Lorenc et al 
(1993) reported a one hundred percent agreement rate for enrolment into the study. 
However, this was qualified by the statement 'To the author's knowledge all patients 
approached at the surgery agreed to be interviewed'. It is possible that refusing 
patients were not reported. 
Refusing interventions 
A small number of subjects in the current study refused all interventions. It was not 
always apparent why although it may be related to their desired level of control. A 
subject who is afraid of losing their independence may refuse assistance, if the 
intervention is perceived as diminishing their control rather than enhancing their 
ability to remain in control. 
In order to help with compliance, Mrs. SW (39SW080425) filled her own Medidos® 
each week. She was found to be at moderate risk of non-compliance however, she 
refused all offers of help for her poor manual dexterity because she did not feel that 
she was in need of any input. Similarly, Mrs. ID (3910151114) lived alone but 
receive a visit from a home carer three times a day. This assistance did not involve 
reminders of when to take her medication. She was found to be at high risk of non-
compliance but she was independent and was unwilling to accept any new 
intervention. Mrs. JR (39JR240413) also lived, alone but received support from her 
daughters. She was found to be at moderate risk of non-compliance however, she 
refused all interventions. 
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A lack of willingness to accept an intervention may also reflect the lack of 
importance the subject assigns to complying with medicines. This may be caused by 
a number of factors, but if this results in complying being assigned a low priority 
then the subject may not bother trying to take his medicines at the correct time. An 
intervention may therefore be viewed as an imposition attempting to rectify a 
problem that is inconsequential. This was the case for Mr. JP (3 7 JP231209), who 
was found to be at moderate risk of non-compliance but refused all interventions as 
he was not interested in trying to take his medication correctly and could not see any 
possible benefit. 
There is an argument that diagnostic and evidence based interventions should be 
viewed as a treatment necessity and not at the whim of patient choice. They should 
be seen as part of the treatment and not an afterthought. However, if they are a 
treatment modality they must be subject to the constraints of concordance and 
therefore patient choice is once more important. 
All healthcare studies must be undertaken without undue pressure on the subjects to 
agree to involvement and after serious consideration. In research using healthy 
volunteers, recruitment can continue until the required numbers are reached. 
However, if benefit to patients is of interest, authentic patients must be used as 
subjects and be given free and fair opportunity to refuse entry. It is unethical to 
coerce subjects or offer inducements that may bias the findings. It is therefore 
possible in any similar study to fail to enrol sufficient subjects. 
Subjects enrolled for follow-up 
Twenty-four subjects were deemed suitable for enrolment into the study as originally 
designed. However, due to loss of subjects, due to death, early discharge or not self-
medicating, and refusals of entry, only seven subjects were enrolled and only five 
were followed up after discharge. Only two were successfully contacted at three 
months. 
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Subjects lost to follow-up 
Two subjects were not available for follow-up at two weeks despite many attempts 
to contact them. Both subjects lived alone but had different levels of social support. 
Both, in common with most of the subjects interviewed, only visited one pharmacy 
to get their prescriptions dispensed. They were not significantly different to any of 
the other subjects interviewed except Mrs. EW (39EW130709), who did want to be 
more involved in decisions about her treatment. Both were happy to sign the consent 
form and no obvious reason for their unavailability at two weeks was found. 
Mrs. DR (39DR150919) 
o 81 year old female who had been admitted with a chest infection and fall. 
She lived alone in a warden controlled flat and with home carers visiting 
three times a day. This support did not include reminders on when to take 
her medication. She always got her prescriptions dispensed from the same 
pharmacy. 
o Mrs. DR reported that her GP always gave her sufficient information 
about her medication but she had not so far been given any information 
whilst she was in hospital. She reported being happy with her level of 
involvement in making decisions about her treatment. 
o Despite having an AMT of 9/10 she was found to be at moderate risk of 
non-compliance because she was able to explain what she was taking and 
the reason why only with some difficulty and some omissions, she was 
unsure if her medicines were effective and she was unable open child 
resistant closures or remove tablets from blister packs. Because of 
rheumatoid arthritis, she could not manage to remove screw caps from 
small bottles. 
e She agreed to receive a number of interventions to improve her 
compliance, namely, a compliance sheet, counselling, large bottles and 
avoidance of blister packs. She consented to be followed up at home but a 
number of unsuccessful attempts were made to contact her after discharge. 
Mrs. EW (39EW130709) 
o 91 year old female who had been admitted with falls. She lived alone and 
had refused help in the past; she was usually fully independent. She 
always got her prescriptions dispensed from the same pharmacy. 
o Mrs. EW reported that her GP only gave her information about her 
medication when prescribing a new drug and she had not so far been given 
any information whilst she was in hospital. She reported wanting to be 
more involved in making decisions about her treatment. 
e She was able to explain satisfactorily what she was taking and the reason 
why. 
o Despite an AMT of 1 011 0 she was found to be at moderate risk of non-
compliance because she was unsure whether she still needed some of the 
medication she was prescribed although she thought they were working. 
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She also wanted more involvement in making decisions about her 
treatment. 
o Mrs. EW agreed to receive a number of interventions to improve her 
compliance, namely a concordant interview and compliance sheet. She 
agreed to be followed up at home but a number of unsuccessful attempts 
were made to contact her after discharge. 
Key issues from 1st follow-up 
Five subjects were interviewed at two weeks post discharge and Table 3ii shows the 
data obtained from these subjects. 
Table 3ii: First follow-up 
Mrs. MC Mrs. MM Mrs.DW Mrs. GM Mr.LO 
Prescription from GP Yes Yes Yes Yes Yes 
Prescription changed Yes Yes Yes Yes Yes 
since discharge 
Pharmacy changed No No No No No 
Interventions continued Yes Yes Yes Yes No 
Interventions helEed Yes Yes Yes Yes Unsure 
All subjects had had changes to their prescription in the intervening two weeks but 
had continued to get their prescriptions from the same Pharmacy. All subjects had 
remembered to get a new prescription within a week of discharge, as their discharge 
medication would have run out after one week. 
Four subjects had received the same interventions when a new prescription had been 
dispensed. These included continuing on a new inhaler, updating the compliance 
reminder chart, counselling on medication, providing large print labels and giving 
screw caps on medicine bottles. For Mr. LO (37L0090524) neither intervention had 
been continued by the community phannacy (updating reminder sheet and 
counselling on medication) and this subject was not sure whether they would help in 
improving compliance. The time taken to follow these subjects up was on average 
eleven minutes. 
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Three subjects were successfully contacted at two weeks but subsequent follow-up 
was not possible. All three lived alone but had some limited help in the form of 
daily visits. Interestingly, one of these subjects, Mrs. DW (39DW070422), used two 
different pharmacies for her prescriptions. This may indicate the fact that she had 
experienced a good service from both of these pharmacies and therefore could not 
choose between them, or she may not have felt that she would benefit from only 
visiting one pharmacy and visited whichever one was most convenient at the time. 
Mrs. DW (39DW070422) 
• 77 year old female who had been admitted with chest pain. She lived 
alone but was mobile about the house with her daughter helping out 
occasionally. She had two phannacies at which she usually got her 
prescriptions dispensed. 
• Mrs. DW reported that her GP always gave her sufficient information 
about her medication and she had so far been given appropriate 
information whilst she was in hospital; she reported being happy with her 
level of involvement in making decisions about her treatment. 
e She was able to explain satisfactorily what she was taking and the reason 
why, despite a complicated regime. 
• Despite an AMT of 9/10, she was found to be at moderate risk of non-
compliance because she was unable to read standard labels and had a 
complicated treatment regime (11 drugs on admission). 
• Mrs. DW agreed to receive a number of interventions to improve her 
compliance, namely, counselling, a compliance chart and large print 
labels. She agreed to be followed up at home but although she was 
successfully contacted at two weeks a number of unsuccessful attempts 
were made to contact her at three months post discharge. 
Mrs. MM (37MM210420) 
• 80 year old female who had been admitted with an exacerbation of chronic 
obstructive pulmonary disease. She lived alone with a home carer only 
providing assistance with shopping. She always got her prescriptions 
dispensed at the same pharmacy. 
• Mrs. MM reported that her GP never gave her any information about her 
medication and she had not so far been given any information whilst she 
was in hospital, however, she reported not wanting to be involved in 
making decisions about her treatment. 
• She was able to explain satisfactorily what she was taking and the reason 
why, despite having a complicated regime. 
• Despite an AMT of 10/10 she was found to be at high risk of non-
compliance because she was unsure if she was happy with her medication 
or whether it was working, she had an inappropriate inhaler, which she 
thought was not working, as she was still breathless and she had a 
complicated treatment regime (five drugs on admission). 
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o Mrs. MM agreed to receive a number of interventions to improve her 
compliance, namely, counselling, a compliance sheet and changing her 
inhaler device. She agreed to be followed up at home. Although she was 
successfully contacted at two weeks, she was later admitted to a nursing 
home before her final follow-up. 
Unfortunately, Mrs. MM (37MM210420) was admitted to a nursing home, which 
caused her exclusion from the study. She was found to be at high risk of non-
compliance and this may be an indicator of a patient's ability to cope with the other 
activities of daily living. However, other subjects found to be at high risk of non-
compliance have successfully returned home with home carers providing support and 
so this event may simply reflect deterioration in her general medical status. 
Mrs. MC (39MC080527) 
~ 72 year old female who had been admitted with decreased mobility. She 
lived alone but used a pendent alarm when necessary, with home carers 
visiting three times a day. She always got her prescriptions dispensed at 
the same pharmacy. 
o Mrs. MC reported that her GP only gave her information about her 
medication when she was prescribed a new drug and she was unsure 
whether she had been given any information whilst she was in hospital; 
however she reported being happy with her level of involvement in 
making decisions about her treatment. 
e She was admitted taking seven different medicines with four different 
frequencies but she was able to explain satisfactorily what she was taking 
and the reason why. 
e Mrs. MC was fairly happy with her medicines but was not sure if she 
needed a change in her Parkinson's Disease treatment; she also did not 
think her antidepressant was working. Despite this she did not want to 
change it and refused to have her sleeping tablets reduced, despite 
understanding the risk of dependence. 
~ Despite an AMT of 9/10, she was found to be at moderate risk of non-
compliance because of a complicated treatment regime which she was 
unhappy with or whether it was effective. 
® Mrs. MC agreed to receive a number of interventions to improve her 
compliance, namely, a compliance sheet and counselling. She agreed to 
be followed up at home. Although she was successfully contacted at two 
weeks, she was later readmitted to hospital before her final follow-up. 
Most of the subjects agreeing to follow-up were satisfied with the level of 
involvement they generally had in the decision making process with regard to 
medical treatment. Their willingness to take part in the study was therefore not 
related to a desire to have greater involvement. An interesting common factor for all 
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subjects who agreed to sign a consent form is that they all had a Abbreviated Mental 
Test Score of greater than the average for the sample. Each had a score of 9 or 
above. This may have meant that they had a greater understanding of what was 
going to be involved after discharge, possibly related to an increased ability to 
understand the information provided to inform the subjects of what would be 
involved in the post discharge follow-up. The consent form (see Appendix I) was 
designed to be easily read and had a Flesch Reading Ease Score of 74.4 (80% of 
people can read). All subjects who refused entry claimed to have understood the 
information and an opportunity was given to allow discussion and questioning to 
allay any fears. However, subjects who do not fully understand what is involved in a 
study will be less likely to volunteer. 
The fact that each of these subjects had a high AMT but were at moderate risk of 
non-compliance also demonstrates the limitations of using the AMT to exclude 
patients with no compliance problem. Confusion level and memory affect 
compliance. However, compliance can also be affected by knowledge of medicines, 
which depends on concordance and also the patient's interest in and attitude to their 
medication. Physical ability to access dosage forms and packaging can also affect 
compliance. None of these factors are included in the AMT questionnaire and 
therefore cannot be predicted by it. 
Key issues from 2nd follow-up 
Two subjects were successfully enrolled into the study and followed up at three 
months. These subjects, one male and one female had no obvious characteristics that 
would allow one to predict that these would complete the study. 
Mrs. GM (39GM031015) 
• 84 year old female who had been admitted with congestive heart failure. 
She lived alone but her son reminded her when to take her medicines. She 
was unable to name the pharmacy where she got her prescriptions 
dispensed. 
• Mrs. GM reported that her GP never gave her any information about her 
medication and she had not so far been given any information whilst she 
was in hospital. However, she reported being happy with her level of 
involvement in making decisions about her treatment. 
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o She was able to explain satisfactorily what she was taking and the reason 
why. 
o Despite an AMT of 1 011 0 she was found to be at high risk of non-
compliance because she was unable open child resistant closures or 
remove tablets from blister packs; she also had difficulty using her aerosol 
inhaler, both in actuating the inhaler and co-ordinating her breathing with 
pressing the canister. She also was unsure if she still required her 
medication and felt it was not working. She also had a complicated 
regime (8 dmgs on admission). 
o Mrs. GM agreed to receive a number of interventions to improve her 
compliance, namely, counselling, changing inhaler device, providing 
screw caps and avoiding blisters. She agreed to be followed up at home 
and successfully completed all phases of the study. 
Mr. LO (37L0090524) 
• 76 year old male who had been admitted with a fall. He lived alone with 
no assistance. He always got his prescriptions dispensed at the same 
pharmacy. 
• Mr. LO reported that his GP always gave him sufficient information about 
his medication and he had so far been given sufficient information whilst 
he was in hospital. He reported being happy with his level of involvement 
in making decisions about his treatment. 
Ql He was able to explain satisfactorily what he was taking and the reason 
why. He was admitted taking three different medicines, but was 
discharged with nine; various doses were altered and he was prescribed 
new medication for constipation, pain, osteoporosis prophylaxis, epilepsy 
and insomnia. 
~ Despite an AMT of 10/10 he was found to be at moderate risk of non-
compliance because he admitted to occasionally forgetting to take his 
medicines and had no special method of remembering when to take them. 
He also admitted that sometimes, when he felt better and thought he no 
longer needed his medication, he stopped taking it without informing his 
GP. He also had a complicated regime. 
• Mr. LO agreed to receive a number of interventions to improve his 
compliance, namely, a compliance chart and counselling. He agreed to be 
followed up at home and he successfully completed all phases of the 
study. 
Both subjects had had further changes to their prescription but were continuing with 
the same Pharmacy. The interventions made for Mrs. GM were continued and were 
still found helpful. Mr. LO still had not had his interventions continued but he now 
felt that counselling had been helpful and asked to be reminded of what his 
medication was for and when was best to take it. 
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The home circumstances of both subjects had not changed and there had been no 
change in their AMT. Approximately 30 minutes was spent reassessing the 
compliance risk of these two subjects. The results of the compliance questionnaire 
are shown in Table 3iii. Individual categories are scored out of five and the total is a 
mark out of 45. A mark of four or five for an individual category indicates that the 
subject is at low risk of non-compliance from that risk factor. 
Mrs. GM showed an improvement in all areas of compliance risk and the overall risk 
of non-compliance reduced from high to moderate risk. At follow-up she was happy 
with her medication and felt that her new medicines were effective. The 
interventions made to overcome her physical impairment were effective and she was 
no longer at risk from her poor manual dexterity. Although still happy with the 
information supplied she reported not being told very much about her medicines by 
her general practitioner and her treatment regime was still very complicated. It is 
interesting that almost all improvements were due to the action of her community 
pharmacist following the letter sent on discharge. 
Table 3iii: Second follow-up 
Mrs. GM Mr.LO 
Baseline Fo1Iow-u~ Baseline 
Storage and administration 5 5 3 
Understanding 5 5 5 
Satisfaction 3 5 4 
Drug efficacy 3 4 5 
Adverse drug reactions 5 5 5 
Information supplied 2 3 5 
Physical problems 1 4 5 
Disease related problems 5 5 5 
ComElexit~ of regime 0 0 0 
Total 29 36 37 
Key: 4-5 =Minimal or no compliance risk due to this factor 
:::::;;3 = Compliance risk due to this factor 
Fo1Iow-u~ 
4 
5 
3 
2 
5 
5 
1 
5 
0 
30 
Mr. LO showed a deterioration of compliance risk but remained within the moderate 
risk bracket. The main problem was deterioration in his eyesight, which accounted 
for the physical problems and resulted in the need for large print labels. The second 
biggest problem was ineffectiveness of his medication. Again this appeared to stem 
from deterioration in his condition and an appointment had been made with a doctor 
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to identify the need for a new dose. Neither of these could have been anticipated 
before discharge. It is possible to assume that had these problems not occurred his 
non-compliance risk score might not have reduced. However, Mr. LO did have a 
slight improvement in his method of administration in that he now appeared to have 
some method of remembering to take his medicines and was less likely to stop them 
without advising his doctor. 
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Questionnaire design 
As has already been discussed, it was decided after a literature search that 
compliance risk (rather than absolute compliance rate) would be measured by means 
of self-report. To ensure that responses were consistent an investigator administered 
questionnaire was decided upon as the method of choice. 
A number of other options were available in carrying out self report of compliance. 
A qualitative approach could be used, asking subjects to answer general questions 
regarding whether they remember to take their medicines and what problems they 
encounter. This could be administered by means of a written questionnaire or a 
structured interview. A written questionnaire of this type relies on the subject 
volunteering information of a variety that can be used and compared. We have 
already described how patients are reluctant to volunteer information on non-
compliance, often believing that health professionals wish to hear that they are 
complying. If a patient fails to admit to non-compliance, nothing can be said about 
the risk that they are under. 
A semi-structured interview would be more useful as the investigator can guide the 
subject to talk about the issues which are appropriate but allow them to volunteer 
information that is important to them. Semi-structured interviews are useful tools for 
defining the main areas of a study and can yield a large amount of information. 
Because of the open ended nature of the questions used, the data obtained can be 
extremely difficult to analyse and requires specialised techniques which are time 
consuming to administer. The information gleaned from such an interview is mainly 
of a general nature, describing issues that are important and problems that patients 
may have. They are less useful when trying to quickly diagnose individual problems 
and find a solution, and they are not very suitable for large samples. It is also 
difficult to apportion causal relationships between changes in responses and 
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interventions made. For this purpose, quantitative methods are required in the form 
of a carefully designed questionnaire. 
Questionnaires can also be subject or investigator-administered. The former can be 
used to provide large amounts of information cheaply but there is a risk of low rate 
of return, often as low as 40 - 50% (Kerlinger, 1992c ). There is also the problem of 
wide variations in subjects' comprehension limiting the range of questions that can 
be asked, and the risk that different subjects will interpret a particular question in 
different ways, limiting the ability to compare answers between subjects. Re-
applying self-administered questionnaires is also less reliable as the subject may be 
less honest, sometimes unconsciously, with the second questionnaire, giving the 
'correct' answers if they believe they can identify where changes are required. 
Anonymity of response can improve the candour with which subjects reply to 
questions, but as the answers in this study need to be applied to make specific 
interventions, anonymity was not possible. 
Investigator lead questimmaires are easier to administer, as the investigator can 
anticipate difficulties and ensure that the subject understands the questions. These 
yield a very high rate of return as only subjects who refuse to be interviewed are 
missed. It is important to ensure that the information asked of each subject is the 
same if comparison between subjects is to be valid and to reduce the risk of 
investigator bias. However, the investigator can try to ensure that understanding is 
of a minimum level and does not bias the results. Long questionnaires can be very 
time consuming to apply and so they need to obtain responses as efficiently as 
possible. In addition, lengthy questionnaires would not have suited the client group 
as some could not concentrate for long periods and the questionnaire could cause 
fatigue. In view of the nature of this study, an investigator-administered 
questionnaire was chosen as the best choice of research tool. 
Designing a questionnaire is a difficult and time-consuming process. Many authors 
have attempted to describe the requirements for a valid questionnaire (Stone, 1993; 
Tully, 2000). The first requirement is to decide what information is needed. 
Extraneous questions add nothing to the results gained and can cause subjects to lose 
interest and miss later questions. The questions must be clear, unambiguous and as 
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easy to answer as possible. Questionnaires with many different methods of 
answering questions (tick boxes, ranking, Liketi scales, open questions) can be 
confusing. However, these are less of a problem in investigator-administered 
questionnaires where the investigator can ask the question and only prompt with the 
options if the initial response doesn't fit with the selection identified. It is important 
that any question including a selection of possible responses is omnicompetant, that 
is there are no possible responses that fall outside the range of responses offered. 
This can be achieved by use of the response other and asking the subject to give 
details. However, if too many respondents chose 'other' this may be a sign that the 
question was poorly devised. 
The combination of open and closed questions is particularly important to ensure that 
the subject is allowed to volunteer information that hasn't been anticipated, but is 
guided when specific information is required. Biased and leading questions must 
generally be avoided. The educational level aimed at must be carefully assessed to 
ensure that the level of the wording is neither too high so that most subjects will not 
understand what is required, nor too low which can cause the more intelligent and 
erudite responder to feel patronised and frustrated. 
Choice of questions 
Nine areas of compliance risk were chosen to form the basic structure of the 
compliance risk questionnaire following a literature revtew. These included: 
physical problems, complexity of medication regime, practice of storage and self-
administration, attitude to medication, efficacy, adverse drug reactions, information 
needs, comprehension of prescribed regime and the presence of age or disease 
related problems. 
a) Physical problems 
Physical problems can reduce compliance by introducing difficulties in accessing 
the dose and in reading directions. 
b) Complexity of regime 
Polypharmacy and complicated regimes have been shown to reduce compliance. 
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c) Practice of storage and self-administration 
Unsafe storage and self-administration can lead to confusion when deciding 
whether to take a particular medicine and can reduce the usefulness of the 
information provided on the original container. 
d) Attitude to medication 
A subject's satisfaction with medication can indicate the likelihood that they will 
take it and highlight potential problems. 
e) Efficacy 
Lack of efficacy can indicate non-compliance but can also cause non-compliance 
by reducing the subject's faith in their medication. 
f) Adverse drug reactions 
These can occasionally cause non-compliance. However, it is useful to know 
whether the subject perceives the adverse reactions to be problematic and worth 
changing practice for. 
g) Information needs 
Lack of information about medication can lead to unintentional non-compliance. 
In addition, a failure of concordance can reduce faith in their medication. 
h) Comprehension 
A good working knowledge of what medicines a subject is taking, and the reason 
they are prescribed, can indicate a higher possibility of compliance. 
i) Age/disease related problems 
Some conditions such as rheumatoid arthritis, depression and dementia, may 
increase risk of non-compliance. 
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Abbreviated Mental Test 
The Abbreviated Mental Test (AMT) is a measure of confusional state. It is a series 
of questions, which are designed to be asked of elderly patients who are in hospital 
or nursing/residential care. These are listed in Table 3iv below. Patients score one 
point for each item that they correctly answer out of a total of ten possible marks. A 
score of seven to ten is normal. 
Table 3iv: The questions asked! in the Abbreviated! Mental Test (and scores) 
• How old are you? 
Ill What time is it? (To the nearest hour) 
e I am going to give you and address to remember 
(e.g. 42 West Street). Can you repeat it? 
e What year is it? 
e Where are you? (Hospital/ward) 
(1) 
(1) 
(1) 
(1) 
e Can you tell what these two people do? (E.g. doctor and nurse) (1) 
Q What is your date of birth? (Day and month will suffice) (1) 
s When was World War I? (1914-1918 or some variation) (1) 
• Who is the current monarch? (Queen Elizabeth required) (1) 
• Count backward from 20 to 1 (1) 
e What was the address I asked you to remember? (I) 
(Maximum score = 10/1 0) 
The purpose of using the AMT in the current study was for: 
a) The selection procedure- patients with chronic confusion as measured by an AMT 
of less than 5/10 were excluded 
b) In determining requirements for interventions - subjects with an AMT of 5-7 were 
offered a Monitored Dosage System 
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The AMT is an abbreviation of a longer test - the Roth-Hopkins test (Roth, 1953 -
see Appendix V), in which the patient is given a score out of 34. This test has been 
validated and has been shown to correlate well with brain changes in senile dementia 
(Blessed, 1968). This longer test is more discerning than the abbreviated test. 
However, being longer, ill elderly patients often lost concentration and therefore 
found the test unacceptable (Hodkinson, 1973). The shorter test achieved more 
consistent co-operation from patients (Hodkinson, 1972). 
The shorter test was designed by looking for correlation between different questions 
in the longer Roth-Hopkins test and looking for questions asking for the same type of 
reasoning. These duplicate questions were then grouped together to shorten the test 
without loss of discriminatory power. The shorter test was shown to be able to 
quantify changes in mental state and hence predict ability to cope, however it did not 
show an ability to discriminate between confusional state and dementia and therefore 
was not appropriate for diagnosis (Hodkinson, 1972). The shorter test was compared 
with the Roth-Hopkins test and the slightly shorter Tooting Bee questionnaire 
(Denham, 1972). The AMT was shown to have high correlation with the other two 
tests (0.82-0.90) (Qureshi, 1974). 
The Abbreviated Mental Test has therefore been shown to be a useful tool for 
assessing patient's ability for independent self-medicating in so far as a low AMT 
score (less than 511 0) would indicate potential problems with ability to comply with 
medication instructions. These subjects were therefore excluded from the study. 
Scores of greater than seven, however, would not sufficiently predict an absence of 
problems because the lack of sensitivity to differentiate between the relative abilities 
of the intellectually more capable and in such cases the test may give an overestimate 
of ability. All subjects with an AMT of 5110 or greater were therefore classed as 
potentially at risk and emolled for interview. 
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Pilot phase and final design 
The pilot phase included two discrete stages: investigating the scale of compliance 
problems and trialing the draft questionnaires. The first stage lasted 3 months and 
patients were assessed for suitability for interview by using the inclusion and 
exclusion criteria described earlier. The baseline data for these subjects are 
described in Table 3v. 
Table 3v: Subject characteristics for pilot phase 
Number interviewed 
Age range 
Mean (SD) 
Number with compliance problems 
Female 
39 
73-100 
85 (6.10) 
26 
Male 
22 
71-95 
82 (6.97) 
13 
64% of subjects had compliance problems which warranted an intervention to ensure 
safety in medicine taking. This is similar to figures found by other authors. The 
assumption that a non-compliance rate of at least 50% would be found during the 
active phase was therefore justified. Rates of non-compliance were similar in males 
and females. More females were interviewed which reflects the greater proportion 
of females in the elderly population (Guralnik, 2000). 
The questionnaire used in the current study was designed after a literature search 
which suggested some questions which may give an insight into compliance 
problems (Aronson, 1992; Grymonpre, 1998; McGavock, 1998; Moriskey, 1986). 
This questionnaire was piloted to ensure that the questions covered all possible areas 
of compliance problems as described earlier (see pages 64-65). The presence of a 
risk factor was sufficient to imply the need for an intervention. However, the 
evidence to state which risk factors are more important than others is not available, 
with the exception of an Abbreviated Mental Test Score of less than five being 
accepted as a reason to avoid self-administration. It was therefore decided to equally 
weight all these issues when making the decision to intervene. 
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The questions asked in the pilot questionnaire are shown in Appendix 11. This 
contained a list of open questions which allowed the subject freedom to volunteer as 
much information as they wished. This questionnaire successfully categorised the 
areas requiring investigation and formed the basis of all subsequent drafts. Each 
draft questionnaire was trialed with five to ten subjects to ensure clarity and ability 
of subjects to understand what was required. 
The open nature of the questions in the pilot questionnaire resulted in a variation in 
response, with some subjects giving too much information and others insufficient. 
This necessitated many supplementary questions, some of which may have been 
leading, and resulted in no two interviews being comparable. In the first draft (see 
Appendix 11 - first draft) an attempt was made to design a questionnaire that 
accurately assessed a subject's risk of non-compliance. It contained both open and 
closed questions. This was more appropriate because closed questions are simpler to 
answer and easier to quantify as the possible responses are limited, whereas open 
questions allow the more intelligent subjects to verbalise their responses in the 
manner they wish. 
There were a number of limitations with this questionnaire. The range of responses 
to the closed questions were not omnicompetant. The question order resulted in 
related questions being separated by unrelated questions. Some questions were still 
ambiguous and some used words in a different context to that understood by the 
average subject. For example, the word 'medicines' is understood by pharmacists 
and doctors to mean all forms of pharmaceuticals including tablets, injections, etc. 
However, to many subjects this was understood only to mean oral liquids. This word 
was therefore changed in subsequent drafts to 'medication'. 
The questionnaire was revised on three more occasions before the final questionnaire 
was designed. The intermediate drafts attempted to score responses to allow a 
quantitative estimation of compliance risk. Each question was scored out of five in 
such a way that a score of four or five indicated no or low risk and one to three 
indicated high to moderate risk. In questions describing attitude and opinions, a 
Likert scale was used. In other questions, for example that measuring the subject's 
knowledge of medication prescribed immediately prior to admission, a simple 
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scoring system was implemented where a proportion of the marks were available 
depending on the level of accuracy which the subject attained. 
In drafts two and three this scoring was not successful as there was either ambiguity 
or overlap, with different problems of equal clinical significance being given 
different weighting. Also, the ordering of questions was still slightly confusing. 
However, equal weighting was accorded to each possible risk factor and so scores 
from questions investigating different aspects of the same risk factor were combined 
to give a score out of five as above. 
In the fourth draft the questions flowed in a logical order. The scoring system also 
appeared effective. However, on assessing responses from subjects it was apparent 
that some questions, although interpreted by a health professional as covering 
different issues, were interpreted by subjects as asking for the same information and 
so added no new information. There were also a few questions which asked for 
extraneous information which was not useful and simply extended the length of the 
interview. Such questions included 'How long have you been taking the medicines 
prescribed for you?' 'How are you getting on with your medication?' These 
questions were removed and the scoring system re-applied giving the final 
questionnaire, which is shown in Appendix Ill. 
In assessing the individual subjects and their risk of non-compliance, ten figures 
were considered: the scores for each of the nine categories described on pages 64-65 
and the sum of these scores (out of 45). The total score was used to decide which 
subjects could be included in the study. A score of 40-45 indicated low risk of non-
compliance, as the subject would have to score four or five in the majority of 
categories to achieve this score. These subjects were excluded from the rest of the 
study as no intervention was required. A score of 30-39 was classed as moderate 
risk and a score of less than 30 high risk. This figure of 30 was chosen as a cut-off 
because patients scoring less than 30 would have exhibited moderate or high risk in 
the majority of categories. For many of the subjects scoring less than 30, the 
interventions required would have been very complicated. These subjects were 
generally excluded as self-administration would not have been safe and social 
services assistance was usually recommended. 
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The individual category scores were used to indicate which intervention was 
required. An intervention was made for any category scoring three or less, with the 
proviso that such interventions were limited to three per subject. Once the 
questionnaire was designed, the protocol was decided on as shown in Appendix VI. 
Interventions 
The aim of this thesis was to assess the success of a number of hospital pharmacist-
lead interventions on compliance. It was therefore necessary to define a limited 
number of interventions that would be appropriate for the majority of compliance 
problems and study the effects of these interventions. The interventions used had 
already been shown to have an effect on compliance and these are described below. 
A simple solution such as ensuring the treatment regime is as simple as possible, 
with once or twice daily dosing, improves compliance (Anonymous, 1991 b; Eisen, 
1990; Lowe, 1995). An attempt was therefore made to simplify the medication 
regime whenever a subject was found to have a complicated regime, that is five or 
more drugs or a frequency greater than twice daily for any drug. The aim was to 
discontinue any medication no longer thought appropriate and change preparations to 
once or twice daily if possible. The effects of polypharmacy and complicated 
regimes is described in more detail in Chapter 8. 
Patients who are gtven sufficient (as determined by the patient), high quality 
information, which is easily understood and followed, have a higher chance of 
compliance than those given insufficient information (Lorenc, 1993). Patients 
receiving this information will have a better understanding of what to do and so will 
be less likely to forget their instructions, the aims of therapy cannot be achieved 
unless the patient understands and follows instructions (Lorenc, 1993; Sweeny, 
1989). Talking to patients about their treatment also gives them an opportunity to 
ask questions and verbalise fears of treatment (Smith, 1983). If these fears are not 
expressed then a potentially major risk to compliance may be ignored. 
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A pharmacist counselling patients on discharge has been shown to improve 
compliance (Sweeny, 1989). Therefore, all subjects were counselled about their 
medication on discharge if they had the following risk factors: complicated regime; 
unsafe storage/self-administration practices at home; drug apparently ineffective 
(with measurable therapeutic effect) or outcome not explained sufficiently to the 
subject in the past; presence of subject identified adverse drug effects; subjects 
voicing the opinion that they had been given insufficient information or the 
information given previously had not been understood. If the information that had 
been previously given was not understood or quickly forgotten the subject was given 
a medication reminder leaflet (see Appendix 11). This could be taken home and used 
as a daily reminder of which medicines to take and when. The information that 
patients require is discussed in Chapter 7. 
A Monitored Dosage System (MDS) (Sweeny, 1989) was supplied for subjects who 
continued to be confused when they should take their medicines despite verbal and 
written guidance; those who frequently forgot whether they have taken a dose or not, 
and those who demonstrated unsafe administration methods. Effort was made to 
ensure that any MDS supplied could be filled safely by a carer or by the subject's 
community pharmacist. This necessitated communication with the subject's 
community pharmacist and general practitioner. 
Concordance in the consultation is important to many subjects and may affect 
willingness to comply (Department of Health, 2000). Subjects who felt they 
required more information, and wanted that information from their doctor, were 
therefore referred to their hospital doctor for a more concordant interview. Subjects 
were also referred if they were dissatisfied with their medication and had not 
communicated this fact to their doctor. These two scenarios cover both aspects of 
concordance breakdown. 
A simple but effective intervention was to produce large print, colour coded or 
Braille labels. These would be suitable for people with impaired vision, as inability 
to follow instructions on a medicine bottle is a well-known risk factor for non-
compliance (Griffith, 1990; Lorenc, 1993). These large print and colour coded 
labels were relatively easy to produce using a word processing package and were 
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attached to containers in addition to the standard pharmacy label which contained all 
the legally required details. Braille labels are harder to produce but are available in 
limited form from the Royal National Institute for the Blind. 
Physical problems have been shown to impair ability to comply (Hughes, 1998; 
Lorenc, 1993; Sweeny, 1989). Subjects with specific difficulties were given 
alternative devices, for example inhalers, or containers to allow self-administration 
of medicines at home. 
If a drug is ineffective, or has serious side effects alternative treatment is required, 
regardless of compliance risk. However, these problems can impede compliance 
(Col, 1990; Misselbrook, 1998b) and so subjects with these risk factors were referred 
to doctor for alternative treatment. 
Subjects who were deemed unsafe to self-administer because of physical or mental 
impairment which put them at high risk of non-compliance, were excluded from the 
study. If no carer in the fonn of a friend or relative could administer medicines on a 
regular basis referral to social services for home or residential care was 
recommended 
It was decided that each subject would receive no more than three interventions. The 
reasons for this were many. Firstly, subjects with multiple problems and therefore 
requiring multiple interventions are often not capable of safely self-administering 
their own medication at home, these subjects would therefore require assistance from 
an outside agency and were excluded from the study. Other subjects with more than 
three problems may have an overlap in requirements allowing the number of 
interventions to be limited to three or less. For example, counselling a subject on 
what their treatment is for and when to take it can help solve problems with 
complicated regimes, lack of understanding, unsafe storage or administration 
practices, and lack of understanding of whether the medicine is working. In 
addition, implementing more than three interventions would make it more difficult to 
determine which intervention helped with any improvement in compliance which 
may be seen. 
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The appropriate interventions were identified and these were implemented prior to 
discharge. Subjects at this stage were asked for consent to continue in the study and 
relevant information was sent to their general practitioner and designated community 
pharmacist. See Appendix VII for the consent fom1. 
Study phase 
After the pilot phase recruitment was undertaken as described earlier. The pilot 
phase had predicted a population size of 160 subjects who would meet the inclusion 
criteria. A sample size of 113 subjects was therefore aimed at. However, during the 
course of the study only 51 subjects were found to be suitable for interview. The 
reason for this lack of suitable subjects was probably due to the case mix during the 
study period. Although there did not appear to be any difference in the age or level 
of sickness between the pilot and active phase groups, an increase was seen in the 
number of patients living in nursing or residential homes. These patients would not 
be suitable candidates for inclusion in the study. 
Of the 51 subjects who were interviewed, only eleven were suitable for follow-up 
and analysis, of which nine were lost to follow-up, four before discharge, due to 
death or early discharge, two in Stage 1 and three in Stage 2. Table 3vi shows the 
reason for exclusion of the other subjects. 
Table 3vi: Reason for exclusion from folHow-up 
Reason for exclusion 
No interventions 
Refused entry into study 
Recommended intervention already 
implemented 
Subject not self-administering 
Referred to Social Services or discharged 
to a residential/ nursing home 
Referred to doctor 
(intervention unsuccessful) 
Totan 
Number of subjects 
(% oftotal) 
10 (20) 
13 (25) 
5 (10) 
3 (6) 
8 (16) 
1 (2) 
40 (79) 
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Thirteen (25%) subjects interviewed refused entry into the study. Four of these 
refused to accept the interventions that were recommended because they did not 
agree that any intervention was required. The other nine subjects accepted the 
offered intervention but refused follow-up. These refusals were for two main 
reasons: the subject did not want to be contacted at home; or they felt their problems 
were minor and their results would not be useful in helping future patients. The 
reasons for refusal have been discussed in Chapter 3a. There was no significant 
difference between the subjects who refused entry and the other subjects interviewed 
(see Table 3vii). 
For five subjects (1 0%) the recommended intervention had already been 
implemented and a further three subjects (6%) were not self-medicating at home. 
These subjects should not have been interviewed, as they did not meet the inclusion 
criteria. However, they had no record in their nursing notes of any assistance by a 
third party. Also, on questioning they did not volunteer this information until after 
the questionnaire was completed and an intervention was suggested. 
Eight subjects (16%) were excluded because they were discharged to a nursing or 
residential home or had a Social Services worker visiting daily to administer 
medication and so would not be responsible for self-medicating after discharge. Of 
these, six were deemed unsuitable for self-medication as a result of the interview and 
so were excluded in response to a successful intervention. One subject was excluded 
as he was referred to the doctor for a concordant consultation, which the doctor 
refused to give. No intervention was therefore made and so follow-up was 
inappropriate. 
Only 10 subjects (20%) were excluded because of unsuitability of any intervention. 
Four ofthese had no compliance problems at all and so no intervention was required. 
Of the remainder, most had potential problems that could not be solved, mainly 
problems with complexity of drugs, which could not be simplified because of 
multiple disease states. Another common risk for these subjects was lack of 
information. However, although these subjects claimed that they had not been given 
any information they did not want any information. In all other categories these 
subjects scored high marks and the significance of these risks on their compliance 
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ability was therefore questionable. There was a slight difference between the 
subjects for whom interventions were identified and those without (see Table 3viii) 
but this was not statistically significant. Subjects who did not require an intervention 
were slightly older and slightly more likely to be male. As would be expected the 
average AMT was higher in the group not requiring interventions, implying a lower 
level of confusion. 
Table 3vii: Comparison of subjects refusing enrolment 
Average age 
Number male(%) 
Average AMT 
Average total score 
Refused entry 
83.0 
4 (33%) 
8.5 
32.9 
Not refused entry 
83.6 
13 (33%) 
8.0 
33.1 
Table 3viii: Comparison of subjects with and without interventions 
Average age 
Number male(%) 
Average AMT 
Intervention 
83.3 
12 (46%) 
7.9 
No intervention 
84.1 
5 (62.5%) 
8.6 
Eleven subjects (22%) were successfully interviewed, interventions implemented 
and plans were made for follow-up. However, six of these were not contacted at 10-
14 days (two died, two discharged early before signing consent form, one unable to 
contact after discharge, one admitted to nursing home after discharge). Three could 
not be contacted at 2-3 months (one admitted to a nursing home and two unable to be 
contacted). Two subjects were successfully followed-up after discharge. These 
subjects are discussed in more detail in Chapter 3a. 
In view of the unsuccessful attempt to follow subjects up after discharge, it was 
decided to analyse the results of the interviews and try to assess whether any useful 
trends emerged. 
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Subject characteristics 
The relevant characteristics data for all subjects interviewed in phase 1 of the study 
are shown in Table 3ix. There were twice as many females as males interviewed, 
this is representative of the proportions of males to females in the elderly population 
(Guralnik, 2000). 
Table 3ix: Baseline data for phase 1 
Age 
Number 
Self-medicating 
Reminder for medicines 
Number of drugs on 
admission 
Number with less than 5 drugs 
on admission 
AMT (x/10) 
Male (mean; SD) 
70-97 (85; 6.97) 
17 
15 
4 
1-9 (5; 2.49) 
4 
3-10 (8; 2.33) 
Female (mean; SD) 
67-98 (82.7; 6.1 0) 
34 
33 
4 
2-11 (5; 2.13) 
14 
1-10 (8; 1.88) 
The majority of subjects were over 75 with only four (three females and one male) 
being 75 or under. This reflects the situation that the lower age range was extended 
late in the data collection phase in order to capture more subjects suitable for 
interview. 
The average number of medicines taken by the subjects was 5 (95% Cl 4.0-6.0). 
Polypharmacy is problematic in the elderly and is discussed in more detail later. 
There was a wide range of scores for AMT in the group, with some subjects being 
obviously unsafe to self-administer medication (1-5/l 0) and other showing no signs 
of confusion whatsoever (9-1 0/l 0). This shows the importance of treating elderly 
people as individuals and not extrapolating the needs of one individual to the needs 
ofthe whole population. 
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3c: Sc9entif~c and ethica~ !basis foil' shAdy design 
The decision was made to not have a control group but enter all subjects into the 
active arm and allow them to act as self-controls, measuring before and after scores 
for each subject and comparing the difference. The absence of a control group is 
unconventional and reduces the power of the study to show significance, however, 
any difference in compliance after an intervention, if present, would be expected to 
be large and the study therefore should be sensitive enough to identify this 
difference. Also, the use of a control group in the presence of a large expected 
difference may be considered unethical in clinical practice. 
Randomised controlled trials offer the best defence against many threats to internal 
validity (Kerlinger, 1992a). However, in order for a trial to have this description, an 
appropriate control scenario must be found. In the current study, a placebo arm 
(Turner, 1994) would have been difficult to achieve. The interventions would need 
to be subject-specific and not general. Each subject would receive those 
interventions that he required, as determined by interview. These interventions 
included counselling on inhaler technique, producing large print labels and supplying 
a Monitored Dosage System. This wide variety of interventions would be difficult to 
imitate in a placebo group. How does one produce placebo large print labels? Even 
if placebos for the various interventions could be found, such methodology would 
cause the study to become very complex. In effect it would become a group of 
individual studies, and with each intervention being compared to it's own placebo. 
In such a study, a sufficiently large sample for statistical significance would be 
difficult to achieve. 
One could deliberately not carry out any interventions, but that would cause two 
problems, one scientific and one ethical. The scientific problem is that rather than a 
placebo-controlled trial this would now become a 'no-treatment' controlled trial. A 
difference may be seen between the groups, but there is no guarantee that it is due to 
the intervention; it may be due to a placebo effect (Chaput de Saintonge, 
1994;Turner, 1994). However, it is possible that scientifically, a comparison with a 
'no-treatment' group may be justified. 
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The implications of the ethical problem, however, are more far reaching. In effect, 
we are suggesting giving each subject an interview, identifying a need for a number 
of interventions, and then failing to meet this need. Although there is no direct 
evidence for the effectiveness of these interventions, that is the reason for the study, 
many pharmacists believe they are important and routinely implement them 
(Sweeny, 1989; Aronson, 1992). There is a distinct possibility that the interventions 
will affect patients' compliance behaviour and potentially affect the therapeutic 
outcome of their treatment. To deliberately fail to make these interventions, after a 
need has been identified, is therefore unethical. 
In any randomised-controlled healthcare trial, the investigator must believe that there 
is no advantage of one treatment over the other. If this is not the case then the 
investigator should refuse to undertake the trial because of personal and professional 
ethical standards (Newell, 1992). Otherwise, they would be knowingly allocating 
patients to a treatment, or lack of treatment, which they know to be inferior. If 
pharmaceutical practitioners believe that the drug treatment that the patient IS 
prescribed is appropriate and essential for their medical condition it follows that non-
compliance with such treatment may lead to unnecessary morbidity or mortality 
(Working Party, 1997). Therefore withholding such an intervention cannot be 
ethically justified. 
In some research scenarios, previous studies have shown alternative therapies to be 
very effective in the condition under review. In such a situation, it would be deemed 
unethical to deny any patient treatment by assigning them to a placebo group (World 
Medical Association, 1989). Comparator-controlled studies are therefore utilised in 
this situation, with the best, or the most predictable, therapy acting as a control. In 
the current study such a comparator intervention would need to be the best possible 
alternative (gold standard) or an intervention with a known or predictable response 
for all patients. There is no evidence available of the existence of such an 
intervention or its objective effect on patient care (Grymonpre, 1998). If such a 
comparator were arbitrarily assigned it would not be possible to predict the effect of 
this intervention on compliance behaviour. Any comparison with the study 
intervention would therefore be meaningless. 
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In order to limit the ethical dilemmas described so far, the control group could be 
assessed for compliance risk only once, either in hospital or at the out-patient visit. 
This would render irrelevant the question of whether interventions were made or not 
as no record of their effect could be made. This baseline measure could therefore be 
compared with the 'after' measure of the second group. This would be ethically 
appropriate. This would furnish some interesting measurements but would not 
answer the question posed by this study. The only inforn1ation we could gather 
would be general data on the compliance behaviour of elderly patients who are 
admitted to hospital. In such a study, this group would not be a true control arm but 
an extension of the active arn1, giving evidence only of the extent to which the active 
group were representative of elderly patients in general with respect to compliance 
risk at baseline. As only subjects with potential compliance problems would be 
included in the study, it would furnish information of limited value. 
One final alternative would be to assess compliance risk and pass on details of the 
required intervention to the subject's general practitioner or hospital doctor. This 
appears to be a good option; ethical considerations are met without the researcher 
needing to make an intervention. It will be seen, however, that there are a number of 
major problems with this option in practice. 
The first problem is that a general practitioner may ignore any advice given to him, 
and the patients in his care will be put at potential risk. This will result in a true 
control group, albeit an unintentional placebo-control group. Alternatively, the 
general practitioner may follow the recommendations given, which may affect the 
results and cause rejection of the hypothesis in error (type 2 error). Although the 
investigator would not make an intervention, the subject would still receive the 
recommended intervention. These two alternatives may result in there being three 
groups: the active group proper; a pseudo-placebo control group; and the pseudo-
active group who receive an intervention from their general practitioner. Data from 
the latter group would show the difference between a doctor and a pharmacist 
following the same advice, and the study may show whether a doctor is likely to 
follow a pharmacist's advice, but these are not the questions under investigation. 
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A second scenario is possible. The general practitioner, on receipt of the advice 
might contact the hospital pharmacist for assistance with the interventions. This 
places the researcher in a difficult professional position. Should the pharmacist 
refuse, a response of doubtful ethical value; or should the pharmacist agree and 
withdraw the subject from the study? This problem is even more likely to occur if 
the information is given to a hospital doctor as they may see it as the pharmacist's 
responsibility to carry through their own advice. Such a study is likely to have a 
high exclusion rate, which may lead to selection bias. 
A similar difficulty might occur from a different source. The ward nurses frequently 
ask pharmacists for assistance with discharge problems. It is probable that they will 
contact the pharmacist to make interventions on behalf of control group patients 
leading to the same ethical dilemma as stated above. It appears, therefore, that in the 
current study it would not be ethically appropriate, or scientifically feasible, to 
introduce a control group of any kind. 
Matched controls are sometimes used when a randomised controlled design is not 
possible to achieve. However, the methodology of matched controls would not be 
appropriate for the current study. It may be used to answer the question 'Do 
interventions made by a pharn1acist help patients who need such an intervention 
more than those who don't?' This is a question that hopefully would be answered in 
the affirmative, but not one relevant to the current study. 
Single group studies are difficult to administer fairly and with internal validity 
(Kerlinger, 1992b ). However, in many health care research situations they are the 
only possible option to satisfy ethical considerations. A pre-test/post-test 
methodology has been used in the current study into the effect of certain 
interventions on baseline measurements. Randomisation and control was not 
possible in this study. However, a number of controls have been introduced in an 
attempt to improve internal and external validity. 
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Maturation effects occur because over any period of time natural agemg or 
development occurs which may affect the reliability of results. The only way to 
correct for this is to use a control group and compare any general trends. This is not 
possible and so great care is required in interpreting results. 
One factor called history describes the possibility of some unforeseen occurrence 
between the pre- and post-tests. This could result in changes in the post-test that are 
not specific effects of treatment, and thus reduce the reliability of results obtained. A 
subject may be re-admitted to hospital between the two interviews, new medication 
could be prescribed or the Community Pharmacist may fail to carry out specific 
recommendations. These could all cause history type errors and so the post-test 
interview will cover each of these scenarios. 
The act of taking the pre-test may affect the scores of the post-test, as similar 
questions will be asked. This may lead to a reduction in internal validity, because it 
would not be known with certainty that the intervention made the observed changes. 
Also external validity is threatened if the pre-test changes response so that the 
sample is no longer representative of the population. The latter problem is not 
relevant, because the same interview would be used to determine required 
interventions if the results of the study are favourable. Any effect of testing would 
therefore be common to the whole population. It is possible that the results could not 
be extrapolated to patients whose compliance risk was assessed in some other 
manner. The former problem causes difficulties, however, because the study is 
looking at whether patient specific interventions are effective, and some diagnostic 
method for deciding on the interventions to implement is essential. However, if the 
act of carrying out the interview (talking to subjects) improves compliance, then this 
would give evidence that counselling patients on discharge would be an appropriate 
intervention. Unfortunately, the reliability of evidence that other interventions are 
appropriate may be compromised. 
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The experimental setting can affect subjects' responses and can render the results 
inapplicable to other settings. The interview setting would be the same for all 
subjects in the study, and would be the same as that which would be used for other 
patients once the study is complete. Experimental setting will not therefore threaten 
external validity. 
Another threat to any uncontrolled trial is regression to the mean. This occurs with 
any variable that fluctuates within an individual, either genuinely or due to 
measurement error. A single measurement may be higher or lower than an 
individual's mean value. This is particularly a problem for studies where subjects 
are selected because of a single high, or low, value. The probability of any 
subsequent value being closer to the 'true' mean is high, and so apparent 
improvements may occur because of regression to the mean, rather than as a result 
of the experimental intervention. Randomising subjects to active or control groups 
will exclude regression to the mean. 
Another method of reducing this effect is to select subjects on the basis of one 
measurement, but assess the effect from another. If regression to the mean has taken 
place between score one and two, the effect is eliminated. However, this is only 
helpful if the correlation between the first and second scores is the same as between 
the first and third. In the current study, it would be difficult to control for this effect 
and care must be taken in interpreting the results. It is worth noting, however, that 
compliance is more likely to worsen after discharge, rather than improve. This is 
because medicines often have changed and so a new routine is required, and patients 
may continue to take old medication or take the new medication incorrectly. The 
effects of regression to the mean may therefore be minimised. 
Changes in measurement between different subjects can reduce internal validity. 
The same investigator will score all subjects, to reduce inter-observer variability, and 
each will be given exactly the same questionnaire. Great care will be taken to 
implement similar interventions in the same manner to reduce intra-observer 
variability. 
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Selection bias can threaten validity. If subjects are not chosen at random, the results 
may be skewed (reduced internal validity). If the selection is too strict, extrapolation 
to the wider population may not be possible (reduced external validity). The current 
study is investigating the compliance behaviour of all elderly patients admitted to 
two Medicine of the Elderly wards. All suitable patients will be enrolled and only 
rejected if they do not exhibit any compliance problems. The sample population will 
therefore be identical to the total population of elderly patients who were admitted to 
the study wards during the study period, and who were shown to have compliance 
problems. It is agreed that this population may be different to the population at, say, 
a period six months later, but this cannot be controlled for. 
Experimental mortality can introduce a further problem with the validity of the 
results. This is when high dropout rates result in a sample that is no longer 
representative of the population. This is not problematic with a pre-test/post-test 
study. However, the effect of multiple treatment interference may be problematic. 
The effect of prior treatment may affect the response to current experimental 
treatment. A check on background and experiences can control this threat. 
Questions about such prior treatment will be asked in the pre-test interview to enable 
the effect of such differences to be assessed. Also in a pre-test/post-test study, all 
possible independent variables associated with the subject's characteristics are 
controlled. 
The important question to ask about any research is: 'Is the question appropriate and 
would the results be both interesting and useful to patient care?' The current study 
confronts an area of practice with little evidence of best practice, which should not 
be condoned in these days of 'evidence based healthcare' (Sackett, 1996). The 
methodology used may not reach the standard of internal validity of which 
propounders of the randomised controlled-trial boast. However, given the current 
ethical and practical limitations, a pre-test/post-test methodology has sufficient 
sensitivity to disprove the hypothesis that a pharmacist can improve compliance 
behaviour, ifthe claim is erroneous. The study would have external validity because 
all suitable subjects will be included, not just a sample. 
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Chapter 4: Summary of findings 
Introduction 
Fifty-one subjects were interviewed and a summary oftheir general characteristics is 
shown in Table 4i. These include age, gender, Abbreviated Mental Test score 
(AMT), total non-compliance risk score, number of medicines prescribed at the time 
of admission and whether they were enrolled, excluded or refused entry into the 
study. 
Only seven subjects were enrolled into the study. Thirteen refused entry into the 
study or refused the interventions offered. The remaining 31 subjects were excluded. 
This chapter will form a general summary of the results obtained in this study. The 
rate of enrolment will be described. The non-compliance risk of the subjects 
interviewed will be presented and the extent to which each of the individual risk 
factors contributed to this. The interventions utilised in the study will also be 
presented. The key findings from the follow-up stages described. Each of these 
issues will be discussed in greater depth in the remainder of the thesis 
Enrolment into study 
As described above, only seven patients from the 51 interviewed were enrolled into 
the study. The key findings for the two follow-up stages will be described at the end 
of this chapter. In this section the reason for refusal and exclusion will be presented. 
Four subjects refused some or all of the interventions offered. These included 
providing verbal advice on discharge by the investigator or doctor and large print 
labels and reviewing medication regime. These subjects all had a non-compliance 
risk score of less than 35 but had an Abbreviated Mental Test Score of eight or nine. 
Interventions were refused either because the subject did not want to lose 
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Talbfte 4i: Subjects' characteristics 
GENDER PATIENT AGE RISK AMT/10 DRUGS ON STATUS 
NUMBER SCORE/45 ADMISSION 
Female 39AT150420 80 42 10 3 Excluded 
390H190712 88 42 9 3 Excluded 
39AE240716 84 41 10 3 Excluded 
39EH230708 92 41 8 3 Excluded 
3908020916 84 39 9 5 Excluded 
39GE110815 85 39 8 4 Excluded 
39E0111219 81 38 6 6 Excluded 
39JG070221 79 37 8 2 Refused 
390P200120 80 37 10 7 Excluded 
39LH181217 83 36 8 6 Excluded 
39JR240413 87 36 9 3 Refused 
39MW151117 83 35 9 5 Excluded 
37MM020233 67 34 9 4 Refused 
39MC080527 72 34 9 7 Enrolled 
390W070422 77 34 9 11 Enrolled 
37AP050312 88 33 8 4 Excluded 
370T071022 78 32 10 4 Excluded 
39E0070821 79 32 10 7 Refused 
390R150919 81 32 9 3 Enrolled 
39LP170702 98 32 8 2 Excluded 
39SW080425 75 31 8 10 Refused 
39AG231221 79 31 9 7 Excluded 
37LG061012 88 31 5 11 Refused 
39EW130709 91 31 10 3 Enrolled 
39ER150215 85 30 5 4 Excluded 
39ML090414 86 30 9 5 Refused 
39CW060123 77 29 9 10 Excluded 
37MM210420 80 29 10 5 Enrolled 
39GM031015 84 29 10 8 Enrolled 
3910151114 86 29 8 6 Refused 
39AS291109 91 29 8 5 Excluded 
390T280515 85 27 6 6 Excluded 
39MB290624 76 26 7 8 Excluded 
37PN120316 84 26 1 5 Excluded 
Male 39SH101120 80 40 9 5 Excluded 
39NW190130 70 38 8 5 Excluded 
37L0090524 76 37 10 3 Enrolled 
39JT060219 81 36 8 4 Refused 
39AB270916 84 36 8 6 Excluded 
39GR290503 97 36 9 6 Excluded 
39JF070716 84 35 9 7 Refused 
37JP231209 91 34 9 6 Refused 
37KJ090117 83 33 8 5 Excluded 
39JP011015 85 33 10 5 Refused 
39WR030922 78 32 9 9 Excluded 
39GR240107 93 32 9 1 Refused 
39JH01 0211 89 29 3 5 Excluded 
39JR260810 90 28 6 6 Excluded 
37NT070508 92 27 4 7 Excluded 
39TH040114 86 26 10 9 Excluded 
37GW281024 76 19 3 7 Excluded 
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independence or because they could not understand the possible benefit to treatment 
outcomes. 
A further nine subjects refused enrolment into the study. The reasons for this were 
many and included a fear of inviting strangers into their houses, wanting 'a quiet 
life' and because they felt follow-up would be an imposition. Some subjects also felt 
that there would be no benefit from enrolling in the study. 
31 subjects were excluded from the study. The reasons included subjects at low risk 
of non-compliance or if it was not possible to implement the intervention identified 
(20). Interventions were not possible if the patient was discharged before the 
intervention was implemented, another party had already implemented the required 
intervention or if no solution could be found. Subjects who were not self-medicating 
on discharge (6) were also excluded as non-compliance risk would be difficult to 
assess at follow-up. In addition, subjects for whom referral to Social Services was 
one of the interventions recommended (5) were also excluded as they would be 
prompted when medication was due. 
Total scores- Non-compliance risk score 
The total scores for the compliance questionnaire for the 51 subjects interviewed 
ranged from 19-42. No subject scored a maximum mark of 45. The scores were 
divided into three ranges representing low, moderate and high risk of non-
compliance. The distribution of scores in these three ranges is shown in Table 4ii. 
Table 4ii: Non-compliance risk score 
Low risk ( 40-45) 
Moderate risk (30-39) 
High risk ( <30) 
Average score 
Standard error 
Male(%) 
1 (6) 
11 (65) 
5 (29) 
32.41 
1.27 
Female(%) 
4 (12) 
22 (65) 
8 (23) 
33.35 
0.79 
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Only five subjects (10%) had low risk of non-compliance that did not require any 
intervention. A quarter of the subjects (25%) were at high risk of non-compliance, 
some of which were not judged safe to self-medicate on discharge. Most subjects 
(65%) had a moderate risk of non-compliance, most of which could be helped by 
simple interventions. 
The rate of high or moderate risk of non-compliance in the study population was 
found to be 90%. This is high but has been seen by other researchers (Aronson, 
1992; Parkin, 1976) although usually rates of 50% are quoted (MacDonald, 1977). 
The high rate may reflect two possibilities; firstly, that the study population is in 
some way unrepresentative of the general population and therefore has a higher rate 
of non-compliance. A claim for an increased rate of non-compliance in the elderly 
compared with younger populations seems to be defensible. The second possible 
reason for a difference in rate is that what is being measured is not comparable with 
previous studies. 
Previous authors have discussed rates of non-compliance and measured these in a 
number of different ways. Each of these studies measured different aspects of non-
compliance and measuring one cause necessarily affects other causes. In this study, 
an attempt was made to assess non-compliance due to all causes. As measuring this 
directly was not possible, the presence of risk factors was assessed. It was not 
possible to state that any risk factor present was definitely responsible for non-
compliance; however, subjects with many risk factors are likely to have a higher rate 
of non-compliance. It is to be expected that elderly patients with multiple disease 
states and physical deterioration will have more risk factors than would a younger 
person without these problems (MacDonald, 1977). 
The vast majority of subjects had problems which caused them to be at risk of non-
compliance. This has been predicted by other authors (Cochrane, 1992; Cantrill, 
1992; Gainsborough, 1990; Ley, 1982; Parkin, 1976; Raynor, 1993; Royal College 
of Physicians Working Party, 1997; Smith, 1983) and was the main reason why an 
elderly population was chosen to be the sample group. The magnitude of this risk, 
however, did not correlate with sex or age, with all ages having a similar range of 
total scores. This is understandable, as the elderly population is not a homogenous 
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population and agemg and its effects progress at different rates in different 
individuals. One would expect that a range of scores would be obtained, as each 
individual would attempt to deal with each situation in a different manner. Also, 
individuals with differing mental and physical abilities would achieve variable 
success at dealing with the problems caused by attempting to take medication in the 
manner prescribed. 
The total scores, and hence risk of non-compliance did not appear to correlate with 
age, which is shown in Figure 4i. All age groups appeared to be on average at 
moderate risk of non-compliance. 
Figure 4i: Distribution of non-compliance risk scores with age 
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In addition, there appeared to be no correlation between total score and gender, with 
both males and females having a similar range of scores. There appears to be some 
slight correlation between total scores and AMT score. This is partially 
understandable as AMT is responsible for 2.5 (6%) of the total scores. The 
correlation does not appear to be significant at low AMT scores but may be 
significant at higher scores as shown in Table 4iii. An interpretation of this could be 
that an AMT of less than seven would indicate a high risk of non-compliance and an 
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AMT of greater than seven is compatible with a moderate or low risk status. The 
clinical significance of this is debatable; however, this is the result that the 
questionnaire was designed to test. 
Table 4iii: Correlation of AMT with total scores 
AMT 
<5 
5-7 
>7 
Average total 
25.25 
30 
34.24 
95%CI 
21.0-29.5 
26.5-33.5 
33.0-35.5 
This discovery was interesting and showed that the questionnaire was sensitive to 
test for level of confusion. One might be tempted to say that rather than spending 
such a long time asking the subjects all the questions in the questionnaire, the much 
shorter AMT could be used to identify patients at high risk of non-compliance. 
Whilst this appears to be borne out by this study, the practical use of this test is 
limited. A knowledge of whether a patient is at high risk of non-compliance on its 
own does not give any indication of the cause of the problem or what solutions may 
alleviate this problem. This is therefore useful tool to identify at-risk patients, but 
would not provide sufficient information to help identify required interventions. 
Risk factors for non-compliance 
The main causes of non-compliance in the study population were complexity of 
prescription (71% ), lack of information (71% ), dissatisfaction with medicines ( 41% ), 
poor understanding of regime ( 41%) and physical and sensory problems (3 5% ). 
These are reported in this section and the possible causes and solutions discussed. 
Each of these will be discussed in greater depth in subsequent chapters (5-8). 
Complexity of prescription 
The majority of subjects (71 %) had complex prescriptions at the time of assessment. 
Thirty had five or more medicines prescribed, with one subject being prescribed 13 
different medicines. Twenty-eight subjects had been prescribed medicines that were 
to be taken three or four times a day, also 32 had three or more different direction on 
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their medicines (maximum five). Having a complicated prescription did not 
correlate with any other risk factor. 
There are many causes of complicated prescriptions. However, the main adverse 
cause was a failure of the doctor to review the prescription regularly. The 
intervention that was used to remove this factor was simplification of the 
prescription. However, often this was not possible because the subject suffered from 
multiple disease states or was optimally controlled. In these cases a compliance 
chart was given to the subject to help them understand when to take their medicines, 
and Monitored Dosage System was supplied to avoid the need for the patient to 
calculate which medicines were to be administered and when. If none of these 
solutions were appropriate, the subject was referred to social services. 
Although frequently no solution was possible for these subjects, asking about 
complexity of treatment regime was useful in identifying patients at risk of non-
compliance. 
Information supply 
Thirty-six (71 %) of subjects were at risk of non-compliance because they reported 
not being given information about their medicines. However 30 (83%) of these, and 
86% of the total population, reported being happy with the level of involvement they 
had in the treatment decision making process. There was no correlation between 
reports of information supplied and any other variable. However, subjects who 
claimed to have been given sufficient information also had high Abbreviated Mental 
Test Scores, which may mean that they had a better ability to recall what they had 
been told. 
Subjects who reported having insufficient information had their medicines explained 
to them by the investigator on discharge or were referred to the doctor for a 
concordant interview. Only one subject who had this risk factor was followed-up in 
the study. This patient did show a slight improvement in this risk factor, but this was 
difficult to assess. 
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As most subjects reported that they did not want any further involvement in making 
treatment decisions this risk factor appears not to be worth investigating in this 
population in tenns of assessing compliance risk. However, to assess a patient's 
desire for concordance, and whether it has been achieved, this is essential. 
Satisfaction with medicines 
Dissatisfaction with medication was found to be a compliance risk factor for 21 
subjects ( 41 %). This was as likely to be a risk factor for men and women, 35% men 
and 42% women claimed to be unhappy with their treatment. Nineteen of these 
subjects also complained of not having been given any information about their 
treatment, however, 15 of them knew why they had been prescribed. All of these 
subjects were found to be at moderate or high risk of non-compliance. 
The reason for the dissatisfaction with medication was not always easy to identify. 
52% of these subjects claimed that a lack of efficacy was the reason for this 
dissatisfaction; other reasons included inability to use inhaler devices. However, 
some subjects reported a non-specific unhappiness with the treatment prescribed. It 
was difficult to find a solution to such dissatisfaction, as the subject could not 
explain what was wrong or how to improve matters. In contrast, some subjects could 
explain what solution they wanted but this was inappropriate medically. 
The required interventions to improve satisfaction with medication was dependent on 
the cause. An attempt to change the prescription was made in three cases and in 
three more the doctor had already changed the prescription before medication review 
by the investigator was possible. Three subjects were referred to a hospital doctor 
because a breakdown in concordance appeared to be to blame. A further three 
subjects were found to be at high risk of non-compliance and so were referred to a 
social worker for home care. The remaining nine subjects were offered more 
information about their treatment and why it had been prescribed. Only one subject 
was followed up and this patient received counselling prior to discharge. On 
reassessment at three months she was found to be happy with her medication, 
although other interventions may have contributed to this improvement. 
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Asking patients whether they are happy with their treatment may provide more 
problems than solutions, however, it is important to know why patients do not want 
to take their medication and so this risk factor was an important one to investigate. 
Understanding of regime 
Twenty-one ( 41%) subjects exhibited difficulty in describing what medication they 
were prescribed or in explaining why it had been prescribed. Most of these subjects 
(81%) also reported not being given any information about their treatment. The 
complexity of regime did not appear to correlate with an ability to describe that 
regime; patients with this risk factor were prescribed an average of six medicines on 
admission as compared to five for those subjects who could adequately explain what 
they were taking and the reason. This risk factor also did not correlate with any 
other variable. Although the ability to describe a treatment regime without 
prompting does not directly equate with ability to take medication correctly when the 
directions are available on the label, patients who do not know how many times a 
day they need to take medicines of any kind will be more likely to forget to read the 
label for a prompt. This risk factor is therefore useful to consider when assessing 
compliance risk. 
A number of different solutions to this problem were implemented. Ten subjects 
were given extra information about their treatment in the form of a medication 
reminder chart or counselling. One subject was provided with a Monitored Dosage 
System in order to decrease the effect of this risk factor. A total of nine subjects 
were not self-administering on discharge, five of them in response to advice from the 
investigator. The final subject wanted to talk to a doctor and not a pharmacist and so 
the relevant referral was made. None of these subjects were followed up and so the 
efficacy ofthese interventions is unknown. 
Physical and sensory problems 
A total of 18 subjects (35%) had physical or sensory problems which inhibited their 
ability to safely self-medicate. Unsurprisingly this did not correlate with any other 
risk factor. 
93 
The majority of these subjects (67%) experienced difficulty in openmg child 
resistant closures (CRCs). Similarly, 44% were unable to remove tablets or capsules 
from blister packs. Other problems included inability to read labels, inability to 
manipulate small bottles due to reduced manual dexterity, difficulty with measuring 
liquids onto a spoon and various problems with using inhaler devices. 
The solutions to these difficulties had to be tailored to the problem. Subjects were 
offered screw caps and doses decanted from strips into bottles and alternative inhaler 
devices. Large print labels were offered and one subject was provided with a 
Monitored Dosage System. However, six subjects could not have their problems 
satisfactorily solved and so Social Services were involved to provide care after 
discharge. Only one subject with this risk factor was followed up. She was provided 
with a different inhaler because she was unable to use the original one. At three 
months she was still able to use the device recommended by the investigator. 
Efficacy 
Thirteen subjects (25%) complained that at least one of their medicines was 
ineffective. In 54% of cases the accused medication was found to be subtherapeutic 
on admission and was changed. The majority of subjects also claimed to be unhappy 
with their medication (85%) and had not been given sufficient information (92%). 
Also five of the subjects who disagreed with their doctor as to whether their 
medication was effective did not know why they had been prescribed, so it is 
difficult to understand how they could tell whether they were effective or not. 
The reasons for subjects reporting a lack of efficacy were that the medication was 
not working, the subject erroneously understood them to be ineffective or because 
they had inappropriate expectation of outcomes. In order to reduce these problems a 
number of interventions were made. Medication review was instigated to ensure 
treatment was optimal, inhaler devices were changed if subjects found difficulty in 
using them. Subjects who did not understand accurately what the medication could 
achieve and how it worked had this explained to them by the investigator or they 
were referred to the doctor. Subjects whose non-compliance had caused a lack of 
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efficacy were provided with home care after discharge if other interventions were 
insufficient. 
Knowing whether a subject thought their treatment was ineffective did not allow 
adequate assessment of compliance unless further information was available, 
especially as a number of subjects claimed to be unhappy with medication that they 
claimed was effective. Combing this factor with general satisfaction with 
medication would therefore make the assessment more sensitive. 
Storage and administration of medicines 
Only seven subjects (14%) reported problems with administration practice. Four had 
no method of remembering when to take their medication, one had a method that did 
not overcome her forgetfulness and two took most of their medicines incorrectly. 
The reasons for administration problems appeared to be either forgetfulness or a lack 
of understanding ofthe importance oftaking medicines correctly. 
Four of these subjects had many other problems and so were referred to Social 
Services, the other three were provided with medicine reminder charts and the 
investigator explained how the medicines should be taken safely. One of these 
subjects was followed up and his method of remembering when to take his 
medicines improved. 
This risk factor equated with a report of how often medicines were forgotten and 
what was done to remember when to take them. This is very similar to self-report of 
compliance and so it was not surprising that few subjects reported this risk factor. 
It's usefulness in assessing non-compliance risk is therefore limited. 
Adverse drug reactions 
Eleven subjects reported adverse drug reactions but only two reported that they 
changed the way they took their medication. Adverse drug reactions only affect 
compliance if the patient reacts to them in an inappropriate way. The solutions 
offered to these subjects were changing treatment where appropriate and explaining 
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the likelihood of side effects and appropriate action. As described in earlier 
chapters, adverse drugs reactions do not affect compliance as much as doctors think. 
This is borne out by the current study and so investigation of this risk factor may not 
be appropriate. 
Confusion level 
Four subjects had an AMT of less than 5110 (incompatible with self-care) 
(Hodkinson, 1972). A further five had scores of five or six (caution with self-care). 
The remainder of the sample population scored seven or more which is classed as 
normal for an elderly person and they were therefore classed as being not confused. 
All four subjects with AMT scores below 5110 were also assessed as being at high 
risk of non-compliance. Most of these subjects lived alone but had some level of 
support with their activities of daily living. In two cases, this did not include help 
with taking their medicines and so they were at high risk of non-compliance with 
little practical support. 
The five subjects with AMT scores less than 7110 all were found to be at moderate or 
high risk of non-compliance. Although a 'normal' AMT score was not predictive of 
low risk of non-compliance, a low AMT had sufficient sensitivity to predict a subject 
at moderate to high risk. AMT therefore would not be appropriate as a sole 
diagnostic tool for non-compliance as too many factors would be omitted such as 
physical problems and efficacy of medication. However, it would continue to play a 
necessary, but not sufficient, role in screening those patients who would be at 
greatest risk of non-compliance. This is especially the case for patients who score 
less than 5/10, who could not be safely left to self-care and no further questioning 
would be required to predict that outside assistance would be required to ensure 
safety. 
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Interventions 
Eleven different types of interventions were identified for a total of 39 subjects 
(76%). Twelve subjects did not require any pharmacist administered interventions. 
Four of these were at low risk of non-compliance and two had already obtained a 
change in treatment prior to interview - this was their main non-compliance risk 
factor. Four of the remaining subjects already had appropriate interventions initiated 
prior to admission and two were discharged to nursing homes on the advice of a 
nurse. The interventions are shown in Table 4iv. 
Twelve subjects did not have any interventions implemented, although suitable 
interventions were identified by means of the baseline questionnaire. Two subjects 
died before discharge and two others were discharged early and so no interventions 
could be made. Two subjects refused all interventions. The remaining six subjects 
had medication review identified as the only intervention required; however, as 
treatment was optimal for these subjects, this was not possible. 
Table 4iv: Interventions made during the study 
Intervention 
Change inhaler 
Compliance aid 
Compliance sheet 
Counselling 
Decant blister strips into bottles 
Large bottles 
Large print 
Refer to doctor 
Refer to Social Services 
Screw caps 
Simplify medication 
Interventions 
identified* 
3 
2 
16 
19 
6 
1 
4 
2 
5 
4 
10 
* Subjects could have up to three interventions. 
Interventions 
actioned (%) 
3 (100) 
2 (1 00) 
12 (75) 
14 (74) 
6 (1 00) 
1 (1 00) 
3 (75) 
2 (100) 
4 (80) 
4 (1 00) 
1 (10) 
The majority of subjects had problems which could simply be solved by using a 
compliance reminder sheet (see Appendix II) or by counselling. Fourteen subjects 
required interventions because of physical or sensory difficulties, three subjects 
required two or three different interventions, with four (8%) requiring larger print 
labels and six (1 0%) unable to remove tablets from blister packs. Only two subjects 
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(4%) required Monitored Dosage Systems such as a Medidos®. Five subjects (12%) 
had such complex needs that referral to Social Services was required to remove the 
need for self-medication. For some of these subjects this included supplying a 
Medidos®. For only one subject did medication review by the pharmacist result in 
simplification of medication and hence reduction of compliance risk. As the 
majority of problems had not been identified prior to interview by the investigator 
(79%) this study supports the hypothesis that pharmacists have a role in identifying 
non-compliance risk factors. 
If interventions are to be effective they must be continued. Many of these 
interventions required continued input from a Community Pharmacy. Forty-three 
subjects (84%) routinely had prescriptions dispensed by the same Community 
Pharmacy and could identify that Pharmacy. Of the remaining eight subjects, five 
did not require any interventions and one was admitted to a nursing home on 
discharge. Two more subjects were referred to social services for administration of 
medicines and so appropriate Pharmacies were identified before discharge. The 
implications ofthese interventions are discussed in more depth in Chapter 6. 
Key findings from follow-up 
First follow-up 
Seven subjects were enrolled into the follow-up phase of the study. The first follow-
up occurred two weeks after discharge. The aim of this was to ensure that 
interventions identified during the in-patient stay had been continued. Only five 
subjects were available for the first follow-up interview. The other two subjects 
could not be contacted despite many telephone calls and two letters. 
All five subjects successfully followed up had received a prescription from their 
general practitioner after discharge once the hospital supply had run out. All of them 
had had changes to their prescription which increases the risk of non-compliance. 
All of the interventions implemented in hospital had been continued except for one 
subject. His community pharmacist was contacted once more to ensure that the 
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interventions were continued. He was unsure whether the interventions had been 
helpful, but the other subjects all agreed that they had been helpful. The 
interventions implemented for these subjects are shown in Table 4v. 
Table 4v: Interventions implemented for subjects followed up 
Subject 
39MC080527 
37L0090524 
39DW070422 
37MM210420 
39GM031015 
Problems 
Unsure if medication appropriate, 
thinks one medicine is inappropriate, 
complex prescription 
Occasionally forgets medication, 
stops taking them when feels better, 
complicated regime 
Unable to read labels, complicated 
regime 
Not sure if happy with medication, 
unsure if working, inhaler unsuitable, 
complicated regime 
Unsure if still needs medication, or 
if working, poor manual dexterity, 
complicated regime 
Interventions identified* 
Compliance sheet, counselling 
Compliance sheet, counselling 
Compliance sheet, counselling, 
large print labels 
Compliance sheet, 
Counselling, change inhaler 
device, screw caps, decant 
blister strips into bottles 
The fact that Mr. LO (37L0090524) had not had his interventions continued 
illustrates the importance of communication between primary and secondary care if 
interventions to improve non-compliance risk are to be effective. 
Second follow-up 
Unfortunately three more subjects were lost to follow-up at three months. Mrs. DW 
(39DW00422) could not be contacted, Mrs. MM (37MM210429) was admitted to a 
nursing home and Mrs. MC (39MC080527) was readmitted to hospital. However, 
two subjects were successfully followed up at three months. The data for these two 
subjects are shown in Table 3iii. 
Mr. LO (37L0090524) was originally at moderate risk of non-compliance, but had 
deteriorated over the three months. However, his main problems were due to a 
deterioration in health which caused him to be unhappy about his treatment which he 
felt was no longer effective. In addition his eyesight had deteriorated. Although his 
risk of non-compliance had not improved, the deterioration appeared to be unrelated 
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to the interventions which had been initiated in hospital. In fact, his administration 
of medicines had improved to the point where it was no longer a risk factor for non-
compliance. 
Mrs. GM (39GM031015) had been assessed as being at high risk of non-compliance 
and improved in all risk factors over the three months except she still had 
polypharmacy and still reported receiving little information from her general 
practitioner. At the second follow up she was assessed as being at moderate risk of 
non-compliance. Her community pharmacist had continued all interventions and she 
was happy about them all. 
No conclusion can be made about the potency of the interventions implemented to 
improve compliance risk status. However, both of the patients followed up found it 
easier to take their medicines conectly and were happier to report problems to their 
general practitioner and pharmacist. Compliance may not have dramatically 
improved but concordance had been, in part, achieved. 
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Chapter 5: Compliance risk in study population 
Although a broad range of non-compliance risk scores was seen (19-41 ), individual 
subjects had different reasons for reaching these totals. These are described in detail 
below. Table Si shows the cumulative data for each of the categories investigated. 
The solutions to these problems (interventions) will be mentioned briefly but 
discussed in greater depth in Chapter 6. At this point the discussion will concentrate 
on the frequency with which these problems occurred in the study group and the 
possible reasons for these problems. 
Administration 
Only seven subjects (14%) exhibited potential problems with administration. The 
data for these are shown in Table 5ii. These subjects did not have any assistance in 
remembering when to take medicines prior to admission. 
Table Sii: Subjects exhibiting problems with administration practice 
Number Gender Age Total AMT Administration problem 
score 
37GW281024 Male 76 19 3 No method of remembering 
when doses due 
37L0090524 Male 76 37 10 Occasionally forgets medicines 
No method of remembering 
doses due. Sometimes stops 
taking when feeling better 
29CW060123 Female 77 29 9 Sometimes forgets afternoon 
medicines 
39ED070821 Female 79 32 10 All medicines taken morning 
and evening regardless of 
prescribed dose. Not always 
careful to follow doctor's advice 
39DT280515 Female 85 27 6 No method of remembering 
doses due 
39JH010211 Male 89 29 3 y2 Patient took all medicines at 
breakfast and bedtime regardless 
of prescribed dose 
39JR260810 Male 90 28 6 Occasionally forgets - too lazy 
No method of remembering 
doses due 
0 101 ... -.....{-
l'abDe Si: Summary of baseHlllle data 
PATIENT AGE SEX AMT TOTAL S&A u A E SE p D C STATUS 
NUMBER 
37MM020233 67 F 9 34 4 5 3 5 5 2 5 5 0 Refused 
39NW190130 70 M 8 38 5 4 5 5 5 4 5 5 0 Excluded 
39MC080527 72 F 9 34 4 4 3 3 5 3 5 5 2 Enrolled 
39SW080425 75 F 8 31 4 3 4 5 5 4 1 5 0 Refused 
37GW281024 76 M 3 19 3 0 3 3 5 2 1 2 0 Excluded 
39MB290624 76 F 7 26 4 3 2 5 4 2 1 3 2 Excluded 
37L0090524 76 M 10 37 3 5 4 5 5 5 5 5 0 Enrolled 
39CW060123 77 F 9 29 3 3 2 4 5 3 4 5 0 Excluded 
39DW070422 77 F 9 34 4 5 5 4 5 4 1 4 2 Enrolled 
37DT071022 78 F 10 32 4 1 3 3 5 2 5 5 4 Excluded 
39WR030922 78 M 9 32 4 5 3 5 5 2 4 4 0 Excluded 
39ED070821 79 F 10 32 3 2 4 4 5 3 1 5 5 Refused 
39AG231221 79 F 9 31 4 3 5 5 5 3 1 5 0 Excluded 
39JG070221 79 F 8 37 4 4 5 5 5 2 5 5 2 Refused 
37MM210420 80 F 10 29 4 4 3 3 5 2 4 4 0 Enrolled 
39AT150420 80 F 10 42 4 5 4 4 5 5 5 5 5 Excluded 
39DP200120 80 F 10 37 4 5 5 5 5 3 5 5 0 Excluded 
39SH101120 80 M 9 40 5 2 5 4 5 5 4 5 5 Excluded 
39DR150919 81 F 9 32 4 3 4 3 5 3 1 4 5 Enrolled 
39JT060219 81 M 8 36 4 4 5 4 5 4 1 5 4 Refused 
39E0111219 81 F 6 38 4 2 5 5 5 5 5 4 3 Excluded 
39LH181217 83 F 8 36 4 5 4 5 5 4 4 5 0 Excluded 
37KJ090117 83 M 8 33 4 4 4 4 5 2 5 5 0 Excluded 
39MW151117 83 F 9 35 4 4 2 2 5 3 5 5 5 Excluded 
39AE240716 84 F 10 41 4 4 5 4 5 4 5 5 5 Excluded 
39DS020916 84 F 9 39 4 5 5 5 5 3 4 3 5 Excluded 
39AB270916 84 M 8 36 4 5 4 4 5 4 5 5 0 Excluded 
39JF070716 84 M 9 35 4 5 3 3 5 2 5 5 3 Refused 
37PN120316 84 F 1 26 4 0 3 4 5 3 1 1 5 Excluded 
39GM031015 84 F 10 29 5 5 3 3 5 2 1 5 0 Enrolled 
39GE110815 85 F 8 39 4 5 2 4 5 4 5 5 5 Excluded 
39JP011 015 85 M 10 33 4 5 2 1 5 4 5 5 2 Refused 
39ER150215 85 F 5 30 4 5 4 4 5 2 1 4 1 Excluded 
39DT280515 85 F 6 27 3 4 1 1 5 3 5 3 2 Excluded 
3910151114 86 F 8 29 4 3 4 4 5 2 1 5 1 Refused 
39ML090414 86 F 9 30 4 3 4 4 5 2 1 5 2 Refused 
39TH040114 86 M 10 26 4 3 3 3 2 3 4 4 0 Excluded 
39JR240413 87 F 9 36 4 5 3 2 5 3 5 4 5 Refused 
37LG061012 88 F 5 31 4 0 5 5 5 3 5 4 0 Refused 
39DH190712 88 F 9 42 4 5 5 5 5 3 5 5 5 Excluded 
37AP050312 88 F 8 33 4 4 2 4 5 2 5 5 2 Excluded 
39JH010211 89 M 3 29 3 0 5 5 5 3 1 2 5 Excluded 
39JR260810 90 M 6 28 3 1 4 5 5 4 1 3 2 Excluded 
39EW130709 91 F 10 31 4 5 3 4 5 2 4 4 0 Enrolled 
37JP231209 91 M 9 34 4 5 3 5 5 2 5 5 0 Refused 
39AS291109 91 F 8 29 5 0 4 4 5 2 4 5 0 Excluded 
39EH230708 92 F 8 41 4 5 4 5 5 5 5 5 3 Excluded 
37NT070508 92 M 4 27 4 3 5 5 5 2 1 2 0 Excluded 
39GR240107 93 M 9 32 4 2 4 5 5 3 1 5 3 Refused 
39GR290503 97 M 9 36 5 1 5 3 5 2 5 5 5 Excluded 
39LP170702 98 F 8 32 4 5 3 5 5 2 1 5 2 Excluded 
Key: 
S&A- Storage and administration; U- Understanding; A - Attitude to meds; E - Efficacy; 
SE - Side effects; I - Information; P - Physical problems; D - Disease based problems; C 
-Complexity; Max for each= 5. TOTAL- non-compliance risk score, Max = 45 
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Four subjects did not have a routine for taking their medicines which might remind 
them to take them or ensure that they knew whether a dose had been taken. Two 
subjects took all medication twice a day, regardless of the prescribed frequency. 
Another subject attempted to take her medication according to the directions she 
understood to be correct, but as this meant that one dose was due immediately after a 
mid-afternoon nap, it was frequently forgotten. One subject described being too lazy 
to remember when to take medicines and one admitted to not always paying much 
attention to what the doctor had said. 
Two of these subjects also had little faith in their medication and this was mainly due 
to a perceived lack of efficacy. The other subjects did not have any obvious reason 
for being careless with their medication. Four of these subjects were found generally 
to be at high risk of non-compliance and were subsequently discharged to a nursing 
or residential home. Of the other three subjects, two were followed up and one 
refused entry into the study. 
Although Mr. LO (37L0090524) knew why he was prescribed his medicines in 
general terms, he was unsure of the need to continue to take them even when he felt 
well. This meant that he occasionally stopped medicines that the doctor had 
intended him to continue; this would place him at risk of further exacerbations and 
potential treatment failure. In addition, he sometimes forgot to take his medicines 
when he had intended to take them. This could result in a lengthy treatment free 
period of which his GP was unaware, risking dose or treatment changes when the 
cause was non-compliance and not necessarily lack of efficacy. Mr. LO did not use 
any particular method to remember when to take his medicines, such as linking them 
to mealtimes or other fixed times throughout the day. If this had been the case, his 
rate of forgetfulness may have reduced. 
In one study, 39.6% of patients who had reported non-compliance blamed it on 
forgetfulness (Col, 1990). Forgetfulness includes forgetting to take one or more 
doses; forgetting whether a dose has been taken, which may lead to overdosing; 
forgetting to get a prescription filled, which may lead to delays in continuing 
treatment; and forgetting what information the doctor or pharmacist gave them, 
potentially leading to administration errors. Patients generally do not report isolated 
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incidents of forgetting to take their medicines (Paes, 1998), possibly because they 
have forgotten such occurrences or because they feel they are not significant. Mr. 
LO reported missing doses and so this could be interpreted as happening relatively 
frequently. 
Mr. GW (37GW281024) claimed that he never forgot to take his medicines and 
always followed his doctor's instruction as to when and how he should take his 
medicines. However, he could not remember anything about his medicines (name, 
dose or frequency) and claimed never to have been given any information about 
them. It is therefore difficult to imagine how perfect compliance could be achieved. 
However, his inability to explain his medicine regime may have been related to his 
acute confusion, which was responsible for his current admission. It is also possible 
that he might have overestimated his ability to comply as he was found to be at high 
risk of non-compliance due to many risk factors. 
The main problem that affected Mrs. CW (39CW060123) was remembering when to 
take her afternoon medicines. This is because she thought that were due at 3pm. 
However, she usually had a short sleep after lunch and often omitted them because 
she either slept too long or forgot to take them when she woke up. This problem was 
encountered because a lack of understanding of when was an appropriate time to 
take her medicines was coupled with an attempt to take them at a time devoid of any 
other natural reminders, for example, meal times (Sweeny, 1989). 
Sometimes patients do not fully understand why the doctor issues certain guidance 
and therefore they do not feel it is necessary to follow that information. In addition, 
some medicines may seem to be of greater importance to a particular patient than 
others, less care may therefore be taken about the apparently less important 
medication; Becker (1975) supports this. Concordance can improve this type of non-
compliance. However, Mr. JR (39JR26081 0) tried to follow what the doctor had 
told him but occasionally found it just too much of an effort to take his medicines, he 
therefore didn't see the point in trying to remember when to take them. 
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There was no correlation between the subjects' ability to store and administer their 
medication safely and any other variable. For all ages and both genders, the risk due 
to such difficulties was similar. Although the data implies that subjects with an 
Abbreviated Mental Test score (AMT) of greater than seven would be at low risk 
compared with other subjects, this was not statistically significant (see Table 5iii). 
Only two of the subjects with problems with storage and administration had an AMT 
consistent with inability to self-medicate. This may be evidence that only some 
problems with storage and administration are caused by poor memory and 
comprehension. Others are caused by a conscious decision to take medication in a 
certain way, which happens to be unsafe. This decision may be based on a 
misunderstanding of the directions given or an attempt to fit medicine taking into the 
activities of daily living. Either situation would be exacerbated by a breakdown in 
concordance. 
Table Siii: Safety with storage and administration compared with AMT 
Storage and Average AMT (SE) 95% Cl Range 
administration score* 
3 6.7 (1.3) 4.1-9.3 3-10 
4 8.3 (0.3) 7.7-8.8 1-10 
5 8.8 (0.4) 8.1-9.5 8-10 
*No subject scored less than 3 
Most subjects reported having adequate methods for remembering when to take their 
medicines. This may have been because these subjects did not wish to admit to 
having problems, giving instead the response that they felt the investigator wanted to 
hear. The questions in this section amounted to self report of compliance, which has 
been shown to underestimate the problem (Haynes, 1996). Therefore, it could be 
argued that these questions could be removed from the questionnaire with no 
reduction in overall sensitivity. This case may be strengthened by noting that six 
subjects with low scores for storage and administration also scored low in a number 
of other areas and so they would still be classed as at-risk of non-compliance. 
However, one subject would have been classed as being at low risk of non-
compliance ifthese questions had not been asked. 
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Understanding 
Twenty-one subjects ( 41%) had a poor understanding of their regime, either not 
being able to recall what they were taking or what condition they were prescribed 
for. Ten of these subjects (48%) were assessed as being at high risk of non-
compliance and five were referred to a nursing or residential home after discharge. 
Two more subjects were not self-administering before admission and a further two 
already received their medication in a Monitored Dosage System. This may explain 
why they had little or no knowledge of their regime as all necessity to remember was 
removed. Six of these subjects refused follow-up. Seventeen subjects (81 %) who 
had low scores in understanding also complained that they had not been given 
sufficient information about their medication. Understanding did not correlate with 
number of drugs on admission, with patients having this risk factor having on 
average six medicines compared with five for those who could explain their 
medication regime. 
Forty-one percent of subjects were at risk of non-compliance because of a lack of 
understanding of their required medication regime. If a patient is unable to 
remember what they are taking or when to take it, they will find difficulty m 
remembering whether they need to take a certain medicine at a particular time and so 
they may not even pick up the container to check the label (Hughes, 1998; Moriskey, 
1986). Patients who catmot understand why they are taking their medicines also may 
not take them because they do not realise the importance of complying. This may be 
illustrated by the case of Mr. JR (39JR26081 0), who could only explain why half of 
his medicines were prescribed. He was admitted taking six different medicines but 
could not name any of them. He was unable to say when he took any of his 
medicines but knew what three of them were prescribed for. He repmied that 
occasionally he forgot his medicines because he was 'too lazy to remember'. He had 
no special method of remembering to take them but claimed that he always tried to 
follow the doctor's instructions on how to take his medicines. 
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Some subjects were prompted on a regular basis when to take their medicines. They 
therefore had less need to remember what medicines they had been prescribed or 
when they should take them. This may have been the reason why they were unable 
to provide this information. Of course a subject who was having difficulty 
remembering when to take a medicine may therefore be provided with a reminder 
that they otherwise may not have been given. It is difficult to tell without much 
more in-depth investigation which event preceded the other. This is discussed in 
greater depth later in this chapter (see Rate of self administration). 
Mr. GR (39GR290503) was admitted taking six different medicines but was only 
able to name two of them. Although he knew both the doses and frequencies for 
these drugs, he was unable to say when he took any of his other medicines and did 
not know why he had been prescribed any of them. He was not self-administering 
his medicines. It was not possible to determine why he remembered these two 
medicines and not the others. As he did not know the reason why he was taking any 
this could not have affected his attitude to them. 
Some subjects received their medicines in a Monitored Dosage System, usually filled 
by carers or community pharmacists. Unless the subject was responsible for filling 
the system, there would be no necessity to remember what they medicines they were 
taking. They would only need to remember when to look in the container and 
remove doses in the relevant section. These subjects therefore might find it difficult 
to remember what they were taking unless they read the information supplied with 
the aid regularly, a practice that is unnecessary for safe use of these devices. 
Mrs. AS (39AS291109) lived alone and was generally independent, however, she 
had a home carer who visited three times a day and her community pharmacist filled 
a Dosett® for her each week. She was admitted taking five different medicines but 
could not name any of them. She was unable to say when she took any of her 
medicines and could only say why she was prescribed one of them; this was 
probably because she did not see them individually and therefore could not identify 
them. Mr. GW (37GW281024) was another subject who took his medication from a 
Monitored Dosage System (in his case a Medidos®). However, he had his medicines 
dispensed in bottles and boxes, as normal, and his sister subsequently put them in the 
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Medidos® for him. This may explain why he knew slightly more details about his 
medicines than Mrs. AS. 
The subjects described above all had external assistance with taking their medicines 
and so many of them should have been excluded from the study because of this 
assistance, as personal non-compliance would not have been a significant issue for 
therapeutic success. The reliability and accuracy of the outside assistance would be 
much more important. However, some subjects did not receive any assistance with 
their daily self-administration of medicines, and so understanding of their regime 
would therefore be crucial in affecting their ability to comply with the doctor's 
instructions. 
Mr. GR (39GR230 1 07) had only been prescribed one drug and so his regime could 
not have been any simpler. He was unable to remember the name of the drug but 
was committed to taking it. He had forgotten what the medicine was for and was 
unable to remember whether he had ever been told why he was taking it; he was 
unsure how much information his GP had given him or what he had been told whilst 
he was in hospital. This is common, as patients routinely forget 31-71% of what the 
doctor tells them on the first telling (Griffith, 1990; Hughes, 1998; Ley, 1982) and 
50% of patients cannot remember anything they have been told about how to take 
their medicines (McGavock, 1998). 
Forgetting what the doctor told you does not necessarily lead to non-compliance if 
the directions are clear on the label and the patient has sufficient understanding to be 
able to follow them. Mr. GR was disadvantaged as he could not read the instructions 
on the label. Although not knowing what his medication was for may not have 
caused non-compliance as he was committed to taking it, it could have caused 
difficulties if new medication had been initiated whilst he was in hospital. 
Many subjects had difficulty explaining why all of their medicines were prescribed. 
This was not reflected in the level of information they claimed to have been given, 
with the majority stating that they received good information from their family 
doctor and only one subject, Mrs. DT (37DT071 022), voiced a desire to be more 
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involved in making decisions about her treatment. Her desire for infom1ation about 
new medication could stem from a need to be in control. She was not unhappy that 
she did not know what she had been prescribed in the past, but possibly wanted to 
ensure that new medicines were chosen carefully. Understanding why you are 
taking a medicine is not necessarily essential if compliance can be achieved without 
it. However, the likelihood of compliance may be decreased if the patient does not 
understand why compliance is important. This will be discussed in greater detail in 
Chapter 7. 
There did not seem to be any correlation between total scores, age or AMT and 
understanding of regime. Females tended to have a slightly higher understanding of 
their medication, but this was not statistically significant. Half of the subjects 
identified with this risk factor were otherwise found to be at high risk of non-
compliance and so would have been identified without this question. However, as 
53% of those who had a moderate to high risk of non-compliance because of 
problems with understanding were self-administering, accounting for 20% of the 
total sample size, questioning subjects' understanding of their medication regime is 
therefore a useful tool in assessing compliance risk. 
Satisfaction with medication 
Twenty-one subjects ( 41%) were at risk of non-compliance due to dissatisfaction 
with their medicines. This dissatisfaction was generally non-specific with the 
subject being unable to explain why they were unhappy and what solutions they 
thought were necessary. Nineteen (90%) of these subjects also reported lack of 
satisfaction with the information they had been given by their doctor. Only half of 
them (11) reported a lack of efficacy as the reason for their dissatisfaction with their 
medication. Fifteen (70%) could satisfactorily explain why they had been 
prescribed. This implies that understanding why something has been prescribed does 
not necessarily lead to an agreement of its necessity. Only eight subjects with this 
risk factor were deemed to be at high risk of non-compliance, although none were 
calculated to be at low risk. 
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Men and women appeared to have similar attitudes to their treatment and age did not 
appear to affect this score. Subjects with higher non-compliance risk scores were 
more likely to score highly with regard to satisfaction with medication, however a 
number of subjects at very high risk of non-compliance reported being completely 
happy with their medication and scores in this area were not a good predictor of 
compliance risk. There was no correlation between satisfaction with medicines and 
the Abbreviated Mental Test scores. 
For half of these subjects, a belief that their medication was not working seemed to 
be the main reason for their dissatisfaction with their medication. In most cases the 
hospital doctor confirmed the lack of efficacy and changed their treatment. It is not 
known why these subjects had not reported that their medicines were not working to 
their general practitioner. However, it is possible that they had voiced these 
concerns but specialised advice appeared to be necessary. It would be hoped that the 
perceived lack of efficacy had not been ignored in primary care. 
Some subjects understood what was wrong and why they required a change in 
therapy, for example, Mrs. AP (37 AP050312) complained of breakthrough pain 
before her next dose of analgesics were due; the main reason for admission was a 
review of her analgesia. This type of problem is likely to encourage over-use of 
medication as the subject may decide to take extra doses to ensure that they last long 
enough. She had discussed this with her general practitioner and so concordance 
was achieved; the risk to compliance was therefore greatly reduced. 
Often, however, the patient's interpretation of what is wrong and the possible options 
for remedying it is often not the same as the doctor's interpretation (Col, 1990; 
Sanghani, 1998). A claim that medication is not working may mask a number of 
alternative problems. Incorrect use of medication or devices, drug interactions and 
insufficient knowledge of what the medication is prescribed for could all present in 
this way, as well as the dose being insufficient or the medication inappropriate. 
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Mr. JP (39JP011015) illustrates the difficulty between reconciling a patient's clinical 
need and his or her attitudes to medication. He had a clear need for a complete 
review of his analgesia as his leg pain was uncontrolled. However, he did not want 
to be addicted to analgesics and frequently missed doses. It is often claimed that if a 
patient understands why he is taking his medication, and he identifies with the need, 
then he will be compliant (Mazzuca, 1982). However, Mr. JP shows that patient's 
have more than one method of evaluating the need for a medicine. If the fear of side 
effects or dependence is greater than the perceived need for treatment, then a patient 
may still be reluctant to comply with the regime, even if this results in hospitalisation 
(Anonymous, 1997b; Lorenc, 1993; Misselbrook, 1998b). Concordance may help to 
improve the success of this subject's treatment, as he believed that his muscle 
relaxant was more appropriate and possibly safer than his analgesic. Increasing the 
dose of his muscle relaxant, whilst at the same time providing him with a stronger 
pain killer, to be used only when he felt he needed it, may have improved his 
satisfaction with his treatment. This is an example of where the doctor can 
unwittingly cause non-compliance by not listening to the patient's opinions and 
desired outcomes of treatment. 
Occasionally subjects had a clear understanding of what was needed which was 
completely irreconcilable with the opinion of the doctors. Mrs. MC (39MC080425) 
had Parkinson's Disease, but this was well controlled and she had no obvious 
symptoms of deterioration that could be treated by adjusting her dose. However, she 
was very clear that she wanted a dosage change, although the reason was not 
possible to elucidate. Interestingly, she felt her antidepressant was ineffective and 
the doctors tried to adjust the dose to improve its efficacy, however, she resisted this 
change. Concordance in this case may have resulted in a more satisfied patient but 
may also have resulted in inappropriate treatment. This illustrates a difficulty in 
reconciling concordance with evidence based medicine. 
Mrs. DT (39DT280515) was generally unhappy with her medication and blamed this 
on lack of efficacy; but although she knew why she was taking them, she was unable 
to explain what she meant by saying they were not working. She felt she needed a 
change in medication because her antihypertensives caused dizziness. It is difficult 
in the elderly to differentiate between a lack of efficacy, deterioration in clinical 
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status and an adverse effect of medication. As we discuss below, few subjects 
complained of side effects of drugs although this is often quoted as a cause of non-
compliance (Anonymous, 1997b; Col, 1990; McGavock, 1998). It is apparent that 
although the terms adverse effect and lack of efficacy have specific technical 
definitions which reflect both the problem and the means of solving them, to a 
patient these may be alternative ways of saying that their condition is uncontrolled. 
It is not known why Mrs. DT's general practitioner did not identify the problem with 
her medication. It may have been that she did not tell him, but this could also 
identity a problem with monitoring and medication review for this subject. 
The responses of Mrs. JR (39JR240413) to questions regarding her treatment were 
interesting. Although she claimed that she was very happy with her treatment she 
wanted a change and thought they were not working. Obviously, she did not 
perceive that these questions were related and so gave conflicting information. This 
could be a problem with the question being ambiguous, or it could reflect the 
complex nature of patient's attitudes to medicines and compliance. The question 
regarding happiness with medicines was intended to detect any non-specific 
dissatisfaction with medication, which may or may not have had an effect on a 
subject's willingness to take it. It was hoped that subjects would admit to 
dissatisfaction when perhaps they had no concrete reason for their desire to change 
their medication and a lack of efficacy was not the problem. For some subjects, like 
Mrs. JR, this question appeared to be interpreted as a criticism of their general 
practitioner and so they answered in the affirmative only to contradict themselves in 
subsequent questions. 
An alternative reason why subjects may give apparently contradictory answers to 
similar questions may be because they are too similar. The subject may view them 
as developments of one theme and so if they claim to be completely happy with their 
medication they may feel free to show a small degree of dissatisfaction later. 
Conversely, a subject who voices unhappiness may contradict himself in subsequent 
questions in an attempt to reduce the severity of his initial response. This illustrates 
the importance both of asking relevant questions in a variety of ways and the 
necessity of taking such answers as a whole. 
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Most subjects who were unhappy with their medicines or wanted a change in 
treatment also claimed to have been given little or no information about their 
medicines, although this was not statistically significant. However, only three 
wanted to be more involved in making decisions about their medicines. This may 
therefore reflect a number of possible scenarios. Firstly, subjects given little 
information about their medicines may therefore have less trust in their medicines 
because they have not been involved in the decision making process. Altematively, 
one may infer that subjects who are dissatisfied with their medicines also have less 
faith in what their doctor has said and so do not remember whether any information 
was supplied. It is not possible, within the confines of the present study, to decide 
whether either of these is active here or whether the coincidence between these two 
risk factors is accidental. 
Mrs. PN (3 7PN 120316) reported being happy with her medication but thought she 
needed a change, in this case because the nurses had not given her any medication. 
Why she was under the impression that her medication had been stopped is not 
known as the nurses had been administering them. It is possible that different brands 
were being supplied and so she was endorsing a change she thought she had already 
received. It is not possible to understand exactly what she meant, but this may 
illustrate the difficulties caused by brand changes and therapeutic substitution on 
admission to and discharge from hospital (Lowe, 1995; Parkin, 1976). 
Becker' s health belief model states that the likelihood of patients following a regime 
is related to their motivation and incentive to do so (Becker, 1975). For example, 
treatment for minor acute conditions may not be complied with once improvement 
occurs because of the low-risk nature of the condition (Moriskey, 1986). The 
decision to comply with medication for chronic conditions, however, is made on the 
basis of the understanding of his vulnerability to sequalae. In contrast, a patient may 
forget to take medication for chronic conditions if they do not feel any day to day 
benefit, whereas medication for acute conditions with clear symptomatic control may 
be forgotten less frequently. 
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Efficacy 
Thirteen subjects (25%) believed they required a new medicine or a dose change 
because of lack of efficacy. In seven cases (54%) the doctor agreed and therapy was 
changed during the admission. Of the remaining six subjects, five did not 
completely understand what they were taking and what it was for. As described 
above eleven (85%) of these subjects were also dissatisfied with their medication. 
All except one of these subjects also reported a lack of information from their doctor. 
There was no difference in belief that their medicines were effective between males 
and females and there was no correlation with age or Abbreviated Mental Test 
scores. There was no significant trend in the relationship between efficacy and non-
compliance risk score. 
Efficacy describes whether a medication achieves the desired outcome. In some 
instances, the subject's view of efficacy was the same as that of the doctor but often 
this was not the case. Many subjects claimed they simply did not know whether 
their medicines were effective because they did not know what to look for. It has 
been shown that if patients see a clear endpoint, or symptoms are controlled, then 
compliance improves (Britten, 12998; McGavock, 1998). There is therefore an 
argument for educating patients in understanding how to tell whether a certain 
treatment is effective. 
For many drugs efficacy is measured by blood tests or a lack of certain physiological 
markers, which may not be observable by the patient unless the doctor clearly 
explains what these test results mean. However, for many medicines such tests are 
infrequently carried out, so this positive feedback is not available for the patient. 
This may cause them to incorrectly judge that a particular drug is ineffective and 
either discontinue an apparently useless medicine or increase the dose until some 
effect is felt - risking toxicity. This error is made because of limited understanding 
of pham1acology, but may also be complicated by exaggerated beliefs in other 
medication which are based on prior experience, not necessarily their own, or 
misguided attribution of efficacy. It is interesting to note that the majority of 
subjects who reported being unsure of efficacy also reported not being given any 
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information by their GP. This may reflect the fact that all information had been 
forgotten although it had been given initially. In other words if a patient cannot 
remember what he has been told, it is just as likely that he will forget that he was 
ever told it. However, it is also possible that no information was given to him. If 
this is the case, it is to be expected that the patient will have a poor understanding of 
what is expected ofthe medication. 
Interestingly, asking whether a patient is happy with his medication and whether 
they are effective may be insufficient to identify problems. Mr. WR (39WR030922) 
reported being 'very happy' with his medicines and was well controlled on his 
current medication; he was admitted for a completely separate reason (fractured right 
hand). However, he said he wanted a nebuliser in place of his inhalers, not because 
they were not working, or because he found difficulty in using them, but to ensure 
they continued to work. It was not possible to elucidate why he felt he might need 
such a change but may have been related to prior knowledge he had of a friend or 
relative who had been given a nebuliser. This may therefore reflect the effect of 
social context on compliance (Ley, 1982). 
It is possible that Mr. WR might have been given a nebuliser in the past and found it 
effective or he may have known someone who had been prescribed one. He would 
have also seen the patients in the beds near him, some of which were using 
nebulisers, and he may have been worried that his breathing might deteriorate and 
become as bad as theirs. Unfortunately, on further questioning all he would say was 
that he thought it might prevent him from being ill. He did not divulge whether he 
had ever used one in the past or where he had got the idea. Elucidating the reasons 
behind a patient's satisfaction, or otherwise, with medication is complicated by the 
number of factors involved: past experience, social pressure, efficacy of medication, 
perceived susceptibility to illness and a number of others. Overcoming these 
difficulties depends on the patient being able to explain why they are dissatisfied, 
something which patients often find difficult. 
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Adverse drug reactions 
An adverse drug reaction is an unwanted event, which can be directly attributed to 
medication use. Eleven subjects (22%) claimed to have adverse effects from their 
medication. However, only two blamed adverse effects for a change in the way they 
took their medication. Mrs. MB (39MB290624) claimed that one of her medicines 
made her dizzy and so she now took it at night so it affected her less; the change was 
appropriate and had been recommended by her doctor. 
Mr. TH (39TH040114) claimed that one of his medicines caused breathlessness and 
another caused diarrhoea and so he stopped both of these. He was the only subject 
for which adverse drug reaction was a risk factor for non-compliance. The decision 
that Mr. TH made may have been appropriate; however, as he had not contacted his 
general practitioner, he was at risk of stopping a drug to which he may have 
erroneously attributed the adverse effect he described. It was also possible that all of 
these symptoms, which had been attributed to certain medicines as adverse effect, 
may have been a presentation of a new illness and therefore should have been 
investigated. This shows the importance of regular medication review and 
monitoring in the elderly. 
As described above, many patients have difficulty in differentiating between illness, 
lack of efficacy and adverse drug reactions. Those that do report adverse effects 
may be erroneously attributing them. As most subjects claimed that adverse effects 
did not affect the way they took their medicines it appears not to be a significant 
cause of non-compliance. Other authors support this (Ley, 1982). However, it is 
also important for the prescriber to select drugs with the safest side effect profile and 
the maximum efficacy. In some medical conditions this is difficult, as all treatments 
carry high rates of problematic side effects, such an example would be 
schizophrenia. However, where a choice is available, for example hypertension, the 
treatment with the least number of side effects should be selected. If a patient 
complains of adverse reactions or this limits compliance, an alternative treatment 
should be selected whenever possible. 
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Asking about side effects does not appear to give any extra benefit when trying to 
calculate a patient's risk of non-compliance. It is essential, however, in the 
therapeutic management of disease, as reports on adverse effects may mask new 
diagnoses or sub-therapeutic treatment. 
Information needs 
Thirty-six subjects (71 %) were judged to be at risk because of the level of 
information they had been given about their medication by their general practitioner 
or hospital doctor. Of the 15 subjects who were judged to have been given sufficient 
information from health professionals, seven were assessed as being at low risk of 
non-compliance. These accounted for 54% of all subjects who did not require 
interventions. Of the remaining eight subjects, three were not self-administering on 
discharge and three refused entry into the study. 
Although 36 subjects were judged by the investigator to have received insufficient 
information about their medication, 30 of these were happy with the level of 
information the had been given, that is they were happy to continue to trust their 
doctor and had no wish to attempt to achieve concordance. Table 5iv shows these 
details. 
Table Siv: Satisfaction with information supply 
Sufficient information from GP 
Sufficient information from hospital 
Happy with information supply 
* As judged by the investigator 
Information given* 
(n=lS) 
14 
8 
15 
Information not* 
given (n=36) 
21 
0 
30 
Very few subjects in this study (eight) recalled being given any information about 
their medicines, even about medication changes, during their hospital stay. 
However, most subjects (68%) recalled their general practitioner or community 
pharmacist giving them sufficient information. A quarter of the subjects who 
reported receiving infom1ation from their general practitioner (nine) stated that this 
was normally only when they received a prescription for a new drug. 
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There was no correlation between information supply and non-compliance risk 
score, gender or age of subject. Fourteen subjects from the 15 judged to not be at 
risk from this non-compliance factor had an Abbreviated Mental Test score (AMT) 
of eight or above, however, this wasn't statistically significant (see Table 5v). It 
could be suggested that the reason behind this apparent correlation is due to 
prescribers offering more information to those patients who appear to be better able 
to understand it, which could include those with a higher AMT. However, it could 
also be explained by the fact that subjects with a lower AMT may not give reliable 
responses if memory is required to give that response. In other words, a subject with 
a low AMT may describe not being given any information, when they have actually 
forgotten that this information was given. 
Table Sv: Distribution of AMT scores with information supply 
MeanAMT 
Standard deviation 
Information given 
(n=15) 
8.4 
1.25 
Information not 
given 
(n=36) 
8.0 
2.27 
The desire which subjects had for information and the possible implications are 
discussed in Chapter 7. Although most subjects reported low levels of infonnation 
supply, the majority of subjects were happy with this level and their involvement in 
the decision making process. There may be a number of reasons for this, which will 
be discussed in more detail later. 
Physical and sensory problems 
Physical problems showed potential to affect compliance in 18 subjects (35%). The 
range of these problems is described in Table 5vi. Although physical ability 
increased generally with non-compliance risk score, this was not statistically 
significant. Physical ability did not correlate with any other measure such as safety 
of storage and administration practice or Abbreviated Mental Test score. 
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A third of subjects had physical problems that caused difficulties with compliance. 
Some subjects had already successfully solved a number of these problems. 
However, many subjects still required further assistance because their difficulties 
had not been identified by anyone else and the subject was unaware that any 
assistance was available. The range of solutions that can be offered are described 
below and include different sized print on labels, dispensing medicines in different 
containers and providing compliance devices such as the Haleraid® for inhalers and 
the Autodrop® for eyedrops. Community pharmacists could easily identify these 
problems by asking simple questions and the pharmacist could offer solutions. Some 
Health Authorities provide leaflets describing what is available to enable patients to 
volunteer this information proactively (Southern Derbyshire Community Health 
Services, 1992). Better advertising of these solutions should be available in primary 
care. 
Table 5vi: Physical problems encountered 
Physical problem 
Unable to open CRCs 
Unable to remove tablets from blisters 
Unable to read any print 
Unable to read standard print 
Unable to remove lids from small bottles 
Difficulty measuring liquids onto a spoon 
Unable to actuate inhaler 
Unable to co-ordinate breathing with 
actuation of inhaler 
* Subjects could have more than one physical problem 
CRC = child resistant closures 
Frequency* 
12 
8 
3 
5 
1 
1 
2 
1 
Three subjects were unable to read print of any size or density. One of these was 
registered blind, the other two had impaired vision but had not been registered as 
partially sighted. Being unable to read labels is an obvious potential cause of non-
compliance (Lorenc, 1993; McGavock, 1998; Sweeny, 1989) as a patient who is 
unable to read labels will not benefit from the regular daily reminder of the dose and 
time of day which medicines must be taken. For one subject, Mr. GW 
(37GW281024), this did not pose a particular problem as his sister arranged all his 
medicines for him and so there was no need for him to read the labels. The other 
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two subjects, however, were at significant risk of non-compliance and because of 
this a daily prompt and other assistance was required. 
Five more subjects were unable to read labels of a standard print size ( 10-12 points), 
but could read larger labels (18-24 points). Being unable to read standard print 
labels put a subject at a similar risk to being completely unable to read labels. 
However, large print labels or using a magnifying glass can be used to allow these 
subjects the possibility of using the label as a reminder (Lorenc, 1993; Sweeny, 
1989). Other patients with severe visual impairment may benefit from use of Braille 
labels, however, not all visually impaired people can read Braille, and careful 
selection is required. Other limitations of Braille labels are the lack of facilities to 
produce these in a Pharmacy. This means that information is restricted to that 
produced by organisations such as the Royal National Institute for the Blind, which 
generally only included details of number of tablets and frequency. It is important to 
provide information in a form that the patient understands; however, the European 
Council Directive 92/27/EEC states that labels and manufacturer's information 
leaflets must be written in English and conform to certain standards (Appelbe, 
1997). For foreign nationals and patients with difficulty in reading English, 
additional information may be supplied which is easier to understand and follow. 
Two subjects found difficulty in actuating inhalers, and one of these, Mrs. GM 
(39GM031 015), also found difficulty in co-ordinating her breathing with pressing 
the canister. Aerosol inhalers have been very useful in the treatment of asthma and 
chronic lung diseases. However, they are very difficult to use, with few people 
accurately timing the dose to the breath (Johnson, 2000). Pressing the canister is 
also difficult for patients with poor manual dexterity. An inability to use these 
devices correctly can mean that although the dose is taken at the correct time, an 
insufficient amount is deposited in the lungs and so the patient does not receive the 
expected benefit. Both of these subjects had difficulty using their inhalers and 
required alternative devices to ensure they received maximal benefit (Lowe, 1995). 
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Manual dexterity can cause many other problems with unintentional non-
compliance. Inability to remove tablets from their packaging is potentially a cause 
of non-compliance (Hughes, 1998; Lorenc, 1993; Sweeny, 1989). This can cause 
doses to be missed whilst the patient is waiting for assistance in removing them or 
they may decant the doses into another container, losing all the benefit of having a 
labelled container and potentially reducing the shelf life of the product. Many 
elderly people encounter difficulty in removing tablets and capsules from blister 
packs. Eight subjects in the current study encountered this problem. Social Services 
home carers are not allowed by their contract to remove doses from blister packs and 
so only a verbal reminder was available to them. In order to be able to take their 
medicines these subjects would therefore have to decant them into other bottles that 
may have the wrong label or out of date instructions leading to confusion and non-
compliance. An alternative would be for the Pharmacy dispensing medication to 
decant them at the time of dispensing. 
Similarly, medicine bottles can be problematic for elderly people to open if child 
resistant closures are used. Twelve subjects encountered this difficulty. Although 
these closures reduce the risk of young children accidentally gaining admission to 
the contents of a medicine bottle, they can also effectively prevent a patient from 
being able to take their medicines. If a screw cap is not provided at the time of 
dispensing, then the patient may decant their tablets into a bottle for which they have 
a screw cap, with all the attendant risks described above. One subject, Mrs. SW 
(39SW080425), solved this problem by decanting her medicines straight into a 
Medidos, a safe and effective container to allow her to accurately take her medicines. 
Other subjects did not have such safe solutions. A quarter of subjects could not open 
child resistant closures and others preferred screw caps; it would be appropriate 
therefore to ask all elderly patients whether they would require screw caps on their 
bottles. 
A number of subjects had significant physical problems, which could impinge on 
their ability to comply with medication. These problems did not occur in any 
particular age group or correlate with any other compliance risks. Also, the range of 
problems, although predictable if a detailed knowledge of the subject's medical 
condition was known, they could not necessarily be predicted without such 
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knowledge. There did not appear to be any single physical problem that required 
intervention for the majority of subjects. It is important therefore to identify 
individual physical problems when assessing a patient's compliance risk. This 
question was a useful tool and identified the pharmaceutical needs of some subjects 
who would otherwise have been missed. 
Complexity of regime 
Most of the subjects (36 = 71 %) were at risk of non-compliance due to the 
complexity of their medication regime. A complex regime was defined as one with 
five or more drugs and in which the maximum frequency for any drug was greater 
than twice a day. The data are shown in Table 5vii. These figures are different to 
those shown in Table 3ix as this table relates to pre-admission data, whereas Table 
5vii relates to data after a medication review had taken place and represents drugs on 
discharge. 
Table 5vii: Complexity of regime 
Number of drugs 
~ 5 =at risk 
Mean (S.D.) 
Range 
Number of subjects at risk* 
5 (2.5) 
1-13 
30 
* 22 subjects had both risk factors 
Maximum frequency of doses 
~ tds = at risk 
Once daily 
Twice daily 
Three times a day 
Four times a day 
Number of sub"ects at risk* 
7 
16 
1 1 
17 
28 
The number of drugs prescribed and the frequency of doses were equally likely to be 
the cause of the increase in non-compliance risk. Thitiy-two subjects also had three 
or more different directions as to when medicines should be taken, for example in 
the morning, at night, twice a day, etc. One subject had five different sets of 
directions for a total of ten different medicines. 
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71% of subjects studied were at risk of non-compliance because of the complexity of 
their regime. There was no correlation between age, gender of subject or non-
compliance risk score and complexity of regime. As complexity did not correlate 
well with the non-compliance risk score, measuring complexity would not allow 
assessment of the subject's full range of compliance problems. Use of this measure 
is therefore essential, but not sufficient, for assessment of a subject's complete 
compliance picture. 
In many cases complexity of regime increased or remained the same at discharge 
compared to pre-admission levels. This reflects the difficulty of rationalising 
medication regimes for patients with multiple conditions and complex requirements. 
Assessing risk of non-compliance due to polypharmacy is important but it is often 
not possible to reduce this risk factor unless treatment is subtherapeutic prior to 
review. This issue is discussed in greater depth in Chapter 8. 
Correlation between categories 
As has been described earlier there was little correlation between any of the 
categories investigated or the total compliance risk score. This lack of correlation 
could reflect two scenarios. Firstly the questionnaire could be poorly designed and 
therefore the information gleaned would be contradictory with no possibility of 
correlation. Although some of the questions did cause difficulty with a few subjects 
most questions appeared to be understood and answered fully and honestly. The first 
question regarding any assistance subjects received in taking their medicines was 
occasionally misunderstood. In each case, however, the true answer was found 
before the interview was completed and this did not significantly affect the non-
compliance risk score, but rather affected the interpretation of results and 
identification of appropriate interventions. 
The information given by the subjects was occasionally contradictory, especially in 
two particular areas. Firstly, many subjects claimed to be happy with their 
medication but felt it was not working or that they needed a change. Similarly, some 
subjects felt their medicines were effective and did not need any alteration, but still 
they were not satisfied with their medication. This apparent contradiction has been 
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discussed earlier in this chapter and could be explained by the complex way in which 
patients rationalise the need for medication. The second apparent contradiction came 
with questions regarding information supplied by the doctor and the perceived need 
for further information. This will be discussed later and does not necessarily reflect 
a contradiction. 
A second explanation of the lack of correlation is based on the fact that compliance 
is complex and mediated by many factors (Griffiths, 1990). In order to assess a 
subject's risk of non-compliance it was necessary to investigate each of these factors. 
Assuming that each of these risk factors is discrete, a lack of correlation could be a 
sign of a well-designed questionnaire. No claim can be made regarding the 
exhaustive nature of the questionnaire although this was attempted. Lack of 
correlation would indicate that the questions were not overlapping or ambiguous, 
ensuring that each problem is accurately assigned to the correct risk factor. 
Correlation would be expected in some isolated cases where the subjects have a 
number of risk factors. For example, a subject who is confused would score low in 
the Abbreviated Mental Test (AMT) and the understanding of medicines category. 
However, a subject who was not clinically confused could score highly in AMT but 
still be unable to recall the medicines they were prescribed. 
Rate of self-medication 
Of the subjects enrolled into the first stage of the study three were not self-
administering at the start of the study and a further seven were discharged to nursing 
or residential homes, or received significant input from Social Services on discharge. 
These subjects accounted for 20% of the total interviewed. However, a significant 
number of patients were not interviewed because they stated that they were not 
responsible for self-medicating at home. This was particularly prevalent in males 
who generally stated that their wives reminded them to take their medicines and 
frequently counted them out ready to be taken. It is not possible to state whether this 
behaviour is common to all males, or even to males from North Eastern England; 
however, a clear trend emerged with male subjects more frequently denying 
responsibility for their medication. Other sources do not appear to describe such a 
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phenomenon with regard to medicines. However, there may be some evidence to 
suggest that women are more compliant than men are in behavioural circumstances, 
and this may be extended to the lifestyle issues of compliance with medication 
(Ward, 1984). Also, it is claimed that women take on a nursing role more readily 
than men do (Stone, 1987). 
Many of the women interviewed wanted to be in control of their treatment and 
appeared to feel that giving up responsibility of self-administration to another person 
was a sign of weakness. This could be a problem for those women who encountered 
difficulties with taking their medicines but did not want to ask for help. Such people 
may be at higher risk of unintentional non-compliance. Intentional non-compliance 
could be lower in this group, except when the subject disagreed with the doctor's 
opinion as to the appropriateness of the therapy prescribed. 
A number of the men interviewed relied on their wives to remind them when it was 
time to take their medicines. For some men, like Mr. JP (39JP011015) this reflected 
a joint effort and was of little concern as the reminder enabled both of them to 
comply to a greater extent; his wife reminded him when to take his medication 
although he was responsible for getting it out. However, other men were more like 
Mr. SH (39SH101120) who completely relied on his wife to remind him when to 
take his medication and get it out for him. He took little interest in his own 
medication, to the point of not really wanting to know why he was prescribed them 
or when he should take them. 
If a patient is not responsible for their medicines at all, that is another person not 
only reminds them when to take them but also removes them from the container and 
hands them to them, they will have great difficulty in remembering when to take 
them. Mr. SH knew what more than half of his medicines were but could not 
remember when he took most of them. As his wife was completely responsible for 
his medicines, this was not problematic. This may be an example of a man 
abdicating responsibility of his medicines to his wife; or may be indicative of his 
difficulty in self medicating. It was not possible to ascertain whether his 
forgetfulness caused his wife to take on this administration role, or whether her 
125 
assistance removed the need for him to remember, thus causing him to become 
dependent on her. 
Dependence on a spouse to remember when to take medication can potentially cause 
problems if, as is usually the case, the wife is also elderly and may become confused 
herself. Also if the wife is admitted to hospital or she dies, this will result in the 
husband having to take responsibility for administering his own medication, a 
practice in which he has become inexperienced and may therefore become 
unintentionally non-compliant. Alternatively, he may be intentionally non-compliant 
because he does not appreciate the necessity of complying. It is interesting to note 
that although elderly women tend to have a number of caregivers providing 
assistance with transport, shopping, etc., men tend to rely on their spouse for more 
intensive tasks such as personal care and house keeping (Tennstedt, 1989). The 
reciprocal problem was not often seen in widowed women, possibly because they 
had taken on the mother role earlier in their marriage and so their willingness and 
ability to cope may have been greater. It does appear that in old age people tend to 
continue with those roles they traditionally carried out in earlier life. The attitude of 
caregivers also appears to differ with the gender of the person requmng care 
(Tennstedt, 1989). Women tend to outlive men (Guralnik, 2000) and this may affect 
the way women continue with nonnallife after bereavement. 
The subjects in this study had a high level of social support. A total of 34 subjects 
(69%) described having a relation or a Social Services home carer visiting regularly 
to provide help with domestic issues. Three of these were not self-administering and 
a further eight received a reminder if medicines were forgotten. It was unclear why 
these subjects claimed to be independent when they had high levels of support with 
taking medicines. The remaining subjects (n = 24) were independently self-
medicating. 
Patients who are at high risk of non-compliance and also confused will reqmre 
Social Services or family input into their care to ensure that medicines are taken 
appropriately. However, if independence is reduced because of a regular reminder 
then there is a possibility that all ability to manage to take their medicines 
independently will be lost. This can be seen in other aspects of life. Patients who 
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have been long-term in-patients in hospital can become institutionalised and 
therefore find minor tasks, which previously they completed with little difficulty, 
have now become very difficult (Hodkinson, 1981 ). It is important therefore for 
patients to retain as much independence as they wish and are capable of achieving. 
Only 17 subjects in the present study had no regular assistance and therefore were 
also independently self-medicating. Living alone in a socially isolated situation is 
often reported to impair compliance as social reinforcement improves faith in 
medication (Col, 1990; Ley, 1982; Moriskey, 1986). A lack of accountability to 
others may also reduce the perceived need to comply with medication or treatment 
regimes. In the current study this did not appear to be the case, however the sample 
size may be insufficient to detect this phenomenon. 
Three subjects received a measurable beneficial effect from their social input in that 
the carer had already implemented an appropriate intervention before admission to 
hospital. In each of these cases, the intervention was providing a Monitored Dosage 
System ready filled each week. This represented only a small proportion of the 
study group and many more subjects had not received any assistance with their 
medication or received a detrimental intervention. However, this illustrates an 
important point, namely that input can be from many sources and to ensure seamless 
care this input must be investigated and assessed. 
Few sources have quoted rates of independent responsibility for self-medicating in 
elderly people. This appears to be because most studies into compliance 
automatically exclude those patients not self-administering, on the basis that 
compliance with medicines does not rely in this situation on the patient's ability but 
on the carer's. In the current study, patients who were recorded as not self-
administering or who admitted to receiving considerable assistance with their 
medicines were excluded and so accurate rates of self-administration were not 
available except for those interviewed. In one study (Lowe, 1995) 94% of subjects 
were self-medicating. However, patients dependent on another person for 
administration of medicines on admission were excluded before the study 
commenced. 
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Law et al (1976) quoted rates of self-medication of 85% in their study of patients 
over 75 in one general practice. This is much higher than seen in the current study 
and may reflect a difference in the samples tested. Possibly the intervening 25 years 
has affected rates of self-administration, with fewer older people needing to be self-
reliant. This theory is not supported in the published literature, but it is possible that 
as life expectancy has increased more opportunities for assistance have been 
developed. It is also possible that the sample population studied in the current study 
included more frail, elderly patients, and so more of them were in need of greater 
assistance. This is impossible to verify, as the data presented by Law et al (1976). 
does not include age distributions, with all subjects simply described as being over 
75. It would be defensible to suggest, however, that as the population studied by 
Law et al was a general practice population, this may have included a greater 
proportion of fit elderly patients than the hospital population. The general practice 
population will include patients requiring hospitalisation but also patients who are 
fit, well, and in no need of such care. Such a population may require less input into 
taking their medicines because of fewer complications and possibly a smaller 
number of medicines taken. 
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Chapter 6: Enhancing compliance amongst elderly in-
patients -the contribution of hospital based pharmacists 
This study was carried out because a number of authorities have described the 
benefits a hospital pharmacist can confer if certain activities occur at discharge 
(Haynes, 1996). Although the study did not provide any concrete evidence that the 
interventions used did improve compliance it is interesting to consider which 
interventions were used most and what sort of benefit could be expected for the 
subjects. 
The problems encountered by the subjects in this study, and the interventions 
implemented to overcome these risks to compliance are shown in Table 6i. Thirty-
nine subjects required eleven different interventions. Each intervention implemented 
is described below with examples of their potential to improve compliance. 
Medication reminder leaflets 
A medication reminder leaflet (also called compliance reminder charts) such as the 
one shown in Appendix 11 was the most appropriate intervention for 16 subjects. 
This accounted for 40% of subjects who required an intervention. For eight of these 
subjects, the principal need for these reminder leaflets was a complicated regime. 
Mrs. CW (39CW060123) lived alone but coped well and only had a home carer 
assisting with washing and cooking. Mrs. CW reported that her general practitioner 
always gave her sufficient information about her medication but she had so far not 
been given any information whilst she was in hospital. At interview she was taking 
ten different medicines with five different instructions on how to take them; she was 
unable to explain what she was taking but knew the reason why. She claimed that 
she never forgot to take her morning medicines as she took them with her breakfast, 
however, she occasionally forgot to take her afternoon medicines. Treatment failure 
could result from taking doses too infrequently. 
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TabDe 6i: The causes of non-compliance risk and the solutions impDemented 
NUMBER AGE GENDER AMT TOTAL PROBLEMS INTERVENTIONS IDENTIFIED ACTIONED? 
37MM020233 67 F 9 34 Wants more Information, unhappy with medication. Compliance chart, counsel yes 
39MC080527 72 F 9 34 Unsure if medication appropriate, thinks one medicine is Compliance sheet, counsel yes 
ineffective, complex prescription 
39SW080425 75 F 8 31 Poor manual dexterity, unsure what taking or why, Compliance chart, counsel, MDS yes 
complicated regime 
37GW281024 76 M 3 19 Unable to explain medication, wants a change, doesn't know Refer to Social Service yes 
if working, poor manual dexterity, unable to read, confused, 
complicated regime 
37L0090524 76 M 10 37 Occasionally forgets medication, stops taking them when Compliance chart, counsel yes 
feels better, complicated regime 
39DW070422 77 F 9 34 Unable to read labels, complicated regime Counsel, compliance chart, large print labels yes 
37DT071022 78 F 10 32 Wants concordance, unable to explain what taking or why, Refer to doctor- concordance yes 
unsure if still needs medication or working. 
39ED070821 79 F 10 32 Takes medicines BD regardless, not careful to follow Counsel, compliance chart, screw caps, no blisters yes 
instructions, doesn't know what taking or why, poor manual 
dexterity, complicated regime 
39JG070221 79 F 8 37 Wants concordance Counsel, compliance chart yes 
37MM210420 80 F 10 29 Not sure if happy with medication, unsure if working, inhaler Counsel, compliance chart, change inhaler device yes 
unsuitable, complicated regime 
39DR150919 81 F 9 32 Could explain what taking and why with difficulty, doesn't Compliance sheet, counsel, large bottles, no blisters yes 
know if working, poor manual dexterity 
39JT060219 81 M 8 36 Poor manual dexterity Screw caps, bottles not blisters yes 
37PN120316 84 F 1 26 Unable to remember anything about medication, poor manual Refer to Social Services yes 
dexterity, confused 
39GM031015 84 F 10 29 Uns~;Jre if still needs medication, or if working, poor manual Counsel, change inhaler, screw caps, no blisters yes 
dexterity, complicated regime. 
39JP011015 85 M 10 33 Wants to stop taking some medication, ineffective Compliance sheet, change treatment yes 
39DT280515 85 F 6 27 Unhappy with medication, doesn't think they are working, Refer to Social Services yes 
confused, depressed, complicated regime 
39ML090414 86 F 9 30 Unable to open CRCs, complicated regime Bottles not blisters yes 
37LG061012 88 F 5 31 Unable to explain what taking or why, complicated regime, Monitored Dosage System yes 
confused 
39JR260810 90 M 6 28 Blind, unable to explain what taking or why, confused Refer to Social Services yes 
39EW130709 91 F 10 31 Unable to explain what taking or why, wants concordance, Counsel, compliance chart yes 
unsure if still needs medication 
39GR240107 93 M 9 32 Unable to explain why takes medication, unable to read labels Counsel, compliance sheet, large print labels yes 
39NW190130 70 M 8 38 Complicated regime Simplify regime (*simplification not possible) no* 
39MB290624 76 F 7 26 Poor manual dexterity, unable to read labels, unable to Compliance chart, counsel, large print labels (*discharged no* 
explain what taking or why, unsure if happy, complicated regime before interventions implemented) 
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NUMBER AGE GENDER AMT TOTAL PROBLEMS INTERVENTIONS IDENTIFIED ACTIONED? 
39CW060123 77 F 9 29 Unable to remember what taking, forgets afternoon medicines, Counsel, compliance chart (*died before discharge) no* 
complicated regime 
39WR030922 78 M 9 32 Wants a new medication, complicated regime Simplify medication (*regime optimal) no* 
39AG231221 79 F 9 31 Can't use inhaler, complicated regime Haleraid, counsel (*discharged before signing consent form) no* 
39E0111219 81 F 6 38 Unable to explain what taking or why, confused, complicated Counsel and compliance chart (*discharged to nursing no* 
regime home) 
39LH181217 83 F 8 36 Complicated regime Simplify regime (*not possible) no* 
39AB270916 84 M 8 36 Complicated regime Simplify regime (*not possible) no* 
39JF070716 84 M 9 35 Unsure if needs medication, didn't know if working, Simplify regime (*not possible), counsel (*refused)) no* 
complicated regime 
39GE11 0815 85 F 8 39 Unsure if happy with medicines, thinks she needs a change Review medication (*regime optimal) no* 
3910151114 86 F 8 29 Unable explain what taking or why, unable to read labels, Counsel, large print leaflets and labels (*refused no* 
complicated regime. wants concordance intervention) 
39JR240413 87 F 9 36 Thinks need a change in medication, ineffective Review regime (*optimal, refused intervention) no* 
37AP050312 88 F 8 33 Unhappy with medication, wants a change, not working, Review regime (*optimal), counsel, compliance sheet no* 
couldn't remember what taking (*discharged before intervention possible) 
37JP231209 91 M 9 34 Not sure if still needs medication, complicated regime Refer -concordance (*refused intervention) no* 
39EH230708 92 F 8 41 Complicated regime Simplify regime (*optimal) no* 
37NT070508 92 M 4 27 Poor manual dexterity, confused, complicated regime Refer to Social Service (*died before discharge) no* 
39AT150420 80 F 10 42 None None n/a 
390P200120 80 F 10 37 Complicated regime None (doctor already solved) n/a 
39SH101120 80 M 9 40 Unable to explain what taking or why None (not self-administering) n/a 
37KJ090117 83 M 8 33 None None n/a 
39MW151117 83 F 9 35 Unsure why taking medication, feels she needs a change, None (doctor already solved) n/a 
not working 
3908020916 84 F 9 39 Rheumatoid arthritis of hands Screw caps (*already implemented) n/a 
39AE240716 84 F 10 41 None None n/a 
39ER150215 85 F 5 30 Poor manual dexterity. Bottles not blisters (*daughter supervises) n/a 
39TH040114 86 M 10 26 Unable to explain what taking or why, unsure if needs a None (Monitored Dosage System already in use) n/a 
change or if working, complicated regime 
390H190712 88 F 9 42 None None n/a 
39JH010211 89 M 3 29 Unable to explain what taking or why, poor manual dexterity, None (referred to Social Services) n/a 
confused 
39AS291109 91 F 8 29 Wants more information, unable to explain what taking or why. None (Monitored Dosage System already in use) n/a 
39GR290503 97 M 9 36 Unable to explain what taking or why, not sure if working None (not self-administering) n/a 
39LP170702 98 F 8 32 Poor manual dexterity, doesn't want to take medication None (discharge to nursing home) n/a 
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Patients often have difficulty deciding what time of day each of their medicines 
should be taken and in which order. Also, medicines are often labelled 'as directed' 
or with instructions such as 'Take one tablet once a day'. It is much better to put full 
instructions on the label, including whether a once daily drug is taken in the morning 
or at night. Unfortunately, if the prescriber has not put this information on the 
prescription it cannot be put on the label. This information can be clearly marked on 
the medication reminder leaflet allowing the patient to understand quickly what they 
need to do. Patients with polypharmacy may be unsure how many different 
medications they need to take each time and reading each label may not help. 
Problems can occur if a container is left in a different room to the rest of the 
prescribed medication as that label will not be read and, unless the patient 
remembers to go and find it, it will be omitted. With a medication reminder leaflet 
the patient can use the chart to decide which medicines are required, and he is given 
an extra reminder if the number of tablets counted out is less than that indicated on 
the chart. 
Some subjects wanted more information about their medicines but did not want to be 
more involved in making treatment decisions. This is discussed in greater depth in 
Chapter 7. Using a medication reminder leaflet can most efficiently provide this 
information. The example shown in Appendix II demonstrates that in addition to the 
time of day each medicine should be taken being clearly indicated, the chart contains 
a column into which other useful information can be added. An example of such 
information could include the reason for the prescription, i.e. the condition the 
medicine is prescribed to treat. Other useful infonnation could include how to 
determine whether the medication is effective, the main adverse affects that are 
likely to be encountered and the action to take if they occur. The information 
included is by necessity brief and relatively standardised. However, it can provide 
the patient with the basic information they need and allow them to make informed 
requests for further information they may feel they require. 
Mrs. CW (39CW060123) and Mrs. ED (39£0070821) both made errors in 
administration of their medication, which were caused by a misunderstanding of 
when they should be taken. Mrs. CW tried to take one particular medicine at 3pm 
but often forgot to take it, as that time of day was inconvenient for her; teatime 
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would have been a more appropriate administration time. Mrs. EO took all her 
medicines twice a day because she found it too complicated to read all the labels on 
the containers. Many people, especially the elderly, have difficulty reading labels on 
medicine bottles. This is exacerbated if too much information is fitted onto the label. 
Having the information clearly laid out as shown in Appendix II reduces the 
confusion by arranging it under useful headings. 
There has been controversy over whether medicine reminder leaflets should be 
supplied to patients. The argument is such that all the information that a patient 
requires should be on the medicine label, a second reminder is therefore not 
necessary. Also, if the instructions change on a new prescription then it is important 
to change the reminder sheet, otherwise the patient will continue to take their 
medicines incorrectly. These criticisms are sound and the usefulness of a reminder 
sheet depends on its continued accuracy. It is important that someone takes the 
responsibility to update the information. Patients could be encouraged to take the 
chati with them each time they visit a doctor to ask them to enter changes. They 
could also ask the community pharmacist to update the form each time they get a 
new prescription. However, this is only completely safe if the patient always visits 
the same Pharmacy and their Patient Medication Records are updated regularly. 
Medication reminder leaflets are relatively simple for hospital pharmacists to 
complete and there is a possibility that with the development of information 
technology capabilities, these could be produced automatically using a pharmacy 
dispensing programme. Because of the potential benefit which medication reminder 
leaflets provide, they should be offered to all patients with complicated regimes or 
those who appear confused about their medicines. They should also be available for 
other patients who request one. As this would include the vast majority of elderly 
patients, they should routinely be provided for this population. 
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Provision of verbal information 
Nineteen subjects were provided with individually tailored verbal information on 
discharge. This included advice on what had been prescribed, the reason for the 
prescription, and when the medicines should be taken. This conversation, which 
lasted ten minutes on average, allowed the subject to ask questions regarding their 
treatment and offered an opportunity for last minute won-ies to be addressed. 
This subject is discussed in greater depth in Chapter 7. A chance to discuss the 
prescribed medication should be offered to all patients who have had a change in 
medication and those for whom non-compliance is suspected. This would include 
the majority of patients discharged from hospital and should be a routine service 
offered prior to discharge. 
Physical needs 
35% of subjects had physical problems, which could affect compliance. These needs 
were specific to individuals and broad generalisation cannot be used in order to 
improve compliance for all patients. For example, most subjects in this study who 
had physical needs had difficulty in opening child resistant closures (CRC). It would 
be defensible to generalise and give all elderly people screw caps. However, many 
people do not have difficulty in opening CRC and routine provision of screw caps 
may result in grandchildren or great grandchildren being put at risk because of the 
easy accessibility of medication. Similarly, removing tablets from blister packs and 
dispensing them in bottles would greatly assist some patients. However, doing this 
can potentially reduce the shelf life of the medicines and can remove the useful 
reminder of the days of the week often printed on the back of such blister packs. 
The difficulties introduced by an inability to open a container of tablets, capsules, 
liquids and many other dosage forms are relatively obvious. If a dose cannot be 
accessed it cannot be taken. The risks of patients decanting doses into other 
containers has been discussed earlier and therefore decanting should be can-ied out at 
the time of dispensing. 
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Physical problems with using other devices can introduce other risk factors for non-
compliance. For example, Mrs. MM (37MM210420) had uncontrolled asthma. As 
she was still symptomatic, it was clear to her that her treatment was sub-optimal. 
However, the patient's interpretation of what is wrong and the possible options for 
remedying it is often not the same as the doctor's (Col, 1990; Sanghani, 1998). Mrs. 
MM had decided that the device she had been given was not working. This 
illustrates the importance of giving patients medicines in the correct device or most 
appropriate form for their needs or expectations (Lowe, 1995). 
Mrs. MM's doctor's had recently changed her inhaler device because many patients 
find a dry powder device (such as a Clickhaler®) easier to use than a metered dose 
inhaler (a standard aerosol inhaler) as the later relies on the patient's ability to co-
ordinate breathing with pressing the canister. Unfortunately, Mrs. MM had not been 
instmcted how to use the new device and was therefore using it incorrectly causing 
deterioration in her asthma. In these circumstances, demonstration and explanation 
are usually sufficient to improve compliance. However, Mrs. MM had become 
convinced that the device did not work properly and the only solution was to swap to 
an alternative device, with adequate demonstration and explanation. 
No two patients will have identical physical needs and therefore there cannot be one 
universal solution. However, it is also the case that many physical problems can 
dramatically reduce a patient's ability to comply; ignoring such needs is therefore 
not an option and it is important to assess all patients for physical needs. This can 
generally be by means of a simple question, but may involve a more time-consuming 
trial and error assessment of suitable devices and interventions. For many of the 
subjects interviewed, the process of identifying and solving certain physical 
problems potentially reduced non-compliance risk more than any other intervention. 
It is essential for a hospital pharmacist to address these problems when they occur. 
However, it is of greater importance that these interventions are continued in the 
community. 
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Monitored dosage systems 
A great emphasis has been placed on Monitored Dosage Systems (MDS) by some 
authorities (McGraw, 2000). Many nurses request these for patients who may not 
have taken medicines correctly in the past, regardless of the cause. However, only 
one subject in the current study was given an MDS. The criteria for receiving a 
MDS included confusion when to take medicines despite verbal and written 
guidance, those who frequently forget whether they have taken a dose or not, and 
those who demonstrated unsafe administration methods. 
The MDS used in the hospital NT was the Medidos®. This is a small wallet that 
contains seven individual containers, one for each day. These containers can be 
taken out and carried in a handbag or pocket. Each daily container has three 
moveable dividers, dividing it into four sections labelled 'Breakfast' 'Lunchtime' 
'Teatime' and 'Bedtime'. Solid doses can be placed in the Medidos®, which can 
provide a reminder of when each medicine is to be taken and reassurance whether 
the previous dose has been taken. Other MDS such as Nomad®, Dosett®, Redidose®, 
etc., are based on a similar system, but differ in minor ways making them more 
appropriate to some patients than others. 
Although MDS are liked by many patients and recommended by many nurses, they 
are not universally helpful. Firstly, if the patient does not want to take their 
medication (intentional non-compliance), MDS will not improve compliance as they 
do not affect motivation. Secondly, if a dose is to be omitted or changed on medical 
advice it is not always possible to identify the relevant tablet and remove it, unless 
expert advice is sought. Another problem is that many of these containers are not 
child-resistant. 
Many patients fill their own MDS. This may limit their usefulness, as if a patient is 
confused about their regime they may fill the box inconectly. This may also apply 
to relatives filling these containers. The safest way for these to be filled is by a 
community pharmacist; however, this is costly and time-consuming for the 
pharmacy and means that the patient must always get their prescriptions filled at the 
same pharmacy to allow continuity. 
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Many MDS are difficult to open for certain people. It is important to ensure that the 
patient can open the container or there would be no benefit in supplying it. This may 
be a particular problem for patients who have had a stroke. MDS are often 
recommended for these people, as short-term memory loss may be present; however, 
the physical sequalae of a stroke may render such a container impenetrable. 
Although these containers can help with most solid dosage forms such as tablets and 
capsules, they cannot accommodate many other dosage forms including liquids, 
powders, inhalers, suppositories, eye drops or very large tablets, for example, 
effervescent analgesics. They cannot be guaranteed to be moisture proof, and so 
they cannot be used to store medicines that require a desiccant. They are also 
unsuitable for medicines prescribed 'when required', as the patient may not always 
need to take them at the same time each day. Unless the vast majority of prescribed 
doses can be placed in the MDS, there is little benefit to be gained from supplying 
such a container, as the patient will still need to read individual labels to decide when 
to take the excluded medication. 
Very confused patients, who do not know what time of day it is, will not be helped 
by MDS as they require a reasonable level of comprehension to know which section 
to open and will require outside assistance from a relative or carer to ensure 
medication is taken appropriately. It is worth noting at this point that occasionally 
the carer will require an MDS to ensure they give the patient the appropriate 
medication at the correct time. Most patients with poor vision will not be able to use 
MDS as they rely on visual prompts on the most part. Although a small number of 
visually impaired people may derive some benefit from MDS, other interventions 
such as large print labels, Braille labels, different sized containers, etc., may be more 
appropriate. 
If a patient is identified in hospital as requiring a Monitored Dosage System then it is 
essential that they are supplied on discharge as the first few days following discharge 
often present the greatest risk to non-compliance due to changes in treatment. Also a 
small number of subjects in the current study were using an MDS prior to admission. 
It is essential that these patients are identified early and the device brought into 
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hospital to be filled ready for discharge. Neglecting to do this and subsequently 
dispensing medication in bottles and boxes can mean that these patients are at a 
greatly increased risk of non-compliance on discharge from hospital. 
There are a few patients for whom MDS may greatly improve their ability to take 
their medicines. This includes those with complicated regimes that cannot be 
simplified, those for whom other solutions are inappropriate and patients with short-
term memory loss and confusion. These patients must be identified and offered 
these devices, despite the time-consuming nature of filling these devices. As nurses 
frequently recommend MDS inappropriately, a pharmacist should assess all patients 
who potentially require these devices for their suitability. It is essential that safe and 
appropriate continued filling of these devices is available after discharge. 
For many patients Monitored Dosage Systems will not offer any improvement in 
compliance and may introduce more difficulties (McGraw, 2000). This emphasises 
the importance of patient focused interventions and not offering one solution for all 
patients. 
Simplifying the regime 
Chapter 8 will discuss the finding that simplifying complicated regimes of individual 
subjects was often not possible. However, it is essential to ensure that patients have 
the best possible regime. This combines treating each condition with the most 
effective medicines, avoiding medicines which can cause troublesome side effects, 
ensuring unnecessary medicines are removed and making the final treatment regime 
as simple to take as possible. Medication review should occur for every patient and 
not just those for whom non-compliance is suspected. This should be carried out by 
all health professionals each time the patient is assessed. However, the hospital 
pharmacist has an important role to play. 
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Other interventions 
A number of other interventions were implemented for individual subjects. 
Although they appeared to be accepted well by the subjects, it is not possible to state 
whether compliance was improved, although they did eliminate or reduce the effect 
of at least one risk of non-compliance. These interventions were tailored to 
individual subjects and would not have been appropriate for all subjects. For 
example, clear printing on labels is important for the majority of people, but large 
print would only be appropriate for patients with poor but extant visual capabilities. 
The blind would not benefit from large print and those with no visual impairment 
may find the duplication of information confusing and the flagging of labels, which 
is often required when using large print labels, problematic. If other interventions 
are required then these should be tailored for individual patients, as broad 
generalisation of requirements is not possible. 
Continuation of interventions 
In order for patients to benefit from interventions initiated in hospital, they must be 
continued in the community. The role of primary care in improving compliance is 
discussed in Chapter 9. 
The appropriateness of pharmacy generated interventions 
90% of subjects were identified as being at moderate or high risk of non-compliance 
and required some type of intervention. The ward nurses and doctors appeared to 
identify those patients who required referral to Social Services quite easily as this 
was often on the basis of the subject's Abbreviated Mental Test, which was routinely 
assessed for all confused patients. Similarly, subjects with severe physical 
disabilities were readily identified and referred to Social Services or to the 
pharmacist. The other risk factors for non-compliance did not appear to be 
considered by the other health professionals and so were not solved without the 
pharmacist's intervention. 
140 
Although there is an absence of evidence that these interventions had a positive 
benefit on the subjects' ability to comply with their medication, the interventions 
used have been justified earlier. It is possible that the subjects interviewed would 
have continued with the same practice regardless of the intervention, but it is the 
case that the problems identified were real and therefore required some solution. 
All of the interventions, except providing verbal information or medication reminder 
leaflets, needed to be implemented by a pharmacist or member of the pharmacy 
department. This is because they involved alterations in dispensing techniques, a 
role for which responsibility exclusively rests with a pharmacist. A ward nurse 
could discuss the medication with subjects on discharge. Similarly creating 
medication reminder leaflets is not exclusively the domain of pharmacy. However, 
there is an argument that a pharmacist may have a better ability to give appropriate 
information about medicines on discharge than a nurse as the pharmacist has greater 
knowledge and training with regard to medicines. It is definitely the case that 
pharmacists are in a better position to answer less routine questions, which may be 
asked during counselling sessions. 
Potential benefit to subjects 
The rationale for using the particular interventions that were used in the current 
study has been discussed earlier (see Chapter 3b). It is hoped that if appropriate 
interventions were offered and implemented then the subjects would improve their 
ability to comply with medication. They would have a more acceptable regime, 
which contained medication they understood and were able to take correctly. The 
likelihood of forgetting to take a dose would be reduced. All this would improve the 
therapeutic outcome and reduce morbidity, and possibly even mortality. 
However, this depends on the patient being prescribed appropriate treatment. If 
subtherapeutic or incorrect medication is prescribed, or if essential medication were 
omitted, then fully complying with a treatment regime would not confer the full 
benefits described above. Evidence based medicine combined with concordance and 
reduction of barriers to compliance should improve the outcome of medicines use. 
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Improving the efficiency of the intervention process 
Using the questionnaire to identify non-compliance risks and implementing the 
required interventions was costly in terms of the pharmacist's time. The interview 
took an average of 22 minutes to implement. Using a shorter questionnaire could 
successfully reduce this element of the costs incurred, but possibly at the expense of 
the sensitivity ofthe questionnaire. 
An altemative solution could be to improve multidisciplinary team working. The 
ward nurses could be asked to select certain patients for further questioning by the 
pharmacist. This referral could include useful information such as home 
circumstance and confusion level. If the criteria for selection and referral were 
carefully designed then this information could effectively be used to screen out those 
patients without any problems, and those not self-medicating. This would reduce a 
lot of the background fact-finding that this study required of the investigator before 
the decision to include or exclude the subject from the interview stage. This 
information is often readily available to the nurse, even if not clearly documented in 
once easily accessible place. 
The most costly interventions in terms of time taken were producing large print 
labels and leaflets and filling MDS. Amending the pharmacy computer software to 
enable automatic printing of supplementary large print labels and medicine reminder 
leaflets could reduce this aspect of large print label production. This is possible with 
some dispensing programmes and should be investigated further. However, the 
limited number of patients this will benefit may not justify the expense of a software 
upgrade. 
Supply of MDS were the most expensive intervention both in cost of intervention (a 
Medidos® costs approximately £6) and in time taken to implement the intervention. 
We have already described how these are often inappropriate for many patients and 
should be limited to those patients for whom need and potential benefit is proven. 
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Making appropriate interventions for patients at risk of non-compliance is an 
essential aspect of pharmaceutical care and should be carried out by hospital 
pharmacists whenever possible. Involving the patient themselves and other health 
professionals is important and can improve the outcome of the intervention and 
reduce the time taken to investigate the problems and implement appropriate 
solutions. 
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Chapter 7: Factors affecting concordance ~ Patients' need for 
medication information 
Introduction 
Many patient advocacy groups, for example the Patients' Association, have 
demanded the right for patients to be given sufficient information about their 
medicines (Anonymous, 1997a). It is this right that concordance is based on; all 
health professionals are encouraged to provide good quality information to patients 
in order to increase a patient's ability and intention to comply with a medication 
regime (Sweeny, 1989). As has been discussed previously, patients who are given 
sufficient high quality, easily understood information have a greater chance of 
compliance than those patients who are given insufficient information (Lorenc, 
1993). Talking to patients about their treatment also gives them an opportunity to 
ask questions and verbalise fears associated with treatment (Smith, 1983). If these 
fears are not expressed then a potentially major risk to compliance may be ignored. 
In this chapter the problem of reported levels of information supply will be discussed 
and contrasted with the subjects' apparent lack of enthusiasm for being involved 
with making treatment decisions. The implications of this for achieving concordance 
in the population investigated will be considered followed by a more general 
discussion of the failure to achieve concordance in the wider population. The 
chapter will conclude with some suggestions for improving compliance and 
achieving concordance. 
Reported level of information supplied 
Thirty-six subjects (71 %) were judged to be at risk because of the level of 
information they had been given about their medication by their general practitioner 
or hospital doctor. Fifty-eight percent of the subjects who were judged by the 
investigator to have been provided with insufficient infonnation, reported being 
given sufficient information from their general practitioners. In total 68% of the 
study population reported being happy with the information supplied by their general 
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practitioner. However, all apart from eight subjects ( 43 = 84%) claimed not to have 
been given any information about their medicines from the hospital doctors or other 
staff. 
The higher reporting rate of general practitioners supplying infom1ation over hospital 
doctors is interesting; it is generally assumed that GPs have too many patients to see 
and insufficient time to see them all. A figure of seven to ten minutes per patient is 
often quoted (Sanghani, 1988); the corollary of this is that there would be 
insufficient opportunity to give their patients good quality information. Attaining 
concordance in such a restricted time period is near impossible (Anonymous, 2000a; 
Dean, 2000). In the hospital setting the situation may be slightly improved in that 
outpatient appointments may be under less pressure of squeezing in emergencies and 
a longer time may be available for discussion. However, the time allocated is still 
limited and may not be sufficient to address each of the patient's concerns. 
Conversely, hospital in-patients would be expected to have greater opportunity to ask 
the doctor questions, as a longer period of time is spent clerking the patient and 
discussing the case on consultant ward rounds. There is often the possibility of 
discussing an issue and making a decision the following day, after the patient has 
had opportunity to consider all the implications of the suggestion. Also, the need for 
new information would be greater for an in-patient than for a patient visiting their 
general practitioner as medication is likely to be altered to a greater extent during a 
hospital admission. Therefore, it might be expected that more information would be 
provided in hospital. The opposite was seen in this study with hospitals giving less 
information to the subjects questioned. This may reflect the pressure on junior 
doctors' time, with the result that discussing issues with the patient is not possible. It 
may also be an indictment of consultant ward rounds in which patients are discussed 
as cases, rather than being a discussion involving the patient. However, in-patients 
may be acutely unwell and therefore unable to make these important choices. In 
addition, a patient who is considering different options may be blocking a bed, which 
may be required by another patient who is more unwell. 
145 
Patients may feel their family general practitioner is someone they know well, 
possibly building a relationship over many years, and is therefore viewed as a helpful 
source of information. Hospital doctors may be new to them, consequently they may 
feel inhibited about asking 'too many questions'. In addition, the hospital may be 
seen only as a place where diagnoses are made and treatment prescribed; any 
changes will be explained to them by their GP on discharge. Such an expectation 
may inhibit the asking of questions. In addition, a hospital doctor may explain their 
actions but, because the patient is unwell or uncomfortable about requesting 
clarification, this information may not be understood. Details of a new diagnosis 
may attract the patient's attention and cause them to miss advice regarding treatment. 
In other studies, only 50% of patients were shown to get detailed information from 
their doctor (Hughes, 1998) and patients often do not understand what they have 
been told (Anonymous, 1992). In the current study, it was not necessary to 
objectively determine the quality of the information supplied by various doctors. 
Firstly, it is not possible to measure the information given in a confidential 
consultation unless recordings are made and assessed. Secondly, and more 
importantly for the current study, it is the subjects' recall of this information that 
affects compliance and therefore their subjective report of information supplied was 
of more use in assessing non-compliance risk. However, the responsibility for non-
compliance may lie with the doctor or pharmacist if insufficient information has 
been given to the patient in a manner understood by the patient (Parkin, 1976; 
Sweeny, 1989). There is here an opportunity for hospital pharmacists to share the 
task of explaining medication and discussing patients aspirations and attitudes to 
prescribed medicines. This will be discussed in more detail later in the chapter. 
Reported desire for medication information - does this meet concordance 
Despite the above, only six subjects were unhappy with the information they had 
hitherto received and wanted to be more involved in the decision making process. 
This point does not seem to be discussed in the published literature. Most papers 
describing how the provision of information to subjects improves compliance take 
no account of the patient's desire to be given this infonnation. Some authors 
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describe how patients' information needs can vary with time and circumstances and 
that health professionals have not always been good at identifying patients' needs 
(Entwistle, 2000). However, this same author described how health professionals 
tend to underestimate people's information needs, a point that does not seem to be 
borne out by the current study. Many more subjects were assessed as being in need 
of further information than would have been identified by means of self-report of a 
desire to have more information or in satisfaction with the information supplied. 
All six of the dissatisfied subjects were female. This may reflect the level of 
independence seen in females as described earlier. For example, Mrs. DT 
(3 7DT071 022) lived with her son but was self-caring. She was satisfied with the 
level of information given by her GP but she had difficulty remembering what she 
was taking and why it was prescribed. She wanted to have greater involvement in 
making decisions about her treatment. Mrs. JG (39JG070221) lived alone and was 
very independent and so also wanted to remain involved in the decision making 
process. This could be achieved by encouraging her to ask her general practitioner 
more questions about her treatment but also by explaining her wishes to her general 
practitioner direct. A discussion with the hospital pharmacist could also help her 
decide what she needed to know in order to facilitate concordance. Mrs. AP 
(37 AP050312), however, was also very independent but she reported that she had 
not been given any information, and despite reporting subtherapeutic outcomes, she 
did not want to be involved in making decisions regarding her treatment. 
Men are traditionally seen as needing to be in control and taking a greater interest in 
the technical aspects of a solution - how it works and how to improve its efficacy. 
However, the current data appear to suggest that in the particular elderly population 
studied the men did not want to be involved in making decisions about their own 
treatment. None voiced a desire to have greater involvement in making treatment 
decisions. This implies that they wished to don the health role of the helpless 
patient, and to be looked after, rather than acting as equal partners in the decision 
making process. This may have implications for concordance in the elderly male 
population. 
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Neither the reported level of information supplied to subjects, or satisfaction with the 
information supplied, correlated with overall compliance risk. For example, both 
Mr. AB (39AB270916) and Mr. WR (39WR030922) were calculated to be at 
moderate risk of non-compliance. However, Mr. AB reported being given sufficient 
information by both his general practitioner and hospital doctor; Mr. WR reported 
that he had not been given any information from either source. Both gentlemen were 
satisfied with the level of involvement they had in making decisions regarding their 
treatment and were not judged to have this risk factor. 
Perhaps the desire for infom1ation shown by patient advocacy groups does not reflect 
the true desire for infom1ation in the elderly population. Although 71% of subjects 
in the current study were classed as being at risk of non-compliance because of lack 
of information, only one sixth of these felt this was problematic. In addition, 
understanding of regime was not affected by the level of information supplied, which 
implied either that the information supplied was of insufficient quality to improve 
understanding, or subjects could not remember what infom1ation had been given. 
The latter could be caused by a lack of understanding of the importance of 
remembering or by general forgetfulness, as described by McGavock (1998). He 
reported that 50% of patient's couldn't remember what they were told by a doctor. 
It is interesting to note that there may be some correlation between the level of 
information supplied, or with satisfaction with that information, and attitude to 
medication, although this was not statistically significant. This could be explained 
because subjects who have been given sufficient information about their medication 
may be more likely to expect that medication to work. Similarly, subjects who are 
happy with their medication and feel it is appropriate and efficacious may not feel 
the need for further infom1ation. Conversely, subjects with a low faith in their 
medication, regardless of efficacy, may have no interest in knowing about that 
medication. It may be that these two areas can be considered as contrasting aspects 
of the same issue. 
148 
Being involved in making decisions regarding treatment was defined in this study as 
taking an active role, with the doctor, in deciding what treatment is appropriate and 
in reviewing whether it continues to be required. However, a number of subjects 
wanted to know what they were taking and why, but when asked whether they 
wanted to have greater involvement in making treatment decisions they said they 
were happy to trust their doctor. 
A patient wanting to leave all decisions regarding treatment to their doctor is 
incompatible with concordance. Some subjects in this study may have had some 
prior involvement; however, the majority claimed not to be involved and to be 
satisfied with that. This may be due in part to fear, as they often come into a 
consultation with no prior knowledge and therefore would find it difficult to assist 
with devising a treatment plan. In the current study, the reason for this lack of 
enthusiasm with respect to involvement with decision making was not possible to 
identify. Many subjects did say that they would rather leave all decision making to 
the doctor. This may have been out of a desire not to upset the doctor or to end the 
consultation quickly, without any intention of carrying through the treatment course. 
However, most of these subjects did want to comply with their treatment, even if 
outside influences and other problems caused them to unintentionally fail. This was 
a case of intentional non-concordance rather than intentional non-compliance. 
It is also possible that these subjects said they did not want to be involved because a 
treatment decision had already been made and they did not want to cause a problem. 
If this were the overriding rationale behind the stated position, a difference would be 
found between those who were satisfied with their medication and those who wanted 
the doctor to review it. This did not appear to be the case, and so this hypothesis 
does not seem to be active here. The subjects' judgement as to the efficacy and 
appropriateness of certain medicines differed from the doctors. This may reflect the 
fact that in general, members of the public who are not medically trained have 
limited ability to assess the risks and benefits of certain medicines and an otherwise 
competent individual may be prevented therefore from making an informed decision. 
However, it may ref1ect the fact that because the doctor did not discuss their 
medication with them they had no way of knowing how to interpret the results they 
see. Work should be carried out on developing simple but accurate information on 
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the relative merits of different medicines. As this task is so vast it would probably 
be best undertaken by the Medicines Information Pharmacists Group, a national 
organisation which co-ordinates medicines information within the National Health 
Service. 
Health professionals need to supply certain information to patients; however, this 
need does not necessarily coincide with their patients' desire for that information. 
Unless elderly patients can be encouraged to take a more active interest in their 
medication then concordance may be difficult to achieve in this group. 
Other barriers to concordance in the elderly population 
Concordance was introduced as a concept because it was shown that patients who 
agree with the therapy prescribed and who feel in control of their condition are more 
likely to comply with the prescribed treatment (Conrad, 1985). Also, making such 
fundamental decisions about medical treatment can be seen as a basic human right. 
However, there are many situations when concordance is limited or impossible to 
achieve. The general application of such a concept is therefore restricted and may 
prove only to be of theoretical value. In the first instance, concordance itself is 
innately difficult to achieve because it involves a significant paradigm shift. 
Concordance tries to remove the paternalistic imposition of compliance with the 
doctor's wishes, and replace them with an agreement between the prescriber and the 
patient. Secondly, there may be accidental or unintentional barriers to achieving 
concordance. 
In the current study, the first barrier to concordance encountered was that of 
communication between the subjects and the medical professionals. The hospital 
doctors generally failed to give subjects any information about their medication. 
This may have been because the prescriber did not agree with the concept of 
concordance and failed to give the patient sufficient information to be able to make 
an informed decision or did not allow the patient to be involved in the decision 
making process at all. Whether either of these were active in this situation or 
whether an oversight occurred, it was not possible to assess. 
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The doctors may have felt that the information they supplied was of a sufficiently 
high quality to be useful to the subjects but poor communication skills inhibited their 
ability to convey this information. Both the quality of the information supplied, and 
the specific facts that are conveyed, are important in achieving concordance; this has 
previously been discussed. Communication skills must be developed if doctors are 
to be able to communicate sufficient information of a suitable quality to enable 
patients to make the important decisions expected of them in achieving concordance 
(Anonymous, 2000a). However, the need for further development of the knowledge 
base of doctors on therapeutics, diagnosis, etc., and the limited time available within 
the undergraduate degree, may limit the extent to which teaching of communication 
skills to medical students can develop. A further problem imposed on the 
consultation is time restriction; this has been discussed earlier in this chapter. A lack 
of opportunity to discuss medicines will, by definition, reduce the ability to achieve 
concordance. 
Doctors are by definition professionals in healthcare. They are highly trained in 
diagnosis and selection of appropriate therapies. The majority of patients, however, 
will have no prior knowledge of appropriate treatment and the relative benefits of 
individual medicines over others. It remains difficult for these two parties to agree 
together to follow the choice of the less expert party, as the patient may encounter 
difficulty in understanding the intricacies of the differences between proposed 
treatment options without a detailed explanation. 
Six ofthe subjects interviewed had a very low AMT score (5/10 or less), that would 
generally be associated with an inability to make decisions about appropriate 
treatment. Concordance would not be possible with these subjects, as they would 
not be able to have a sufficient grasp of the issues involved to make an informed 
decision. This raises the interesting question of whether treatment should be 
withheld from such patients until they are in a position to undertake concordance. 
Alternatively, would concordance be required in order to make a decision to 
withhold treatment? The prescriber must take into consideration whether ethically 
the good of giving a specific treatment to a patient, who cannot be considered 
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competent to make an informed decision, overrides an infringement of the patient's 
human rights to choose whether to accept or refuse treatment. 
The approach we have termed prescriber focused therapeutics is generally accepted 
to be justified for patients who are not expected to regain competency. Concordance 
is especially problematic for patients with dementia or those with learning 
disabilities. Patients who have been sectioned under the Mental Health Act can be 
forcibly given medication which has been prescribed to reduce the risk of self-harm 
or danger to others. In this situation an act of parliament has exempted these patients 
from the benefits of concordance. However, it is worth considering whether patients 
with similar conditions, who have been shown to exhibit diminished responsibility 
but have not been sectioned, should be involved in making decisions about their 
treatment. It is possible that such a decision would not be an informed, logical 
decision. 
Circumventing the obligations of concordance can also be justified for patients for 
whom treatment is the only means of regaining competency, for example an elderly 
person with a urinary tract infection that is causing confusion. In conditions such as 
coma and patients who are heavily sedated in theatre or in an Intensive Care Unit, it 
would not be possible to discuss the various treatment options prior to 
commencement of therapy. A similar difficulty occurs with acute life threatening 
situations, for example in an Accident and Emergency department. However, if the 
patient is expected to recover competency spontaneously, should treatment be 
imposed before they have an opportunity to make an informed contribution? Many 
may argue that this situation is ethically unsound. 
It is in these circumstances that the doctor must decide whether making a decision 
without reference to the patient is appropriate or whether the next of kin should take 
the place of the patient in making treatment decisions. Although this may allow 
concordance to be achieved it is still possible that if the patient regains 
consciousness that they may disagree with the decision made. This therefore 
introduces the interesting dilemma of who takes the responsibility for the decision if 
it has been made as a result of concordance: the doctor or the next of kin? This is 
especially pertinent if the action taken was contrary to evidence based medicine. 
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Most hospitals have formularies, a list of medicines available for prescribing within 
the hospital, often with prescribing guidelines. These formularies are decided on by 
individual hospitals but the NHS executive prescribes their existence (Anonymous, 
1994). The National Institute for Clinical Excellence (NICE) also imposes decisions 
on prescribers. In a fully concordant consultation the prescriber would recommend a 
number of medicines but the patient would have the freedom to choose any of these, 
an alternative treatment not recommended but which they felt was more appropriate, 
or no treatment at all. Hospital formularies limit this choice to one or two 
(occasionally more) medicines within each class. On rare occasions no drugs from a 
particular class may be offered. It is generally hoped that these formularies take into 
account evidence based medicine, unfortunately this still limits concordance as the 
patient is not given a free selection of all possible treatments and a patient who 
wishes to use an alternative therapy may be refused. 
In addition to these prescriber-based limitations, there are a number of patient-
centred barriers to achieving complete concordance. The patient may not want to be 
involved in making a decision or may agree to something, out of a desire not to upset 
the doctor or to end the consultation quickly, without any intention of carrying 
through the treatment course. Additionally, the patient's ability to assess the risks 
and benefits of treatment with certain medicines may limit concordance. The patient 
may have been given sufficient and appropriate information and may understand 
why treatment is required and some of the potential adverse effects, but still be 
unable to judge the appropriate action to take. Risks are interpreted differently by 
doctors and patients. The patient's understanding of the severity and risk of 
deterioration and possible consequences of the condition under treatment will affect 
their ability to make decisions, making objective judgement difficult. The effect of 
feelings of vulnerability to disease and adverse effects has been discussed in 
previous chapters. These fears and attitudes must be taken into account by the 
prescriber when making therapy decisions but are relatively simple to identify. More 
difficult to address in trying to achieve concordance is a patient's understanding of 
the benefits oftreatment. 
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Some patients will want a complete cure and will not accept failure; others would be 
happy with minor symptomatic improvement. These two scenarios could be quite 
easily explained to a patient and they could decide which they were willing to 
accept. However, other grey areas of medicine are much more difficult for patients 
to contend with. A doctor or pharmacist may have the ability to deal with statistical 
probabilities of therapeutic success but these may be too complicated for a patient 
with no scientific or medical background to understand as they often need to 
combine a number of risks and benefits. 
Many decisions can be simplified into an understandable risk, for example, a 50% 
chance of a complete cure. However, in order to achieve concordance a full grasp of 
the implications is required. For example, Dmg X may not provide a complete cure 
but may control symptoms in 50% of cases and prevent deterioration; however, in 
20% of cases it has to be stopped because of severe side effects. Dmg Y may have a 
cure rate of 10% but provide adequate control in a further 55% of cases but also has 
a withdrawal rate due to adverse effects of 20% and requires regular blood tests to 
avoid other toxic effects due to a narrow therapeutic range. Such scenarios are 
common but are difficult to interpret. 
Concordance cannot be achieved once and then forgotten, it is a process which 
should continue throughout the course of the disease. However, patients may not be 
able to make informed decisions if they do not understand how to interpret the 
success or otherwise of a specific medicine. This inability to interpret outcomes may 
be due to a lack of clarity in those outcomes. For example, the outcome of a course 
of steroid inhalers is often not clear to a mild asthmatic as no immediate benefit is 
felt from using them. Evidence based medicine may indicate the appropriateness of 
such treatment but this would be less clear to the patient. 
The majority of the subjects in this study did not want to be involved in making 
therapy decisions for reasons which were not always vocalised. Making the subject 
take part in this consultation process could then be seen as an imposition. Most of 
the subjects did not want to be kept completely without information, but they did not 
want to have to use this infonnation to make a decision that they did not feel capable 
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of making. There are also many other difficulties in achieving concordance. It is an 
ideal to aim for but is often limited. 
How should information be offered? 
To achieve concordance 
In order for patients to take full part in concordance, a number of issues must be 
addressed: the various treatment options must be discussed with the patient and they 
must be assisted in assessing the risks and benefits involved and interpreting 
outcomes. Unless patients are offered a concordant consultation it is not possible for 
concordance to be achieved. The prescriber follows a decision making process that 
results in the prescribing of particular medicines; within concordance the patient 
must be involved at an early stage, i.e. from the moment of diagnosis. 
If a patient wants a concordant consultation then the health professional must make 
every attempt at accurately but simply describing why treatment is necessary, the 
various treatment options available, and the merits and risks of each. Time must be 
provided for the patient to decide which option to take, which may involve a second 
appointment at a later date. At this point providing written information for the 
patient to take away and consider may be appropriate. This can take the form of 
product information leaflets, material provided by self-help groups or other 
information provided by the doctor. 
If a patient decides that they do not want to be involved in making decisions about 
their treatment, the health professional must respect their decision, but still provide 
appropriate information about the choice that they have made. It is the responsibility 
of the prescriber to ensure that the reasons for this lack of willingness to participate 
are investigated; some of these reasons have been discussed above. However, 
patients often do not comply because of their attitude to medication (Griffith, 1990). 
Barriers to compliance may include a feeling of invulnerability to the disease and the 
inconvenience of taking tablets (Misselbrook, 1988b ). The health professional must 
try to understand what the patient believes and attempt to explain the relative risks 
and benefits of treatment compared with non-treatment. 
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Decreasing fear, frustration or resentment towards illness can improve compliance 
(Lorenc, 1993). Sometimes these opinions have been formed with reference to 
outside influences such as the media, friends and relatives and previous experience 
(Lorenc, 1993). Increasing family member understanding and support can improve 
compliance (Moriskey, I 986). To meet these problems concordance is the only 
solution. It is worth remembering that in some studies up to 85% of patients 
strongly believed that medicines were necessary for good health (Anonymous, 
1997b). However, this figure may vary depending on social background. 
New prescribers (Department of Health, I 999b) such as nurses and pharmacists may 
find concordance difficult to achieve as they will generally be prescribing from a 
limited formulary. The limitations that are imposed by formularies have already 
been discussed. Nurse prescribers may find involving the patient in the prescribing 
process easier than many doctors, as nursing roles have traditionally been more 
patient-centred than doctor's roles. However, these nurse prescribers may not have 
sufficient depth of knowledge of the medicines they prescribe to be able to explain 
them satisfactorily to the patients they care for. Prescribing pharmacists should have 
greater capability to explain the various treatment options to patients than nurses. 
Hospital pharmacists in particular are trained in evaluating the appropriateness of 
treatment decisions and are experienced in explaining prescribed medicines to 
patients. Ensuring that concordance is achieved when making treatment decisions 
may therefore be easier for a pharmacist. 
The mam focus of concordance centres on the initial consultation between the 
prescriber and the patient. Until pharmacists become independent prescribers, there 
will be little scope of developing this role (Anonymous, 2000a). However, hospital 
pharmacists are being encouraged to be pharmaceutical care practitioners (Hepler, 
1990) and are expected to assess and meet pharmaceutical needs. Concordance will 
flounder if all members of the healthcare team are not actively delivering the same 
message. The pharmacist therefore has an important role in maintaining a 
concordant relationship with the patient (Sanghani, I 998). A pharmacist needs to be 
a professional who understands medicines and their risks but are accessible when the 
public requires advice (Anonymous, 2000a). Hospital pharmacists can also act as a 
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reference source for prescribers and help identify those patients with whom 
concordance was not achieved. 
During a consultation, certain types of questions must be asked of the patient and 
particular information given to the patient in order to enable the patient to answer 
them. The patient should be asked primarily if they want any treatment at all, with 
the proviso that in certain conditions, such as schizophrenia, the necessity for 
treatment must override the patient's wishes. However, in general, in order to 
answer this question the patient must have explained to them all the possible 
consequences of refusing and accepting treatment. The prescriber must respect the 
various fears and aspirations of the patient and understand that these are specific to 
that patient, with large inter-individual variation. These dictate that the most 
appropriate treatment option may be different for each patient presenting with the 
same condition. 
Once the decision to treat is made then a number of treatment options should be 
described to the patient. The benefits and risks of these options must be explained 
and the patient assisted through the decision making process. Once treatment has 
been initiated then it should be reviewed regularly. For concordance to be continued 
then the patient must be given opportunity to continue with the same medication, 
change to an alternative medicine, or stop treatment. The patient must also be given 
assistance in interpreting outcomes as patients often attribute outcomes erroneously; 
this can be addressed and an appropriate review made. This phase in concordance in 
particular is suitable for a pharmacist to provide assistance: patients may give 
valuable feedback when picking up repeat prescriptions as an inforn1al discussion 
may allow the patient to volunteer their true opinion of the treatment. 
To achieve compliance 
There are a number of reasons why health professionals believe that patients should 
be given good quality information about their medicines. Firstly, a patient who 
understands what is required of them will find it easier to comply with the advice. 
Secondly, a patient for whom the advice makes sense to them, in the light of their 
own perceptions of the illness, is more likely to follow that advice. Concordance is 
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based on the premise that patients are more likely to comply if they have been 
involved in the decision making process; this seems to be born out by experience 
(Anonymous, 1997b; Mazzuca, 1982). Also, we have discussed how mistaken 
beliefs about efficacy and side effects can reduce compliance and addressing these 
mistaken beliefs may improve the patient's willingness to comply and is an essential 
part of pharmaceutical care (Sanghani, 1998). However, in one study of patients 
with infections who were given information about adverse events there was no 
improvement in either compliance rate or outcome (Haynes, 1996). 
The content of the information supplied is important because g1vmg extraneous 
details may confuse the patient and cause them to forget details that are more 
important. Previous authors believed that general information about medicines 
should include details of the regime and the importance of following it (Lorenc, 
1993); more general information about the condition such as disease progression and 
complications (Sweeny, 1989); and a description of possible side effects with advice 
on what to do if they occur (McGavock, 1998). Concordance also dictates that 
alternative treatment options and the relative merits or demerits of each should also 
be given (Misselbrook, 1998b ). 
Providing all the information described above can be complicated and time 
consuming. Even simple medicines, which can be bought without a prescription, can 
have multiple adverse effects, be dangerous when taken with other medicines and 
require close monitoring for some patients. The choice of what information to give 
and what to omit poses a dilemma. It is also important to consider that if a patient 
has been newly prescribed three or more different medicines, as may be the case in a 
newly diagnosed asthmatic or a patient who has recently suffered a myocardial 
infarction, then the amount of information required could be prohibitively long. 
Patients with no underlying levels of confusion, and prescribed simple regimes, will 
probably be able to cope with a greater proportion of the available information for 
each medicine than clinically confused patients with complicated regimes could cope 
with. It is probable that the greater the variety of verbal directions given for a 
regime then the harder it will be for the patient to be able to follow it without other 
written reminders. 
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When deciding what information to give to a patient then a number of factors must 
be considered: the level of involvement with decision making that the patient wants; 
the most important things you need to convey to the patient; the patient's level of 
understanding; the patient's desire for further information and any time constraints 
imposed on the patient and the health professional. 
Considering the latter point first, if the patient has an ambulance waiting or has 
another engagement, for example, needing to pick up children from school, there is 
little point in spending lots of time discussing their medicines with them when 
handing them out. This is a scenario that often presents to hospital out-patient 
dispensaries and on discharge from hospital. Patients in a hurry are unlikely to 
remember what they have been told because they will be preoccupied with getting 
away as soon as possible. Similarly, a patient in such a situation is unlikely to give 
feedback, which is important in determining whether they have understood the 
inforn1ation given or whether they have any unresolved fears and unmet 
expectations. In this situation it may be better to provide written information and an 
opportunity to discuss any issues at a later date. This written information could take 
the form of a medicines information sheet such as that in Appendix II, product 
information leaflets, which can be found inside the majority of manufacturer's 
dispensing and patient packs, or other leaflets that can be produced by a pharmacy 
department. 
In the hospital situation it may not be convenient for the patient to return to the 
pharmacy for further discussion. However, patients can be referred to community 
pharmacists or practice nurses, or can be provided with a telephone number, which 
they can use to speak to the pharmacist at a later date. With the development of the 
Internet it may also be possible for electronic helplines to be created in order to 
provide this service. The role of the community pharmacist is particularly important. 
In addition to explaining what the new treatment is for and when to take it, they are 
in an ideal position to allow the patient to provide feedback on the efficacy of 
treatment and whether they continue to be satisfied with it. 
159 
If the lack of time is on the health professional's side then this poses a more of a 
strategic problem and must be tackled. It is unacceptable to leave a patient with 
genuine concerns and worries and not attempt to deal with them. Workload should 
be rearranged to ensure that patients can be provided with the time and attention they 
need, to ensure that they receive all the information they require. If a health 
professional is finding that lack of time is causing such a difficulty, then this may be 
symptomatic of the low priority that such interaction with patients is held within the 
organisation or department. 
If there is no externally dictated time limit to the consultation it is tempting to 
provide the patient with all possible infonnation about their medication; however, 
this may be self-defeating. It is better to give small amounts of important 
inforn1ation over a period of no more than, say, ten minutes and repeat it frequently 
at subsequent consultations. If the information is repeated consistently by all health 
professionals caring for the patient, he is more likely to remember what is required 
(Moriskey, 1986). Patients tend to forget 31-71% of what they have been told but 
this reduces to 18-33% on repeated telling (Ley, 1982). This has been attempted in a 
number of ways: making a telephone call in the first week after prescribing a new 
drug (Anonymous, 1997b ); the pharmacist counselling patients on discharge or when 
new drugs are prescribed (Sweeny, 1989); visiting patients at home (Smith, 1983) 
and involving specialist nurses in conditions such as diabetes. This repetition can 
also be achieved by providing the patient with written instructions to read in their 
own time in addition to the verbal instructions given during the consultation 
(Haynes, 1996; Lowe, 1995; Sweeny, 1989). It is important to remember that the 
quality of this written information is as important as that of the verbal information if 
a patient is to be able to follow it. Good quality reminders have been shown to 
improve both compliance and therapeutic outcome in asthma and infections. In 
epilepsy, however, such interventions improved compliance without a significant 
improvement in outcomes (Haynes, 1996). 
Patients often do not take their medicines because their faith in the doctor or the 
treatment that he has prescribed is low. This may be exacerbated if the doctor fails 
to consult the patient about treatment options and gives insufficient inforn1ation, thus 
causing the patient to be dissatisfied with the doctor (Anonymous, 1999; 
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Anonymous, 2000a; Ley, I 982). A lack of information from the doctor may cause 
the patient to conclude that the doctor also has little faith in the medication, thus 
reducing the patient's determination to follow the treatment plan (Griffith, 1990). 
This is particularly a problem for patients with a high demand for control who may 
be finding a way of exercising control over his disorder and find difficulty in coming 
to terms with their illness (Anonymous, I 992; Misselbrook, I 998a). Compliance has 
been shown to be related to the quality, duration and frequency of the interaction of 
the patient and doctor (Moriskey, 1986) with short impersonal consultations 
resulting in the lowest levels of compliance (Griffith, 1990). 
It is important to remember that the label on the tablet bottle, etc., is a source of 
information. Pharmacists must ensure the labels on medicines clearly state the 
correct instruction in a form easily read and understood. This is easier with printed 
labels; hand-written labels should never be used. Similarly, labels stating 'Take as 
directed' are inappropriate as these give no guidance to the patient. Patients dislike 
these labels (Griffith, 1990) but it is much easier for prescribers to write 'as directed' 
on the prescription, especially for repeat prescriptions, which may be written by a 
doctor who does not know the patient. However, it is essential that prescribers put 
full instructions on the prescription so that the pharmacist can label the container 
clearly. This should not be difficult in general practice where most records are 
computerised and details of dose and frequency can be entered when the treatment is 
initiated and repeated at the press of a button when repeats are required. Efficient 
use of technology can improve patient care. 
The content of the information will vary from patient to patient and with different 
drugs and combinations of drugs. A patient who has no comprehension problems 
and who is prescribed only one simple medication will probably only need to be 
told: what condition the medication is for, how and when to take it and any side 
effects which it is important for them to watch out for (or common side effects which 
they can ignore). If the patient wants fmiher information, then questioning about 
specific concems is essential. Giving extra information that has little clinical value 
and of little interest to the patient merely increases the risk of forgetting important 
information. 
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When regimes are reviewed, it is important to ensure the patient does not continue 
with discontinued medicines. Hoarding of these old medicines may lead to non-
compliance (Parkin, 1976). This may be removed by asking patients to hand in old 
medicines on admission to hospital or when they visit their GP. Complications may 
still occur if patients are reissued the same drug but in a different brand if they do not 
realise they are the same medication and only one should be taken. Ensuring that the 
information supplied does not only include advice about new medicines, but also 
about current and discontinued medicines can prevent therapeutic failure and 
interactions. 
Patients who do not want to receive any information about their medication are a 
particular concern. One would assume that most patients would want to know 
whatever information they were offered regarding medical treatment. We have 
already discussed the special case of patients who have insufficient time to spend 
discussing their medicines with a pharmacist. However, a small number of subjects 
in the current study did not want to be given any information. This was generally 
associated with a high risk of non-compliance: namely, the subject did not want to be 
told anything because he didn't want to take anything. This may have been 
symptomatic of the fact that the prescriber had not attempted to achieve 
concordance. The second group of subjects who did not want to be told anything 
about their medicines were reliant on a spouse to remember when to take their 
medicines. For these subjects, talking to the spouse would have been more helpful. 
However, patients who do not want to be told anything about their medicines may 
also be afraid that it will be too complicated to understand or give information they 
do not want to hear ('bad news'). 
Taking medicines incorrectly reduces their efficacy and may be a cause of toxicity. 
It is therefore important that patients have a chance of taking them correctly and this 
often includes giving extra information in addition to that provided on the label. The 
literature that describes the effect of extra information does not use objective 
measures and often describes multiple interventions; it is therefore difficult to tell 
which causes the greatest improvement (Haynes, 1996). It may be that simply 
spending more time with the patient and showing an interest in their condition and 
response improves their likelihood of complying. This is known as the Hawthome 
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effect (Smith, 1983). Interventions that simply deal with improving knowledge have 
a success rate of 64%, whereas behavioural strategies have a success rate of 85% 
(Mazzuca, 1982). 
The author suggests that a minimum level of information should be given to all 
patients. This would include the condition the medication is prescribed for, the 
frequency and method of administration and the likely length of the treatment 
course. If there are any other important aspects to treatment (for example regular 
blood tests) these should be mentioned. This will give the patient the minimum 
information they require in order to be able to comply. However, as with all 
patients, they should be asked if they have any further questions about anything to do 
with their treatment, as sometimes patients do not vocalise their concerns and 
opinions (Stevenson, 2000). 
Patients have a right to know what they are being prescribed and the reason. They 
also have a right to be involved in the decision-making process. However, they must 
also have the ability to forgo this right without any loss of respect or increase in 
preventable risk. Health professionals must try to meet the individual needs of the 
patients they care for and ensure that where the patient implicitly trusts the health 
professionals to make the correct decisions then they will find this trust well 
founded. Hospital pharmacists in particular can play an important role in ensuring 
that patients are offered the most appropriate treatment and are satisfied with that 
treatment and the information they have been given. 
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Chapter 8: Addressing the problem of Polypharmacy 
Introduction 
Polypharmacy was found to be a problem for most subjects in the study and is 
problematic for many elderly people (RCPWP, 1997; Reid, 1997). Polypharmacy is 
used to describe the administration of too many drugs in one prescription (Thomson, 
1974), although the exact number of drugs which would cause problems would be 
different for each patient and is dependant on their ability to cope. Different authors 
disagree on whether three or five drugs constitute polypharmacy (Anonymous, 
1991 b; McGavock, 1998; Royal College of Physicians Working Party, 1984) 
although all agree that more than five drugs constitute polypharmacy. 
Parkin (1976) described a study in which 8% of patients taking two drugs did not 
comply. This rate increased to 42% in patients taking four or more drugs. Sweeny 
(1989) showed a similar drop in compliance, although patients showed significantly 
higher rates of non-compliance at all levels, for example, 67.5% for patients taking 
two drugs. Polyphannacy can lead to non-compliance in two ways (Royal College 
of Physicians Working Party, 1997; Reid, 1997; Wandless, 1977). Unintentional 
non-compliance has been shown to be related to the number of drugs prescribed due 
to forgetfulness and confusion. Polypharmacy may also cause intentional non-
compliance; patients with large numbers of prescribed medicines may selectively 
take those they think are important and omit the rest, or deliberately stop taking a 
drug they erroneously blame for adverse effects. 
Patients taking drugs which have been prescribed as once or twice daily doses 
exhibit much better compliance than those prescribed three or four times a day doses 
(Eisen, 1990; Griffith, 1990; Parkin, 1976). For example, Hughes (1998) quotes 
rates of medication enors of 15% for once daily dosing and greater than 35% for 
doses of four times a day or more. The knowledge of drugs also decreases, from 
75% for a once daily dose, to 40% for four or more times a day. No significant 
difference has been shown between once and twice daily dosing (Anonymous, 
199lb). 
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Polypharmacy may be the result of a failure to review and discontinue unnecessary 
medication. However, the reason for polypharmacy can be different in each case and 
may cause different levels of complication for different individuals. In addition to 
the detrimental effect on compliance, polypharmacy is potentially problematic 
because it increases the risk of adverse drug reactions and drug interactions (Hughes, 
1998; Ley, 1982). 
One example of a patient with polyphannacy was Mrs. LG (37LG061012). This 88 
year old woman was admitted taking eleven different medicines. Table 8i indicates 
the medicines she was admitted taking and the changes made to her treatment. 
Table 8i: Changes to medication for Mrs. LG (37LG061012) 
Medicine on admission Reason for ~rescri~tion Outcome 
Gliclazide 40mg daily Diabetes Continued 
Aspirin 75mg daily Anti-platelet Changed to warfarin daily 
Isosorbide dinitrate 20mg Angina Changed to isosorbide 
three times a day mononitrate MR 60mg daily 
Atenolol 1 OOmg daily Anginalh ypertensi on Continued 
Frusemide 80mg daily Ankle oedema Continued 
Calcichew D3 Forte® 2 daily Osteoporosis Changed to Adcal D3® 2 
daily 
Cimetidine 400mg twice a Gastric acid Changed to ranitidine 
day 150mg daily 
Betahistine 16mg three times Unknown, possibly 
a day dizziness Stopped 
Mebeverine 135mg three Unknown, possibly 
times a day irritable bowel Continued 
Glyceryl trinitrate spray 2 
puffs when required Angina Stopped 
Tramadol 50-100mg when 
reguired Pain StoEEed 
Mrs. LG was prescribed 11 different medicines on admission. Her reason for 
admission was a fractured neck of femur, which was not thought to be drug related. 
During her admission a number of changes were made to her treatment. Mrs. LG's 
angina was not completely controlled and so her isosorbide dinitrate was changed to 
isosorbide mononitrate, a preparation which is slightly more potent, but also has the 
165 
advantage of being available as a modified released preparation which can be taken 
once a day. 
Mrs. LG had been prescribed betahistine for a number of years but had no 
documented requirement for this medicine, it was therefore stopped. Tramadol was 
prescribed prior to admission because of pain. Treating her fractured neck of femur 
with a replacement hip reduced her pain and so it could be stopped. This was 
important to achieve before discharge otherwise Mrs. LG could be discharged on a 
medicine that could cause drowsiness, confusion and constipation. The reason for 
pre-admission prescribing of mebeverine was unknown, however, as it has few side 
effects, the doctors were reluctant to stop it. This could affect compliance therefore 
this may be classed as mismanagement. 
Mrs. LG had had a previous myocardial infarction and on review the doctor decided 
that she would benefit from warfarin as aspirin would be insufficient to prevent 
future thrombosis. Cimetidine was prescribed to reduce gastric acid, it would also 
protect against gastrointestinal bleed which may be exacerbated by warfarin. 
However, cimetidine inhibits the metabolism of warfarin and can lead to an 
increased International Normalised Ratio (INR) which is a measure of warfarin 
efficacy and toxicity; such an increase can lead to uncontrolled bleeding. Ranitidine 
was therefore prescribed as this does not interact with warfarin. The dose was also 
altered to a bedtime only, because protection from gastric acid was not required by 
Mrs. LG during the day as she had no symptoms of dyspepsia. 
Certain medicines remained the same throughout Mrs. LG's time in hospital. These 
included atenolol, frusemide and gliclazide. Calcichew 03 Forte® was changed to 
Adcal D3® simply because the latter was the hospital formulary choice. This was 
required to prevent further fractures and the high risk of mortality and morbidity that 
can follow from hip fractures. 
Because of the changes described above Mrs. LG was discharged taking eight 
different medicines at three different frequencies; there were changes to seven of her 
medicines. Mrs. LG had an Abbreviated Mental Test score of 5/10 and was 
confused about her medicines on admission. She could only explain what one was 
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prescribed for and knew the dose or frequency for only five medicines. It was 
therefore unlikely that she would be able to take her new prescription safely on 
discharge and she was supplied with a Medidos®, which would be filled on a weekly 
basis by her pharmacist. 
Polypharmacy can cause significant problems, but cannot always be avoided. Mrs. 
LG exemplified this. In this chapter, the causes of polypharmacy for the subjects in 
this study and the possible options to avoid or remedy the problem will be discussed. 
New treatment prescribed 
The most obvious way that polypharmacy occurs is when a patient presents with a 
new condition that requires new medication; this often cannot be avoided. 
Medication is usually required when the consequences of not treating the new 
condition are potentially serious. For example, a patient with angina who is not 
offered treatment is at high risk of developing cardiac problems of a more serious 
nature and may suffer from a fatal myocardial infarction. However, if new 
medication is prescribed then the risk of non-compliance will increase. 
Mr. LO (37L0090524) was a 76 year old male who had been admitted after a fall. 
He was admitted taking three different medicines, but was discharged with nine. 
Table 8ii shows the changes in his treatment and the reasons. 
Prior to admission, Mr. LO visited his doctor infrequently and this admission saw the 
diagnosis of a number of new conditions. Dose adjustment was required for the 
medicines he was taking on admission to ensure effectiveness. All of the new 
conditions that were diagnosed for Mr. LO were mutually exclusive, so different 
medicines were required for each condition. For example, during the fall that he 
sustained prior to his admission to hospital, he fractured a bone in his arm; he 
therefore required analgesia. This was introduced in a complicated regime, four 
times a day dosing, but would be possible to stop when his armed healed. Although 
he was still taking both analgesics at his 14-day follow-up, the codeine had been 
stopped at 3 months. 
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Table 8ii: Changes to medication for Mr. LO (37L0090524) 
Medicine on admission 
Aspirin EC 75mg daily 
Salbutamol inhaler 2 puffs 
three or four times a day 
Beclomethasone 
1 OOmcg/puff inhaler 2 puffs 
three or four times a day 
Reason for prescription 
Anti-platelet 
Chronic obstructive 
airways disease 
Chronic obstructive 
airways disease 
Outcome 
Continued 
Changed to four times 
a day 
Changed to 
200mcg/puff inhaler 2 
puffs twice a day 
Medication added on discharge Reason for prescription 
Lactulose 1 Oml twice a day 
Paracetamol 1 g four times a day 
Didronel PMO® 1 tablet daily 
Codeine 30mg daily when required 
Phenytoin 300mg at night 
Zopiclone 7.5mg at night 
Constipation 
Pain 
Osteoporosis 
Pain 
Epilepsy 
Insomnia 
The reason for the fall was investigated on admission and epilepsy was found to be 
the cause based on clinical and EEG findings. Mr. LO was also found to have 
osteoporosis, which increases the risk of fractures. Both of these conditions required 
treatment to ensure that he did not suffer any further increase in morbidity and so 
phenytoin and Didronel PMO® respectively were prescribed. 
Many patients who are admitted to hospital develop constipation and require 
laxatives. In addition, Mr. LO was prescribed codeine: an opiate analgesic which 
causes constipation. Lactulose was added to treat this. Similarly, insomnia is 
common in hospital and zopiclone was added to aid sleep. Both of these should be 
short-term therapy and should be stopped soon after discharge. Adequate medication 
review in primary care should identify when these could be discontinued. 
Sometimes non-drug therapies can be offered to patients when new conditions are 
diagnosed. For example, counselling may help with some cases of anxiety or 
depression and thus avoid the need for antidepressants. In other conditions 
physiotherapy, hydrotherapy or an exercise regime may reduce pain and 
inflammation and negate the need for analgesia. In other cases, dose adjustment of 
current medication may be sufficient. Ensuring that evidence based medicine is 
applied to the situation, and the treatment regime is reviewed prior to prescribing a 
new medicine, then polypharmacy can be avoided in many cases. 
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Requesting inappropriate medicines 
Sometimes, however, patients request medication when the evidence in the medical 
or scientific literature and the prescriber's experience advises against a prescription. 
This is particularly a problem with overuse of antibiotics; this may reflect patient 
demand (Linder, 2001). Many people have come to depend on antibiotics and so 
request them for viral infections, conditions which are not treatable by antibiotics. 
Although in this case any resultant polypharmacy is short-lived and ceases when the 
course is complete, such over-use of antibiotics can cause problems such as the build 
up of resistance in the bacterial population which may lead to treatment failure in 
future uses of that antibiotic. 
In the study population, nobody demanded unnecessary antibiotics, however a 
number of subjects did request apparently unnecessary medicines, examples of 
which follow. The consequences of non-compliance in such a scenario may be 
greater than in the case of appropriate treatment being added to a patient's regime. 
In the latter case, if the patient decides to discontinue a particular medicine, or 
forgets to take one, then the remaining medicines are all required and some 
therapeutic benefit will be achieved. If a patient requests an inappropriate medicine 
then it is possible that this medicine will be continued and any discontinuation or 
forgetfulness will affect another medicine which is possibly more necessary for 
therapeutic control. 
Mrs. MC (39MC080425) was admitted taking seven different medicines with four 
different frequencies. Mrs. MC was fairly happy with her medicines but was not 
sure if she needed a change in her Parkinson's Disease treatment. She also did not 
think her antidepressant was working, but despite this she did not want to stop it and 
refused to have her sleeping tablets reduced, despite understanding the risk of 
dependence. Mrs. MC was happy to accept all assistance offered except prescription 
review. She was worried that in stopping some of her medicines some apparently 
unrelated symptom would return. She disliked taking seven medicines, but dare not 
stop any of them. There is little which can be done in this circumstance except 
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ensuring that the decision has been made by the patient after consideration of the full 
facts, that is that concordance has been achieved. 
Mr. WR (39WR030922) reported being 'very happy' with his medicines but he 
wanted a nebuliser to replace his inhalers because he wanted to 'make sure 
everything was OK'. However, he thought his medicines were working and this was 
not the reason for his desire for a change. Nebulised therapy for asthma is 
appropriate for patients with severe symptoms. However, this can introduce adverse 
effects which are not present for standard inhalers. Mr. WR was controlled on 
aerosol inhalers and was therefore not prescribed nebules. The reason for this 
decision was explained and he reluctantly agreed to try the inhalers for a further 
period of time. 
There are various methods of reducing the likelihood of patients requesting 
inappropriate medicines; most of them involve patient education. This can be 
achieved by introducing concordance into the consultation and by providing advice 
and information as described in Chapter 7. National advertising campaigns have 
been used in the case of inappropriate requests for antibiotics and may be effective 
for other therapies (Anonymous, 2002; Regional Drug and Therapeutics Centre, 
1999). However, each patient is different and may request different medicines 
depending on their experience and that of their friends or relatives. It would not be 
possible therefore to address all problems of patient demand using national 
advertising campaigns. 
One area in which such advertising appears to have failed is in the area of single 
component vaccines to cover measles, mumps and rubella as alternatives to the 
MMR vaccine. Despite scientific and government reassurance that the combined 
MMR vaccine is safe and effective, public opinion appears not to believe this and 
views it as propaganda. It is interesting to consider that for concordance to be 
achieved, as discussed in Chapter 7, then the patient must be able to have a free 
choice of any medication, including ineffective medication, if that is what they wish. 
The only limitation is that the patient has been given sufficient information to make 
an informed decision. It is arguable therefore that the majority of parents requesting 
single component vaccines have been given sufficient information to be able to make 
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such an infom1ed decision and concordance would therefore dictate that this is what 
should be prescribed. 
Polypharmacy is difficult to avoid for patients with multiple conditions with 
mutually exclusive treatments. However, it should be avoided wherever possible by 
medication review, using alternative therapies and avoiding prescription of 
unnecessary medicines. 
Failure to review medication 
Polypharmacy often occurs because new medicines are prescribed and old medicines 
are not discontinued. We have already commented on the problem of restricted 
consultation time (Sanghani, 1988). It is not always possible for a general 
practitioner to review all of a patient's medication during one consultation. Often the 
patient has limited time but also the GP has other patients waiting to be seen. It is 
usually only possible to consider the treatment of the presenting complaint and leave 
other conditions, which are apparently under control, until they require attention. 
This may mean that a patient is receiving subtherapeutic treatment, which is not 
reviewed, because the patient does not understand that something can be done. 
Alternatively, the patient may be suffering unnecessarily with side effects, which 
could be avoided by using an alternative medication. 
Although all the conditions Mr. GW (37GW281024), aged 76, was being treated for 
were still requiring treatment, his doses and choice of medicines were no longer 
appropriate. Table 8iii shows the changes instigated to optimise his treatment. 
Trifluoperazine has a long half-life and therefore can be given once a day. It was 
unknown why Mr. GW was prescribed it twice a day on admission. Similarly, 
prednisolone should be taken as a single daily dose with breakfast to reduce adverse 
effects. The opposite applied to mesalazine, which should be taken three times a 
day, Mr. GW had therefore been receiving a sub therapeutic dose. All three of these 
medicines were prescribed at inappropriate doses and had not been reviewed. 
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Table 8iii: Changes to medication for Mr. GW (37GW281024) 
Medicine on admission 
Trifluoperazine 5mg twice 
daily 
Cimetidine 800mg at night 
Codeine phosphate 30mg 
four times a day 
Prednisolone lmg four times 
a day 
Benzhexol 5mg twice a day 
Mesalazine 400mg daily 
Calcium carbonate 500mg 
three times a day 
Reason for prescription 
Schizophrenia 
Gastric acid 
Pain 
Inflammation 
Unknown, possibly an 
adverse drug effect 
Crohn's disease 
Osteoporosis 
Outcome 
Changed to 1 Omg at night 
Changed to lansoprazole 
30mg daily 
Stopped 
Changed to 5mg daily 
Stopped 
Changed to three times a 
day 
Changed to Adcal 03® 2 
tablets daily 
Cimetidine is not recommended m the elderly because of an increased risk of 
confusion and the possibility of drug interactions. This was therefore changed to 
lansoprazole, a safer and more potent gastric acid-lowering agent. Calcium alone is 
ineffective at preventing steroid induced osteoporosis as vitamin D is also required. 
Mr. GW's calcium tablets were therefore changed to Adcal D3®, which contains 
both medicines. 
Mr. GW was also taking two medicines for which the indications were not known. 
Codeine phosphate is an analgesic, but as Mr. GW was not in pain this could be 
stopped, with a reduction in constipation, drowsiness and confusion. Benzhexol had 
presumably been prescribed to treat extra-pyramidal adverse effects, but this was not 
documented. As benzhexol can cause nausea and postural hypotension this was 
discontinued. Mr. GW did not experience any adverse effects on withdrawal and so 
he was discharged without it. Although he still had polypharmacy on discharge, his 
regime was much simpler, with three different frequencies compared with the six he 
was admitted with. His regime on admission bore all the hallmarks of a prescription 
that had not been reviewed recently. 
172 
Polypharmacy can also occur if a medicine is discontinued but the prescriber forgets 
to remove it from the patient's repeat prescribing list. This mismanagement is 
particularly a problem with patients who have recently been discharged from 
hospital, when changes made in hospital may not be accurately recorded. The 
patient may receive both the old medication and the new one when they order a new 
prescription. If the patient understands what they should be taking they may only 
order the new medication, but is at risk of taking potentially conflicting medication 
or toxicity due to overdose. This cause of polypharmacy is particularly addressed 
within the National Service Framework for older people, with patients over 70 years 
of age and more than four regular medicines receiving six-monthly repeat 
prescription reviews (Department of Health, 2001 ). 
Mrs. GE (39GE11 0815), an 85 year-old woman, was admitted to hospital feeling 
generally unwell and, although was unsure whether she was happy with her 
medicines, she felt she needed a change. The hospital doctors confim1ed this and the 
changes outlined in Table 8iv were made. 
Table 8iv: Changes to medication for Mrs. GE (39GE110815) 
Medicine on admission 
Digoxin 125mcg daily 
Metoprolol 25mg twice a day 
Lisinopril 15mg daily 
Frusemide 40mg daily 
Reason for prescription 
Atrial fibrillation 
Hypertension 
Left ventricular failure 
Left ventricular failure 
Anti-platelet 
Outcome 
Continued 
Continued 
Stopped 
Stopped 
Aspirin 75mg daily added 
Mrs. GE had two medicines stopped because she was found to be suffering from 
postural hypotension. However, aspirin was added because of the increased risk of 
thromboembolism for patients with atrial fibrillation. Mrs. GE did not have 
polypharmacy when she left hospital, however, if the information regarding the 
stopping of two medicines was not transcribed to her repeat prescribing list then she 
would be at risk of adverse effects. In particular the postural hypotension that 
necessitated the discontinuation, which could precipitate falls and possible fractures 
and subsequently lead to further admissions to hospital. It is important that general 
practitioners record changes accurately as soon as information is received from the 
hospital. 
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The failure to review repeat medication on a regular basis, and particularly 
immediately after a patient is discharged from hospital, can cause many medication 
errors and precipitate adverse effects. A solution would be to increase patient: 
doctor contact time by lengthening consultations. However, it is difficult to imagine 
how the length of time available for consultation with a general practitioner can be 
extended unless requests for consultations decrease or the number of general 
practitioners increases. In the meantime, medication review must become a routine 
part of the service offered by doctors to their patients, which may require a change in 
attitude and priority for some clinicians. 
The role of pharmacists in medication review 
Medication review is possible when the patient is not in the surgery and it does not 
have to be carried out by doctors. In response to the National Service Framework for 
Older People, many surgeries are employing pharmacists to carry out these reviews. 
The pharmacist can access a patient's notes and medication record and decide 
whether the medication is still required or whether the patient should be requested to 
attend the surgery to discuss changes that could be made. If pharmacists were 
dependent prescribers they could make the changes themselves. However, in most 
circumstances the recommendation is given to the general practitioner to action as 
soon as practicable. 
During pharmacist led medication review sessions hospital discharge letters can be 
reviewed to ensure that changes are made where appropriate. This information 
would not routinely be available to community pharmacists and therefore if not 
followed by the doctor then there would not be any possibility of the error being 
spotted during dispensing. However, there would be opportunity for a hospital 
pharmacist forwarding the relevant information to the community pharmacist to 
ensure that the patient has the maximum chance of receiving the correct medication. 
The hospital pharmacist has often been involved in advising on dose adjustments and 
treatment changes and would be in an ideal position to share this knowledge with 
pnmary care. 
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In order to prevent adverse effects and prescribing errors, medication must be 
regularly reviewed, even for patients on apparently stable treatment. General 
practitioners and hospital doctors can carry this out, but increasingly pharmacists 
have been recognised as having a role to play in this important area. 
Lack of information 
If a medicine is stopped in a medicine review or on discharge from hospital, the 
patient may still be at risk of polypharmacy. If the patient has hoarded medicines in 
former years and does not completely understand the reason for stopping certain 
medicines, then they may continue to take ones which should have been stopped 
(Parkin, 1976). It is for this reason that patients are often asked to bring all the 
medicines they may have stored at home to the clinic when a medication review 
takes place. At this time the doctor or pharmacist can identify which medicines are 
no longer required and dispose of them safely. 
It is important when patients are discharged from hospital, or when the regime is 
otherwise changed, that they have explained to them what the changes mean and 
whether they should continue taking previously prescribed medicines or dispose of 
them. This can be a problem on discharge from hospital (Bums, 1992) or when 
prescribing generically, as the patient may have other medicines at home which may 
have different brand names on them and which the patient may believe are different 
medicines and take all of them, putting themselves at risk of overdose. 
None of the subjects in this study were obviously continuing medicines that should 
have been stopped, but this is difficult to assess as often the other sources of 
information on drug histories are flawed (Audit Commission, 2001 ). It is often not 
possible to clearly identify whether the patient is taking a medicine that they should 
not be prescribed or whether the GP has failed to record the prescribing of that 
particular drug. 
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The treatment cascade 
Sometimes medicines can cause side effects, and often these adverse effects can 
require further treatment. It is important for the prescriber to decide with the patient 
the best course of action. One suggestion is to stop the medicine that caused the side 
effects; a second is to add a second medicine to treat the effects of the former. The 
latter should only be considered if the need for the first drug outweighs the benefits 
of stopping it to prevent the adverse effect. The second medicine has also the 
possibility of causing side effects, which may need the addition of a third drug. This 
procedure can continue until it is impossible to distinguish which conditions are 
primary and which are secondary to a medicine. This is termed the treatment 
cascade. Drug-disease interactions become more likely and the patient may suffer 
from worse health than if all medication is stopped. 
A review by the Royal College of Physicians (Working Party; 1984) describes a 
situation where polypham1acy, due to both changed clinical need and a treatment 
cascade, led to hospitalisation. This patient was taking an anti-inflammatory drug 
for joint pain and a treatment for angina. Unfortunately, worsening renal function 
meant that the doses of both were too high and heart failure developed. The nature 
of the adverse reaction was not identified and so a diuretic was added to remove 
excess fluid. This in turn caused lowering of her potassium, which needed to be 
treated with supplements. On admission, her regular angina medicine was replaced 
with an alternative preparation which could be taken as and when she required it. 
Her anti-inflammatory drug was replaced with a simple analgesic. This reduced all 
side effects and allowed the discontinuation of the diuretic and potassium 
supplements. 
A similar scenario occurred with Mr. WR (39WR030922), aged 78. He was taking 
nine different medicines prior to admission. Table 8v shows the alterations made to 
his medication 
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TabDe 8v: Changes to medication for Mr. WR (39WR030922) 
Medicine on admission 
Prednisolone 1 Omg daily 
Clomipramine 50mg twice a 
day 
Co-codamol 30/500 2 four 
times a day 
Mebeverine 135mg three 
times a day 
Isosorbide dinitrate 20mg 
four times a day 
Beclomethasone 1 OOmcg 
inhaler 2 puffs twice a day 
Salbutamol inhaler 2 puffs 
four times a day 
Glyceryl trinitrate spray 1 
puff when required 
Co-amilofruse 5/40 2 daily 
Reason for prescription 
Chronic obstructive 
airways disease 
Depression 
Pain 
Diverticular disease 
Angina 
Chronic obstructive 
airways disease 
Chronic obstructive 
airways disease 
Angina 
Oedema 
Outcome 
Continued 
Adcal D3® added to 
prevent osteoporosis 
Continued 
Changed to 2 at night and 
Co-codamol 8/500 2 three 
times a day when required 
Fyboge~ and senna added 
to prevent constipation 
Continued 
Continued 
Continued 
Continued 
Continued 
Changed to 1 daily 
In spite of a confusing combination of medicines, Mr. WR was able to accurately 
describe his regime in detail without prompting. In fact, his drug history was more 
accurate and included more useful information than the referral letter sent by his 
general practitioner. He was also able to explain why he was taking each medicine 
and reported being satisfied with the efficacy of his medication. During his 
admission two medicines were changed but three more were added to treat adverse 
effects of his current medication. 
Mr. WR was admitted with a fractured right hand, which was not related to any other 
clinical condition. However, because fractures can be caused by steroid induced 
osteoporosis, Adcal D3® was added to reduce the risk of further fractures. Also, the 
analgesics he had been taking caused constipation, which was controlled only by 
taking a further two medicines: Fybogel® and senna. As his clinical condition was 
stable and none of his admission medication was judged to be inappropriate, he was 
discharged with 12 medicines, three of which were to prevent side effects of three of 
the other medicines. His only problem with compliance was removing tablets from 
blister packs because of his fractured hand. 
177 
It is important for prescription reviews to include investigation of whether particular 
medicines are being used to treat the side effects of other drugs. If such a problem is 
identified then both drugs should be discontinued together. If a patient is prescribed 
a medicine that can cause nausea then an anti-emetic may be added. This in itself 
may cause Parkinsonian type symptoms, which may be confused with Parkinson's 
disease and treated with a dopamine agonist. If the first drug is stopped then there is 
a risk of the other drugs remaining, but now with no purpose. The above is a real 
situation which occurred on one of the study wards but to a patient who was not 
interviewed. On discontinuation of the two drugs that had been used to treat side 
effects, the patient's clinical condition improved. 
Doctors have strengths in diagnosis and prescribing but may assume that new 
diseases cause new symptoms. In contrast, pharmacists often assume that symptoms 
are drug related. A teamwork approach between these two parties could ensure that 
adverse effects are identified and treated appropriately, avoiding the problems of the 
treatment cascade. 
Polypharmacy induced compliance risks 
71% of subjects studied were at risk of non-compliance because of the complexity of 
their regime. However, as complexity did not correlate well with total scores, 
measuring complexity would not allow assessment of the subject's full range of 
compliance problems. However, as polypharmacy predisposes a patient to a number 
of problems both related and unrelated to compliance it is worth considering. 
Most of the subjects in the study had no change in the number of medicines they 
were taking at discharge, and some were prescribed more than they had been on 
admission. As described above, it is often not possible to avoid polypharmacy. 
However, more importantly, many of the subjects had medicines changed because 
they were no longer effective or causing adverse effects. If a patient has the optimal 
treatment prescribed with no extraneous medicines then the risks of polypharmacy 
may be reduced to that of non-compliance. 
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Polypharmacy occurs in many different ways but should be avoided whenever 
possible. If avoidance is not possible then other measures such as prescription 
review, counselling and medication reminder sheets should be used when possible to 
limit the risk to the patient. 
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Chapter 9: The role of primary care in improving compliance 
for elderly patients discharged from hospital 
Introduction 
In previous chapters, compliance has been discussed in general and the role of the 
hospital pharmacist in particular. This included discussion of the reasons why 
patients do and do not comply with the medication they have been prescribed and 
what can be done by a hospital pharmacist to improve the likelihood that medicines 
that have been prescribed will be taken appropriately by patients. This chapter will 
discuss how the health professionals in primary care can help with compliance. 
For a small number of patients medication review exclusively occurs within the 
hospital. However, the vast majority of older people are treated in primary care. 
These people visit their general practitioner for consultations or visit a community 
pham1acy for advice or for medication for minor ailments. These two professionals, 
the general practitioner and the community pharmacist, therefore have the greatest 
opportunity amongst health professionals to effect change in compliance behaviour. 
General practitioners influencing compliance 
68% of subjects in the current study reported being given sufficient information by 
their general practitioner. This was higher than the rate of satisfaction with 
information from hospital doctors, and the reasons for this have been discussed in 
earlier chapters. Most of the subjects appeared to want to trust their family doctor 
and were upset if they did not find him approachable or felt that he did not deserve 
their respect. Because of this they may listen to the advice of their doctor and want 
to comply with it more. However, they also may not want to upset their doctor by 
admitting to not wanting, or remembering, to take the prescribed medicines; in this 
situation concordance may help improve compliance. 
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In chapter 7 it was suggested that many patients may expect general practitioners to 
explain to them what happened whilst they were in hospital and why they have been 
prescribed certain medicines. There is often a delay in this information being 
supplied to the general practitioner; faster communication between primary and 
secondary care is therefore essential to reduce prescribing errors after discharge from 
hospital. This may be achieved by involving hospital pharmacists in this information 
transfer. Once a solution to the problem of delayed communication is found, it 
would be very useful for patients to visit their general practitioner soon after 
discharge from hospital. The doctor could identify any problems or worries that the 
patient might have regarding their treatment and advise on how to deal with the 
medication they might have stored at home, but which has been discontinued. 
Consultation time with general practitioners is restricted, but spending extra time 
with patients who are suspected of non-compliance may improve compliance and 
reduce the number of consultations they require. General practitioners need to learn 
how to ask the questions that will prompt patients to divulge any difficulties that 
they may have with particular regimes. They need to try to achieve concordance in 
each consultation, even if it is retrospective. This means that once a medicine has 
been tried for a period of time, the GP must assess whether the medication is 
working, therapeutic effect, but also whether the patient has been able to take it, 
namely compliance. This assessment must not be judgmental, acknowledging that 
often the regime or choice of therapy may be causing the difficulties of compliance 
rather than the patient deliberately choosing not to comply. 
Concordance, in the simplest understanding of the term, occurs during the first two 
stages of the medicine process, namely, the decision to treat and provision of 
treatment stages. Concordance is achieved if the patient, after being given sufficient 
information, enters into an agreement with the prescriber to proceed with a course of 
action, a therapeutic plan, which may include taking medication. Note, however, 
that this definition combines the writing of a prescription and the handing of the 
dispensed drugs to the patient into one stage, as this is how a general practitioner 
would perceive it. In practice, however, these are two separate stages and further 
input can be made at both stages. 
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For concordance to be meaningful, however, it must take into account the two 
further stages in the medicines process: administration and feedback or review. If 
the patient tries to take the medicine but fails, or decides that the therapeutic plan 
was flawed, then this information must be taken into account when reviewing the 
medicines. It is this stage which is so difficult in in-patient hospital medicine as 
administration of medication occurs within a controlled environment and patient 
satisfaction and non-compliance with new treatment cannot be assessed accurately. 
This has been discussed earlier and is the reason why non-compliance risk factors 
were investigated in the present study. The general practitioner, however, can assess 
the impact of patient satisfaction and non-compliance and with the patient make a 
decision that is much more richly informed, and probably more closely adhered to. 
This is the true fulfilment of concordance. 
In the current study, 88% of subjects claimed they did not want to have a greater 
involvement in making decisions about their treatment. As the majority of these also 
said they had not had any involvement so far, it could be claimed that most of the 
subjects did not want to be involved in making treatment decisions. The reasons for 
this have been discussed earlier; but it is interesting to note that many of these 
subjects did want to provide feedback on the medicines they had already been 
prescribed. It may be that, whereas elderly people may be afraid or feel unable to 
make a choice between a number of theoretical options that they have not yet 
experienced, they do feel capable of interpreting the success of a particular 
medication if guided by an health professional. It was apparent that the subjects in 
the current study expected their opinions to be taken into account by the pharmacist. 
Whether they would feel the same about voicing opinions to their general 
practitioner remains to be seen, but general practitioners must develop the skills 
necessary to draw this information from their patients. Asking patients whether they 
are satisfied with their treatment and discussing what their aims of treatment are may 
allow greater involvement in the decision making process and hence achieving 
concordance. 
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Sometimes, however, patients will not divulge non-compliance behaviour to their 
general practitioner (Moriskey, 1986). In this situation he must use other clues to 
discover whether the patient is taking the medicine appropriately. Lack of response 
or toxic side effects may provide clues to compliance level achieved. If a patient 
mentions particular adverse effects, or appears worried about their treatment, this can 
reveal areas that need further investigation. 
Repeat prescriptions are often ordered and produced by the receptionist and signed 
by a doctor who may not pay much attention to what is being ordered. The problems 
which can be caused by failure to review repeat prescriptions have been discussed in 
Chapter 8. However, rates of ordering of repeats could indicate non-compliance and 
computer systems could quite easily register potential problems. Many prescribing 
systems have a facility to limit the number of repeats allowed before a review 
occurs. However, it is essential that this is not overridden or ignored as in this 
interval many problems may occur without the doctor being aware of them. 
A doctor's failure to provide medication review may be blamed on lack of time. 
However, it may be due to a failure to prioritise. It is easier for a doctor to assume 
patients are on appropriate treatment and only concentrate on issues raised by the 
patient. Ultimately, however, if patients are left on inappropriate therapy this may be 
viewed as mismanagement or even negligence. 
For patients over 75 years-of-age, the National Service Framework for Older People 
(Department of Health, 2001) recommends annual medication reviews and 
recommends a decrease in the interval to six months for patients with more than four 
medicines. This hopefully will reduce the number of unnecessary medicines patients 
receive and allow patients to be more involved in the review process. However, 
patients with unstable medical conditions, or who have demonstrated compliance 
problems or adverse reactions to medicines, should be reviewed more frequently. In 
particular, the doctor should review newly prescribed medicines within two months 
of initiation, especially if dose adjustment and monitoring may be required. 
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General practitioners have many opportunities to assess and prevent non-compliance. 
However, because of their lack of accessibility, they require assistance from other 
members of the primary care team. The community pharmacist is in an ideal 
situation to assist with this. 
Community pharmacists influencing compliance 
Community pharmacists have two main roles: responding to symptoms with advice 
and supply of over the counter medicines; and the supply of prescription medicines 
with the necessary information to enable the patient to take it correctly. The 
pharmacist is therefore in an ideal situation to minimise many of the factors that may 
cause non-compliance. 
The effect that communication with patients has on improving compliance has been 
discussed in Chapter 7. The community pharmacist is in an ideal situation to be able 
to explain to patients what is required whilst showing them what has been 
prescribed. This verbal and visual reinforcement of the information that the general 
practitioner has given should make understanding and remembering how to take the 
medicines easier (Haynes, 1996; Lowe, 1995; Sweeny, 1989). 
It is often difficult to make an appointment with a general practitioner, but a 
community pham1acist is always available, when the pharmacy is open, for advice 
and reassurance. The relationship with the patient can also be used to assess whether 
there are any problems with the medication a patient has been given. A patient may 
ask about side effects or complain that the medication is ineffective. A patient who 
appears anxious when the pharmacist explains how to take their medicines, or who 
appears to have little interest in what the pharmacist is trying to tell them, may not 
want to comply with the regime. If a patient routinely visits the same pharmacy, and 
the same pharmacist, rather than locums, usually runs that pharmacy, the pharmacist 
may have a good working knowledge of their social situation and may be able to 
offer advice in tailoring the regime to their routine. This is particularly useful for 
older people who visit day centres or other such activities. 
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Patients may be dissatisfied after consultations with a doctor because they feel their 
wishes have not been respected. Sometimes they are unhappy with the treatment 
decision. On other occasions they may be satisfied with the treatment decision but 
dissatisfied with their role in making that decision. Community pharmacists may be 
able to identify these problems when patients come in to have their prescription 
dispensed. This dissatisfaction can be reported to the general practitioner, with the 
patient's permission, providing the feedback part of concordance. The community 
pharmacist is an important link in this chain, especially because of their accessibility. 
All community pharmacies keep Patient Medication Records (PMRs). These are 
records of all medicines dispensed to an individual patient each time they present a 
prescription. These records often have the ability to store information on non-
prescription medicines bought by the patient, interventions made by the pharmacist, 
and advice given. Using these records, a community pharmacist may be able to 
identify patients at risk of non-compliance. For example, if a patient presents with a 
repeat prescription very early then they may be overusing their medicines, or may be 
having difficulty with dropped or otherwise spoilt tablets. A patient who leaves a 
long interval between successive prescriptions may be hoarding medicines at home 
or they may not be using the prescribed dose. It may be that these patients require a 
medication review to ensure that they are being prescribed the correct medicines or 
they may need reminding of what the appropriate method of taking their medicines 
1s. PMRs can also be used to ensure that patients receive the same brand of 
medication on each occasion to reduce the risk of patients assuming that two 
different brands of the same medication are different and thus the risk of overdose. 
If a patient borrows medicines to tide them over until their next prescription is 
available, or they frequently report losing medication, this may also indicate 
problems with compliance; these patients may need more input from the community 
pharmacist. Similarly, patients who are requesting certain non-prescription 
medicines, such as laxatives, antiemetics or sore throat and cough remedies, may be 
showing signs of adverse effects to drugs, which they may not realise are iatrogenic. 
It is always useful for the pharmacist to be aware of what medicines their regular 
customers are purchasing. 
185 
Another use of PMRs is in identifying patients with frequent or large changes to 
their prescription. We have discussed how this can affect patients' ability to comply 
as the more frequent the changes, the harder it will be for a patient to remember what 
the relevant instructions are for taking it. However, multiple changes are also a sign 
of poor therapeutic control. It is important for the pharmacist to consider whether 
non-compliance is implicated in this poor control. The pharmacist can ask the 
patient why the treatment was changed and whether they were having any problems 
which may require referring to the general practitioner. Although community 
pharmacists cannot change prescriptions and currently have no authority to overrule 
a prescribing decision, they can offer useful advice, both to the patient regarding 
what feedback the doctor will need when reviewing medication and to the doctor 
regarding therapy choice. The community pharmacist can also address the general 
compliance problems presented by complicated regimes. 
Hoarding medicines puts patients at risk of non-compliance (Parkin, 1976): doses 
may change and medicines may be discontinued, but if the patient still has plenty at 
home they may continue to take the old dose. Many pham1acies run so called Brown 
bag clinics, where patients can bring in all their medication from home and have the 
phannacist assess what is still appropriate for use, and dispose of the rest. This can 
help the pharmacist identify at-risk patients and also reduce their level of risk. 
Many pharmacists are getting more involved in medication review for their regular 
customers. This is similar to a review which the general practitioner may carry out 
but concentrates on the medicines being used, drug interactions, and the presence of 
unnecessary medication. Community pharmacists can help reduce polypharmacy 
and simplify regimes by providing the general practitioner with the results of their 
reviews. 
Any interaction with the patient is lost if a carer or other third party collects the 
prescriptions for the patient. The obvious loss is the ability to counsel patients on 
their medication and for them to ask questions. Sometimes, however, these carers 
can provide some insight into the administration practices of the patient and allow 
some interventions. 
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It is important to note at this point that most of the input that a pharmacist can have 
into compliance is only possible if the patient visits the same pharmacy on the 
majority of occasions. Fortunately, this appears to be the case for elderly patients 
and was also seen in the current study with 84% of subjects visiting the same 
pham1acy each time a prescription is dispensed. In addition, if community 
pharmacists identify a problem with compliance, it is important that they 
communicate these problems with the patient's general practitioner. The latter may 
have already identified a problem and attempted to deal with it, or they may not have 
realised that there was a problem and may need to review the patient's medication in 
the light of this information. 
Communication between general practitioners and community pharmacists is not 
automatic. Although patients are registered with a particular general practice, they 
are free to visit any community pharmacist they wish. It therefore follows that the 
general practitioner might not know which pharmacy the patient usually visits and 
therefore cannot share appropriate information with them. It is much easier for a 
pharmacist to contact a general practitioner as the relevant practice is simple to 
identify as the surgery stamp must be on every NHS prescription presented for 
dispensing. In order to rationalise care in primary care and ensure maximum safety 
for patients, the status of community pharmacists must change. Registration with 
community pharmacies, similar to that in other countries, must be introduced if they 
are to provide a clinical service, and not simply a supply service. Registration will 
also allow service level agreements to be agreed by Health Authorities and 
remuneration for some services may be possible. 
Once non-compliance has been identified, then interventions must be made. These 
can involve treatment review and subsequent changes being made, but they can also 
involve providing certain services such as large print labels, Monitored Dosage 
Systems and medication reminder leaflets. There is a wide variation in the provision 
of these services among community pharmacies which can leave some patients with 
no extra assistance because the pharmacy they routinely visit does not offer any non-
core services. Registration may allow standardisation of service provision, ensuring 
that the patient receives the service they require. 
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With their frequent contact with patients and ease of accessibility, Community 
Pharmacists are in an ideal position to assess and improve compliance. However, 
this may be wasted if communication on admission to and discharge from hospital 
does not occur. 
The primary/secondary care interface 
When patients are discharged from hospital, they are at special risk of non-
compliance, as changes in treatment are frequently not transferred to the repeat 
prescription list. This problem is exacerbated by poor handwriting on the immediate 
discharge document, with the typewritten document not received by the general 
practitioner until several weeks have elapsed. A community pharmacist cannot 
intervene to reduce this risk unless they are contacted on discharge and the same 
information relayed to them as to the general practitioner. If this was routinely 
carried out, the community pharmacist would be in a much better situation to help 
the patient with advice than is currently the case. 
Another problem at discharge is that the interventions initiated by the hospital 
pharmacist must be continued in the community. The numbers in the current study 
were low, but four out of the five subjects followed-up at two weeks post discharge 
had received a continuation of the interventions initiated by the hospital pharmacist. 
In order to ensure that interventions are continued after discharge communication 
between the hospital and community pharmacies must occur. The hospital 
pharmacist must inform the community pharmacist of anything they have been doing 
for the patient. Also, the community pharmacist must inform the hospital in order to 
reduce duplication of effort and to ensure that discharge medication is provided in a 
format suitable for the patient. This is particularly important when Monitored 
Dosage Systems are used, as often the particular device offered by the pharmacy 
may be different to that offered by the hospital. Some arrangement or compromise 
must be found if the patient is not to receive two different devices. 
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Compliance is a problem that should be considered by health professionals from 
both sides of the primary/secondary care divide. By working together health 
professionals can give their patients the most appropriate medicines and enable them 
be given the best possible opportunity for taking them con·ectly with the least 
complications. 
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Chapter 10: Compliance and concordance- some 
recommendations 
Problems with assessing compliance and concordance 
In this study problems were encountered in enrolling subjects into the follow-up 
phase. These problems occurred because the subjects were afraid to take part or 
because they were unable to understand why their participation would be useful. 
This may reflect a more general problem, namely that people want various medical 
interventions to be proven before offered to patients. However, many would have no 
desire to take part in those studies. If research governance is adhered to and studies 
are shown to ask specific, measurable, appropriate and relevant questions which can 
be achieved given the resources available then the population can be guaranteed that 
their participation is valuable. What might be helpful would be some sort of public 
awareness programme in which the general population would have the benefits of 
research participation explained to them. In this way evidence based medicine may 
be achievable and the benefits of particular compliance interventions may be proven. 
The instrument used within this study appeared, with the provisos described in 
earlier chapters, to be capable of identifying patients at risk of non-compliance and 
indicating the appropriate solutions. The Abbreviated Mental Test was shown to be 
a useful tool in screening patients who would be at high risk of non-compliance, but 
would not be sufficient to identify those patients at moderate risk or to identify the 
appropriate interventions 
Compliance is problematic in the elderly 
The aim of this study was to investigate the role of a hospital pharmacist in 
improving compliance behaviour in an elderly population after discharge from 
hospital. This thesis demonstrates that compliance is problematic in the elderly 
population studied and requires intervention if treatment failure is to be avoided. 
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All of the subjects interviewed had different levels of compliance risk, although the 
vast majority did present with at least one risk. It would therefore appear appropriate 
to assume that most elderly people would have some problems with compliance. 
Four different risk factors were identified as problems for over 50% of the subjects 
interviewed. Lack of understanding of regime was evidenced by an inability to 
describe what medicines the subject had been prescribed prior to admission or 
explain why they had been prescribed. There was a general dissatisfaction with 
prescribed treatment for many subjects; this was related to a lack of efficacy in 50% 
of cases, but many subjects could not explain why they reported being unhappy with 
their medication. 
Provision of information was found to be poor for the majority of patients, with 
hospital doctors providing much less information regarding treatment regimes than 
general practitioners. However, the majority of subjects appeared to be satisfied 
with the amount of information they had received and the level of involvement they 
had in making treatment decisions. Many subjects had a complex regime which 
exceeded the National Service Framework for Older People (Department of Health, 
2001) standard of four medicines for patients over 75 years-of-age. However, no 
two subjects had identical combinations of problems and therefore generalisation 
into categories was not possible. 
How a hospital pharmacist can address compliance problems 
This study was carried out because a number of authorities have described the 
benefits a hospital pharmacist can confer if certain activities occur at discharge. 
Although the study did not provide any evidence that the interventions used did 
improve compliance, a number of interventions were carried out which may have 
potential to benefit elderly patients at risk of non-compliance. The most commonly 
implemented were counselling on discharge, providing a compliance reminder sheet, 
attempting to simplify the regime and finding solutions to various physical problems. 
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Many subjects reported that they had not been given any medication information 
either by their general practitioner, the hospital doctor, or both. However, most of 
these were happy with the level of involvement they had in making decisions about 
their treatment. The subjects interviewed often were interested to know what they 
had been prescribed and the best way to take it. Providing information about 
medicines is important in improving the ability to comply with a regime. It can 
improve patients' knowledge of why medicines are prescribed and possibly improve 
their understanding of whether they are effective and which medicines can cause 
adverse reactions that they might experience. This was therefore a useful service 
which the majority of subjects appreciated and found helpful and should be offered 
to all hospital in-patients prior to discharge. 
The majority of subjects reported that they would want their doctor to continue to 
make treatment decisions for them and they did not want to be involved. They 
therefore wanted information about their medicines, but not the responsibility of 
making decisions; this is incompatible with concordance. As increased involvement 
in making decisions about treatment options has been shown to reduce compliance 
risk, patients should be encouraged to become more involved. This can be difficult 
in hospital if the treatment required could make the difference between several days 
longer in hospital and early discharge. Allowing patients to consider the relative 
benefits of treatment could lead to bed blocking. Waiting until the next consultant 
ward round may be too long an interval, causing the patient to forget the questions 
they wished answering or the reason why treatment was recommended. Achieving 
concordance in this situation must therefore be multidisciplinary, with all members 
of staff trained to assist patients with their deliberations. Obviously, the hospital 
pharmacist would be the best qualified to offer this assistance and should be 
available to discuss issues with the patient. 
Because of the reluctance exhibited, attempts to achieve concordance in this 
population should concentrate on the treatment review stage, rather than the initial 
therapy choice stage. The majority of subjects were happy to comment on whether 
they felt treatment was working or continued to be necessary and so would be 
capable and willing to increase their involvement in this stage of the process. 
However, if advances were made in the information available to explain relative 
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risks to patients then they may be happier to become more involved in the treatment 
planning process. As recommended earlier, this should be a national initiative with 
easy to understand information packs being developed for various common 
conditions. These should be objective and evidence based. However, the pharmacist 
must take time to understand what level of risk the patient is willing to take; this is 
time consuming but is worthwhile if the outcome is a patient who is happy to take 
the treatment as prescribed. 
In hospital there is more opportunity for the pharmacist to be involved in concordant 
interviews; the consultant can recommend a treatment and refer the patient to the 
pharmacist for more information. However, in general the role of the pharmacist 
would be to identify where concordance has not been achieved and make the 
relevant intervention to achieve concordance. 
Polypharmacy was found to be a problem for most subjects in the study. However, 
the majority of these had no change in the number of medicines they were taking at 
discharge, and some were prescribed more medicines than they had been receiving 
on admission. It was often not possible to avoid polypharmacy. However, if a 
patient has the optimal treatment prescribed with no extraneous medicines then the 
risks of polypharmacy may be reduced to that of non-compliance. Polypharmacy 
should be avoided whenever possible; if avoidance is not possible then other 
measures such as counselling and medication reminder sheets should be used when 
possible to limit the risk to the patient. Of particular concern are the patients who do 
not want to take medicines but are afraid to stop. These may not be predictable non-
compliers as their medicine taking may be erratic. A discussion with the patient to 
understand their true attitude to medication may allow identification of the 
underlying problem and medication review may therefore be possible. 
Medication reminder leaflets were provided to the majority of subjects. These could 
be very helpful for those patients who have complicated regimes or who want a more 
schematic reminder of how medicine taking can fit into the normal daily routine. 
However, they would be inappropriate for patients on very simple regimes who do 
not exhibit forgetfulness, and would also be insufficient for patients who are very 
confused. Medication reminder leaflets should be offered routinely to all elderly 
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patients: they are cheap to produce and so would not be wasteful for those patients 
who do not need them. However, the potential benefit for those patients who do use 
them would be great. 
A number of interventions were implemented to address physical problems; these 
included large print labels, alternative devices and screw caps. These should be 
offered to all patients who need them, but strict selection criteria should be adhered 
to as an appropriate solution for one patient could cause a hindrance to another. Also 
some subjects refused interventions. It is important that these interventions are seen 
as treatment necessities and not as optional extras which can be accepted or rejected 
by patient choice except under the auspices of concordance. 
The study appeared to confirm the hypothesis that elderly patients have various 
compliance problems, and that a hospital pharmacist has a role to play in solving 
these problems. This role should not be exclusive, however, and the role of ward 
nurses in identifying patients with problems and possibly assisting with some 
solutions has been discussed. Similarly, in order for hospital initiated interventions 
to improve compliance risk status, they must be continued after the patient is 
discharged from hospital. The GP and the community pharmacist have the most 
opportunities an1ongst health professionals of being able to effect change m 
compliance behaviour. They must therefore be involved in any decision to 
implement interventions. 
The solutions suggested above are all achievable within current funding and job 
descriptions. Compliance assessment and initiating interventions are time-
consuming but come within the remit of the hospital pharmacist and other health 
professionals within the demands of pharmaceutical care. However, for compliance 
and concordance to be achieved to the maximum extent then links between primary 
and secondary care need to be improved beyond the limits which are currently 
achievable. Admission letters, discharge summaries and ad hoc communication 
between hospital and community pharmacists, hospital doctors and general 
practitioners, are useful but a more structured intervention across the 
primary/secondary care divide is required. 
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The role of primary care in concordance and compliance 
The relationship between the general practitioner and community pharmacist 
requires better definition. Both are health professional but whereas the patient is 
registered with a general practitioner they can chose to visit any community 
pharmacist in any part of the country. The community pharmacist must refer 
patients to their general practitioner but the GP in return does not have any 
requirement to communicate anything with the community pharmacist. In primary 
care, therefore, the doctor carries out the diagnosis and prescription and the 
pharmacist provides assistance in monitoring. It is therefore the responsibility of the 
doctor to provide regular medication review to ensure treatment is optimal. This 
often does not occur but has been prescribed in the National Service Framework for 
Older People (Department of Health, 2001). However, if this occurs but is not 
thorough enough then any resultant non-compliance or morbidity may be thought of 
as resulting from negligence. 
Community pharmacists have an important role in identifying those patients whose 
treatment is not optimal or who are unhappy with their treatment. Solutions 
available may be sale of OTC (over-the-counter) medicines, advice or referral back 
to the general practitioner. It is important that patients at risk of non-compliance are 
advised of the possible solutions available, many of which have been described 
earlier. Unless patients are made aware of services such as filling Monitored Dosage 
Systems or large print labels then they will not be able to take advantage ofthem. 
Bridging the primary/secondary care divide 
Many of the problems presented to the hospital on admission are caused by a lack of 
knowledge of the patient's usual ability to cope with medication and services 
provided by Social Services or the community pharmacist. Similarly on discharge, 
infom1ation regarding changes made to treatment and interventions to improve 
compliance are communicated only when the hospital health professional decides it 
is appropriate or in direct response to a request from primary care. This 
communication should be more formalised and this could be achieved by employing 
a primary/secondary care liaison pharmacist. 
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The primary/secondary care liaison pharmacist post could be funded from the 
hospital with a remit to ensure that all relevant information for at-risk patients is 
obtained from primary care and supplied to those who need it most at discharge. 
Alternatively, this could be an extension of the practice pharmacist role and be 
funded from general practice. The pharmacist could identify all patients from a 
particular practice who are admitted to hospital and ensure that an appropriate drug 
and compliance history is provided to the hospital. On discharge they would liaise 
with the hospital and community pharmacists and general practitioner to ensure that 
all relevant information is shared and achieve seamless care. This role could be 
provided by a hospital pharmacist if more resources were available and provide a 
useful link between the hospital and primary care. 
Errors, due to lack of information regarding drug histories, would be eliminated and 
patients would not find themselves in the situation of failing to have services 
continued in the difficult days after discharge. Also, prescription review would be 
carried out with the maximum available knowledge, ensuring that medicines that had 
failed in the past were avoided and discontinued medicines were not accidentally 
reinstated due to lack of repeat prescription review. Polypharmacy could therefore 
be avoided. 
Interventions instigated in hospital must be continued in the community if patients 
are to benefit. However, patients can change the pharmacy they get their 
prescriptions dispensed from and so continuity of care can be disrupted. In addition, 
if the patient cannot remember the name of the pharmacy they routinely visit then 
communication with that pharmacy is not possible. If patients could register with 
one particular pharmacy, many compliance problems could be addressed. Firstly, it 
would be as easy to provide discharge information to the correct pharmacy as it 
currently is to communicate with a patient's general practitioner. Secondly, 
pharmacists could be given contracts which reflected the level of service they 
provided to their patients. The general practitioner is paid a certain fee for the 
number of patients registered with him and receives extra payment for individual 
non-standard activities. Pharmacy registration could allow similar remuneration 
packages, which would allow extension of services such as Monitored Dosage 
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Systems and enable investment into computer hardware which would enable 
provision of large print or even Braille labels and leaflets. Many aspects of 
pharmaceutical care depend on pharmacists taking responsibility for their patients' 
well being, and not just limited service provision for customers. 
Many patients cannot remember the information they have been given at discharge. 
If patients are offered a hospital-based pharmacy telephone helpline to contact for 
further information after discharge, this could reduce some of the worry that may 
lead to non-compliance. NHS Direct currently provides such a service, but this is 
impersonal and the health professional answering calls would not know any of the 
background to the patient's condition or reason for admission to hospital. A hospital 
pharmacy helpline could access information from the recent admission and could 
explain the reasoning behind any changes. If required, arrangements could be made 
for the pharmacist who had cared for that specific patient whilst in hospital to speak 
to them, ensuring continuity of care. This service could identify treatment failure 
and be used within concordance to suggest a course of action to the patient's general 
practitioner, ifthe patient was in agreement. 
Patients with many potential problems after discharge would benefit from a 
domicilliary visit. The hospital pharmacist, practice pharmacist or community 
pharmacist could identify patients who are at high risk and visit them to ensure they 
understand how to take their medicines and were still coping. At these visits it 
would be possible to check the medicines that the patient may have at home and 
advise on their suitability for continued use and which should be destroyed to reduce 
the risk of continuing discontinued medicines. A telephone call shortly after 
discharge could identify if any problems existed and restrict domicilliary visits to 
those patients who appeared to warrant one. 
With the advent of Training Primary Care Trusts, and the potential for pharmacist 
involvement in medical undergraduate training, pharmacists would be in an ideal 
position to train other health professionals in the skills that they would require to 
ensure concordance and compliance were achieved. Advice on such subjects as how 
to avoid polypharmacy, common drug interactions and the practicalities of drug 
review could be provided to other health professionals, especially doctors and 
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nurses. In this way the burden of reducing compliance and achieving concordance 
would be shared amongst all health professionals and become a priority for all those 
caring for patients. 
Compliance can be problematic for elderly patients, but with innovative thinking and 
co-operation across professional and sectoral divides, it can be addressed and the 
attendant risks minimised. 
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Appendix 1: LREC information sheet and approval 
Information sheet 
INVESTIGATION INTO THE ROLE OF A HOSPITAL 
PHARMACIST IN IMPROVING COMPLIANCE BEHAVIOUR 
AFTER DISCHARGE FROM HOSPITAL 
Can a hospital pharmacist improve patient's ability to take their 
medication when they leave hospital? 
You are being invited to take part in a research project, which is part of 
my Master's degree at Durham University. Here is some information to 
help you decide whether or not to take part. Please take time to read the 
following information carefully and discuss it with friends, relatives, 
your named Nurse or Hospital Doctor if you wish. Ask me if there is 
anything you do not understand or if you would like more information. 
Take time to decide whether or not you wish to take part. Thank you for 
reading this. 
The purpose of the study 
To try and help you take your medication Pharmacists can do a number 
of things. For example we can explain what your tablets are for and try 
to make them easier for you to take. I am doing this study to find out if 
we could help more. 
Why have you been chosen? 
You have been chosen because I talked to you about your medication 
and I felt that there were some things I could do to help you. I would 
like to talk to you after you leave hospital to see if I have helped you. I 
will be asking about 100 people in total to take part in the study. 
What will happen to you? 
If you agree to take part in the study I will ring you or visit you at home 
10-14 days after you leave hospital. I will ask you some questions about 
your medicines and the things I have done to help you. This should take 
about 30 minutes. I will also meet with you when you return to the 
hospital for an Outpatients appointment. 
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What will happen to any information collected about you? 
All the information collected about you during the course of the study 
will be kept strictly confidential. Any published report of the research 
will not identify you. 
Your GP will be informed that you are taking part. If this is a problem 
for you, you should discuss it with me. 
What if you decide not to take part? 
It is up to you to decide whether to take part or not. If you do decide to 
take part, you are free to withdraw at any time and without giving a 
reason. This will not affect the standard of care you will receive. Your 
doctor will not be upset if you decide not to take part. I will try to help 
you in the same way that I would have done if you had chosen to take 
part in the study. 
What risks are there? 
You will receive the same service whether you take part in the study or 
not. Therefore you will not be at any more risk if you decide to take 
part. The only inconvenience is that I will need to talk to you twice after 
leaving hospital to discuss your medication. I will try to find a time 
convenient for both of us. 
Will you benefit from taking part? 
You may or may not receive any direct benefit from taking part in the 
study. We hope it will help us to help future patients. 
If you want any more information please ask your ward pharmacist 
when I visit the ward each day. Or you can ring me on extension 4364. 
Thank you very much for taking part in my study. 
Flesch Reading Ease Score- 74.4 (80% of people can read) 
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LREC approval letter 
NORTH TEES & HARTLEPOOL NHS TRUST 
NORTH TEES GENERAL HOSPITAL 
North Tees Local Research Ethics Committ~e 
Stockton-on-Tees 
Cleveland 
TS19 8PE 
Direct Line: 01 64 2 6241 64 
Fax: 01642 624951 
ELG/LM 
8 June 1999 
Ms J Robson 
Dept of Pharmacy 
NTGH 
Dear Ms Robson 
* 13/99-2000 - Investigation into the role of a hospital pharmacist in 
improving compliance behaviour after discharge from hospital 
Thank you for submitting the above application which was considered by the North 
Tees Local Research Ethics Committee at its meeting today. The Committee were 
impressed with the quality of your application and unanimously agreed that the 
second version of the patient information leaflet should be used. 
NTLREC is fully compliant with the International Committee on Harmonisation 
(ICH) Guidelines for Good Clinical Practice as they relate to the responsibilities, 
composition, function, operations and records of an Independent Ethics 
Committee/Independent Review Board. To this end it undertakes to adhere as far 
as it is consistent with its constitution to the relevant clauses of the ICH 
Harmonised Tripartite Guideline for Good Clinical Practice adopted by the 
Commission ofthe European Union on 17 January 1997. 
I would be grateful if you could submit a study report in one year's time. Please 
advise this Committee if your research does not take place. 
Yours sincerely 
e { E L Gilliland - Chairman 
North Tees Local Research Ethics Committee 
-
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APJpelllltdlnx ~~- Medlocatoon remniT1lder ~eaf~et 
N UrrnitN Ward Dnsclll cl 
MJEDNC!NJE TIMES TO BJE TAKEN REASON JFOR 1I' AKJING/ NO'JI'IE§ 
6am 8am lOam 12 2pm 6pm IOpm 
noon 
Madlop21r dlnsp 62.5mg ONE Dissolve in a glass of water. Take 
before getting out of bed. For 
Parkinson's Disease 
Snnemet CR 50/200 ONE ONE ONE For Parkinson's Disease 
Take with or after food 
Cnt2HOJP!r21!1Il! 20mg ONE Treats depression 
Omepnazone 10mg ONE Reduces acid in the stomach 
Dompe~rndlorrne 10mg ONE ONE ONE To stop you from feeling sick 
Ropirrnn~rolle ./ 
"' 
J Take according to pack. Take with or 
after food. For Parkinson's Disease 
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Appendix Ill - Pilot questionnaires 
Pilot 
• How are you getting on with your medication? ____________ _ 
• How long have you been taking them? ______________ _ 
• Do you know why you have been given your medication? 
---------
• What do you think of your tablets? Are they helping? _________ _ 
• Do you have any problems with your tablets/ any unwanted effects? ____ _ 
• People often have difficulty taking their tablets for one reason or another. What 
about you? 
--------------------------
• Do you have a method of remembering when to take them? _______ _ 
• Many people find they miss a dose from time to time; is this a problem for you? 
• When ...... do you sometimes take an extra dose? ___________ _ 
• Do you find your family doctor or pharmacist helpful when you have questions 
about your medicines? ____________________ __ 
• Remembered drug history 
TDM results 
Full recall D 
Partial recall D 
No recall D 
--------------------------
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First Draft 
1. How are you getting on with your medication? 
Very well 0 
all right 0 
With difficulty 0 
2. What medicines have you been taking and when do you take them? Do you 
take any medication which the doctor has not prescribed for you? (E.g. 
vitamins, paracetamol, lactulose) 
(Need drug name, strength/ dose and frequency) 
3. Do you know what you are taking them for? 
4. Are you happy with your treatment? 
Yes 0 
Fairly 0 
No 0 
5. Do you think your medicines are working? Why? 
Yes 0 
No 0 
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6. Do you feel you still need the same medication which you have been 
prescribed? What different medication do you think you need? Why? 
7. Do you have any problems/unwanted effects from taking your medicines? Do 
these problems stop you from taking your medicines or change the way you take 
them? 
Side effects Yes D No D 
Change 111 medicine taking: 
8. Do you have a method of remembering when to take them? 
9. Do you ever forget to take your medicines? 
Yes D 
No D 
10. Are you careless about taking your medicines? 
Yes D 
No D 
11. When you feel better do you ever stop taking your medicines? 
No D 
Yes D 
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12. When you feel worse do you sometimes stop taking you medicines? 
No D 
Yes D 
13. Has your doctor or pharmacist told you about your medicines? 
Yes D 
No D 
14. Did your doctor discuss with you what medicines were appropriate before he 
prescribed them? 
Yes D 
No D 
15. Would you like to be more involved in making decisions about your treatment? 
No D 
Yes D 
16. Labelling and container requirements 
Container requirements 
None [ ] 
Screw caps [ ] 
Large tablet bottles [ ] 
Different sized bottles* [ ] 
Compliance aids* [ ] 
Measuring pot [ ] 
Oral syringe [ ] 
All items as liquids [ ] 
Other* [ ] 
Labelling requirements 
None [ ] 
Large print size [ ] 
Colour coded labels [ ] 
Other* [ ] 
* Give details 
Device requirements 
Volumatic 
Nebuliser 
Haleraid 
Other* 
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[ ] 
[ ] 
[ ] 
[ ] 
Compliance Assessment 
Subject code: 39/GM/031015 
JINlFORMA TJION PRJIOR TO A]))MJI§§JION 
1. Does anyone help you to take your medication at home? 
Full help 0 
Reminder only 0 
No help 0 
(Excluded from study) 
5 
3 
2a. What medication have you been taking and when do you take them? 
(Need drug name, strength/dose and frequency 1 for each correct and divide by n) 
Drug name JD>ose/strengtllt Frequency §core 
Frusemide 40mg 3 daily 3 
Digoxin 62.5mcg 1 daily 3 
Lisinopril 1 daily 2 
Lansoprazo I e 1 daily 2 
Warfarin daily 2 
Mucogel prn up to tds 3 
(ISMN) 1 tds 2 
(Terbutaline) 2 puffs twice daily 2 
Total 3 
2b. Do you take any medication that the doctor has not prescribed for you? (E.g. 
vitamins, paracetamol, lactulose) 
Drug Dose lFreque]J]cy 
None 
3. Do you know what you are taking them for? 
(Score 2 for each correct and divide by n) 
Drug Reason Score 
Warfarin Clots 2 
Frusemide Water tablet 2 
Isosorbide mononitrate Heart 2 
Digoxin Heart 2 
Lisinopril Heart 2 
Terbutaline Breathing 2 
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Mebeverine Stopped 
4. Are you happy with your medication? 
Very 0 5 
Not very 0 2 
Fairly 
Not at all 
04 
0 1 
Unsure 
Sa. Do you think your medication is working? 
Yes 
I don't know 
Not at all 0 1 
5b. Why? 
05 
03 
Water tablet and warfarin are working 
Digoxin seems to be OK 
Unsure about the others 
I think so 
I don't think so 
04 
02 
Total 
03 
2 
6a. Do you feel you still need the same medication which you have been 
prescribed? 
Yes 
6d.) 
05 Unsure 03 No 0 I 
6b. What different medication do you think you need and why? 
Alternative To replace:- Reason 
medication 
Don't know 
(go to 
7a. Do you have any problem/unwanted effects from taking your medication? (E.g. 
sickness, diarrhoea, constipation, rash, headache, dizziness etc.) 
Side effects: Yes 0 No 05 (go to 8a.) 
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Subject code 39/GM/031015 
7b. Do these problems stop you from taking your medication or change the way you 
take them? 
Yes 
No 
0 
05 
(see below) 
Change in medicine taking (score: 
Drug Side effect 
4 - change appropriate e.g. with food 
2 - ~ dose or miss dose occasionally 
1 - stop using) 
Change 
8a. How often do you forget to take your medication? 
Always 0 Occasionally 0 Never 0 (go to 8d.) 
8b. Why do you forget? 
I Don't know 
8c. Do you have a method of overcoming your forgetfulness? 
Yes 
No 
0 
0 
(see below) 
1 
§core 
Method of remembering when to take medication (score 5- safe and effective 
3- unsafe) 
Method 
Follow compliance chart written by hospital 
Put tablets out for next dose and take at mealtimes 
I 
§core 
5 
5 
5 
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8d. Why do you never forget your medication? 
Reason (score 1- no method 
5 - safe and effective method 
3- unsafe method) 
Reason §core 
9. Are you careful to follow the doctor's instructions about when to take your 
medication? 
Always 0 5 Sometimes D 3 Never D 1 
1 Oa. Have you ever stopped taking your medication because you felt better or worse? 
Feel better 
D 1 
10b.Why? 
Always 
Sometimes 
Never 
D 
0 
D Feel worse Always 
Sometimes 
Never 
0 
D 
3 
5 
Antibiotics sometimes make me sick, so I don't always continue the course when I feel 
like that 
11. When you are given a prescription does your doctor or pharmacist tell you any 
information about your medication? 
Always D 5 
2 
Never 0 1 
If it is a new drug 04 Unsure 0 
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Subject code 39/GM/031015 
POST -ADMISSION INFORMATION 
12. Has anyone told you about your medication since you came into hospital? 
Yes 05 
Unsure 0 3 
No 01 
Who? Nurse 0 
Pharmacist 0 
Doctor 
Other 
0 
0 
13. Has your hospital doctor discussed with you what medication were appropriate 
before he prescribed/changed them? 
Yes 05 Unsure 03 No 01 
14. Would you like to be more involved in making decisions about your treatment? 
Yes 0 1 No 05 
15. Labelling and container requirements 
Container requirements Labelling requirements Device requirements 
None 0 None 0 Volumatic 
Screw caps 0 Large print size D Nebuliser 
Large tablet bottles D Colour coded labels D Hale raid 
Different sized bottles*D Other* D Other* 
Compliance aids* D 
Measuring pot 0 * Give details 
Oral syringe D 
All items as liquids D 
Other* D 
Score 5 - no problems 
4 - problem patient solves safely 
1 - unsolved problem/unsafe solution Score _1 _. 
16. AMT _lQ_/10 >7 score 5 
5-7 3 
<5 1 Score 5 
------='--
17. Conditions which may affect compliance: RA D 
Depression D 
Baseline 5, score -2 for each item Confusion 0 
Other D 
Score 5 
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0 
0 
0 
D 
18. TOM available none 
Normal range score 5 No levels 5 
Borderline 3 
Outside range 1 Score 5 
--=---
19. Likely complexity of drugs on discharge: 
Number of drugs 6 
Maximum frequency tds 
Number of different frequencies, directions (e.g. with food) 4 
< 5 drugs 0 2 
Maximum frequency bd D 2 
~ 2 frequencies 
Final scores 
1+8+9+10+18 
5 
2+3 
4+6 
2 
D 1 
5 
5 
3 
Sum to give score Score __ o __ 
40-45 Low risk of non-compliance 
30-39 Moderate risk ofnon-
compliance 
<30 High risk of non-compliance 
5 3 Any score ~ 3 requires an intervention 
7 5 
11+12+13+14 2 
4 
15 1 
16+17 5 
2 
19 0 
Total 29 
Time taken to complete: 30min 
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First follow-up 
Subject code 39/GM/031015 
INTERVENTION ASSESSMENT 
1 a. Have you had a prescription from your GP since leaving hospital? 
Yes 0 
No D 2 
1 b. What medication was your prescription for? 
Discharge medication New prescription 
Warfarin 2mg daily 5pm ./ 
Frusemide 120mg daily ./ 
Isosorbide mononitrate 20mg bd Isosorbide 20mg tds 
Digoxin 62.5mcg daily ./ 
Lisinopril 30mg od ./ 
Lansoprazole 30mg od Stopped 
Salbutamol inh 2 puffs qds via Volumatic ./ 
2. Which pharmacy did you get your medication from? 
Nominated pharmacy Woodlands- Yarm Lane 
Current pharmacy Woodlands - Y am1 Lane 
3a. On discharge form hospital I arranged for you to have some special services. 
Have they been continued? 
3b. Are they helping? 
Interventions made 
1. Turbohaler ~ Inh. via Volumatic 
2. Screw caps and medicine pots 
3. Counsel and reminder chart 
Continue? ( v") Helpful? 
./ Yes YnsuFe 
./ Yes Ynsl:lFe 
./ Yes YnsuFe 
4. Are you having any problems with your medication? Yes 0 No 
Inhaler keeps falling out ofVolumatic 
5. Interventions required 
1. Explained how to attach inhaler so it doesn't fall out 
2. 
Time taken to complete: 10 min 
Ne 
Ne 
Ne 
D 
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Second follow-up 
Subject code 39/GM/031915 
FOLLOW-UP INTERVENTION ASSESSMENT 
1. Which pharmacy did you get your last prescription from? 
Nominated pharmacy --~W'-'---='o-=-o=dl=a=n=ds=--------------
Pharmacy at 14/7 ____ ....:...W:....oo"-"o=d=la=n=d""-s _______ _ 
Currentpharmacy ___ ~W~o~o=d=l=an=d=so ________ _ 
2. What was your last prescription for? 
Warfarin 2mg daily 
Isosorbide mononitrate 20mg tds 
Digoxin 62.5mcg daily 
Frusemide 120mg daily 
Salbutarnol inh via Volumatic pm 
Lisinopril 30mg daily 
Lansoprazole 30mg daily 
3a. On discharge from hospital I arranged for you to have some special services. 
Have they been continued? 
3b. Are they helping? 
Interventions made 
1. Turbohaler -t Volumatic 
2. Screw caps and medicine pots 
3. Counsel and gave reminder chart 
4. Explained how to manage 1. 
5. 
6. 
Plus compliance sheet 
Time taken to complete: 30 min 
Continue? ( ,() Helpful? 
../ ¥es Unsure 
Sometimes Yes YHsHFe 
../ Yes YHSHFe 
¥es Unsure 
Yes Unsure 
Yes Unsure 
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Ne 
Ne 
Ne 
Ne 
No 
No 
Appendix V- RothmHopkins test 
Question 
Name 
Age 
Time (nearest hour) 
Name & address (5 minute recall) 
Mr.John Brown 
42 West Street 
Gateshead 
Day of week 
Date (number) 
Month 
Year 
Place: Type 
Name 
Ward 
Town 
Recognition (2 people) 
Date of birth (date and month) 
Place of birth 
School 
Fonner occupation 
Spouse/next of kin 
World War I (year) 
World War 11 (year) 
Present monarch 
Present Prime Minister 
Months backwards (Dec-Jan) 
Count 1-20 
Count backwards 20-1 
Total 
Possible Score 
0/1 
011 
0/1 
0/1/2 
0/1/2 
011 
011 
011 
0/1 
011 
0/1 
011 
011 
011 
0/112 
011 
011 
011 
0/1 
0/1 
0/1 
011 
0/1 
0/1 
0/1/2 
0/1/2 
011/2 
x/34 
(Roth, 1953) 
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Appendix VI - Individual subject procedure 
1. Baseline measurements 
1.1 Baseline infom1ation will be obtained from the patient's medical notes and by 
contacting the patient's GP and community pharmacist 
1.2 Each patient will be interviewed using a structured questionnaire by the 
researcher (see Appendix IV) at day 3 of admission or transfer to the study 
wards 
1.3 Using this information a number of problems (:S: 3) will be identified for each 
patient 
2. Intervention 
2.1 Solutions will be sought for each problem identified and actioned before 
discharge 
2.2 Patients with identified problems will be asked for consent to enter stage 3 (see 
Appendix VII) 
2.3 At discharge any relevant information will be sent to the patient's GP and 
designated community pharmacist (e.g. dispensing, counselling and information 
needs of the patient) 
3. Reinforcement 
3.1 Each patient will be interviewed by telephone or at home 1 0-14 days after 
discharge 
3.2 The purpose of this visit will be to ascertain whether pharmacist initiated 
solutions are being continued and whether they are found helpful by the patient 
3.3 Any further interventions will be made as necessary 
4. Outpatient clinic re-evaluation 
4.1 Each patient will be followed up at their first outpatient appointment (unless this 
occurs at less than 2 months) 
4.2 Patients will be assessed for compliance and administration problems and the 
success of the pham1acist' s interventions 
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Appendix VII - Consent form 
Researcher: Jane Robson, Directorate Pharmacist for Medical Rehabilitation 
Please initial box 
1. I confirm that I have read and understand the information sheet dated May 0 
1999 (version 1) for the above study. 
2. I understand that my participation is voluntary and that I am free to withdraw 0 
at any time without my medical care and legal rights being affected. 
3. I am willing to allow access to my medical records but understand that strict 0 
confidentiality will be maintained. The purpose of this is to check that the 
study is being carried out correctly. 
4. I agree to take part in the above study 0 
Name of patient Date Signature 
Researcher Date Signature 
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